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ABSTRACT 
 
The detection of cancerous cells by the immune system elicits spontaneous antitumour im-
mune responses. Still, during their progression, tumours acquire characteristics that enable 
them to escape immune surveillance. Cancer immunotherapy aims to reverse tumour im-
mune evasion by activating and directing the immune system against transformed tumour 
cells. However, the tumours’ intrinsic resistance mechanisms limit the success of many im-
munotherapeutic approaches. The functionally and morphologically abnormal tumour vascu-
lature forms a physical barrier and prevents the entry of tumour-reactive immune effector 
cells, while the immunosuppressive tumour microenvironment impairs their function. To 
block tumour immune evasion, therapeutic strategies are being developed that combine 
cancer immunotherapy with treatment modalities, such as radiotherapy, that reprogram the 
tumour microenvironment to increase treatment efficacies and improve clinical outcome. In 
various preclinical models radiotherapy was shown to enhance the efficacy of adoptive T cell 
therapy. Our group showed that in the RIP1-TAg5 mouse model of spontaneous insulinoma, 
the transfer of in vitro-activated tumour-specific T cells induces T cell infiltration and pro-
motes long-term survival only in combination with neoadjuvant local low dose irradiation 
(LDI). These treatment effects were mediated by iNOS+ macrophages. 
In this thesis, we investigated the mechanisms underlying the improved T cell infiltration and 
prolonged survival upon combination therapy with adoptive T cell transfer and local LDI. We 
demonstrate that combination therapy leads to a normalization of the aberrant tumour vas-
culature and endothelial activation, an increase in intratumoural macrophages, a reduction 
of intratumoural myeloid derived suppressor cells and, most importantly, to tumour regres-
sion. These findings suggest that this treatment inhibits tumour immune suppression but 
also facilitates immune effector cell infiltration through the normalization of the tumour 
vasculature, finally leading to tumour immune rejection. Inhibition of the inducible nitric 
oxide (NO) synthase (iNOS) revealed that these effects largely depend on its activity. Of note, 
the stimulation of human endothelial cells with low doses of the NO donor DETA NONOate 
activates the endothelial cells to upregulate adhesion molecules, indicating that in response 
to the combination therapy, iNOS-derived NO directly activates tumour endothelial cells, 
thereby promoting T cell infiltration and tumour immune rejection. 
Moreover, adoptive transfer of low dose irradiated peritoneal macrophages into unirradiat-
ed RIP1-TAg5 mice prior to adoptive T cell transfer resulted in effects corresponding to the 
combination treatment, which highlights the role of macrophages in this mechanism. Whole 
transcriptome analysis of the irradiated peritoneal macrophages revealed that LDI causes 
gene expression and functional changes in these cells. Specifically, LDI activated interferon 
signalling and induced the upregulation of interferon regulated genes. This effect is likely 
due to the detection of danger signals released from damaged cells, which primes macro-
phages and induces a shift in their polarization state. Signal transduction and amplification of 
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interferon responses is mediated by interferon regulatory factors like IRF7. These transcrip-
tion factors induce the expression of proinflammatory genes such as Nos2. Irf7 but also Nos2 
and various proinflammatory genes like tumour necrosis factor (Tnf) were upregulated in 
response to LDI. Since NO and TNF-α are mediators of endothelial activation, this finding 
represents the link between LDI and macrophage-mediated activation of the tumour endo-
thelium. 
In conclusion, the presented thesis demonstrates that macrophages with proinflammatory 
phenotypes are required for the activation of tumour endothelial cells, which in turn is criti-
cal for the infiltration of immune effector cells and, thereby, for tumour immune destruction. 
Therefore these findings are of great importance for future immunotherapeutic approaches 
in the treatment of cancer patients. 
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ZUSAMMENFASSUNG 
 
Die Erkennung maligne entarteter Zellen durch das Immunsystem löst spontane Immunant-
worten aus, um die entarteten Zellen zu eliminieren. Während der Krebsentstehung entwi-
ckeln die Tumorzellen jedoch Eigenschaften, die es ihnen ermöglichen sich der Erkennung 
durch das Immunsystem zu entziehen. Krebsimmuntherapien haben zum Ziel diese Prozesse 
umzukehren und das Immunsystem sowohl zu aktivieren als auch gegen Tumorzellen zu rich-
ten. Allerdings beeinträchtigen verschiedene Resistenzmechanismen der Tumorzellen die 
Wirkung vieler immuntherapeutischer Ansätze. Dabei stellen die funktionell und morpholo-
gisch veränderten Tumorgefäße ein Hindernis für die Einwanderung von Immuneffektorzel-
len dar. Die Funktion der Immuneffektorzellen wird zudem durch das immunsuppressive 
Tumormikromilieu eingeschränkt. Um dem entgegenzuwirken, werden effektivere therapeu-
tische Strategien entwickelt. Die Kombination von Immuntherapie mit Behandlungsmodali-
täten, die das Tumormikromilieu umprogrammieren, kann die Wirksamkeit der Behandlung 
optimieren und somit klinische Resultate verbessern. Verschiedene präklinische Tumormo-
delle zeigten eine erhöhte Wirksamkeit von adoptiven T-Zell Therapien durch Kombination 
mit Strahlentherapie. Unsere Gruppe hat in RIP1-TAg5 Mäusen, welche spontan Insulinome 
entwickeln, gezeigt, dass der Transfer von in vitro-aktivierten tumor-spezifischen T-Zellen 
sowohl die Einwanderung von T-Zellen in den Tumor induziert als auch das Langzeitüberle-
ben fördert, unter der Voraussetzung, dass der adoptive Transfer mit neoadjuvanter lokaler 
Niedrigdosisbestrahlung kombiniert wird. Weiterhin konnte gezeigt werden, dass die Effekte 
der Behandlung durch iNOS+ Makrophagen vermittelt werden. 
In der vorliegenden Arbeit haben wir die Mechanismen untersucht, die der erhöhten T-Zell 
Infiltration und dem verlängerten Überleben nach der Therapie mit lokaler Niedrigdosisbe-
strahlung und adoptivem T-Zell Transfer zu Grunde liegen. Wir zeigten, dass diese Kombina-
tionstherapie zu einer Normalisierung der abnormalen Tumorvaskulatur, sowie zur En-
dothelaktivierung führt. Außerdem wurde eine Vermehrung intratumoraler Makrophagen, 
eine Reduktion intratumoraler myeloider Suppressorzellen und der Rückgang etablierter 
Tumore beobachtet. Diese Untersuchungsergebnisse weisen darauf hin, dass diese Behand-
lung die Immunsuppression durch die Tumorzellen hemmt und gleichzeitig, mittels der Ge-
fäßnormalisierung, die Infiltration von Immuneffektorzellen in den Tumor fördert. Zusam-
men führt dies zur Abstoßung der Tumore durch das Immunsystem. Eine Hemmung der in-
duzierbaren Stickstoffmonoxid (NO) Synthase (iNOS) zeigte, dass die Behandlungseffekte 
entscheidend von deren Aktivität abhängen. Zudem führte die Stimulation humaner En-
dothelzellen mit niedrigen Konzentrationen des NO-Donors DETA NONOat zu einer erhöhten 
Expression von Adhäsionsmolekülen. Diese Ergebnisse deuten darauf hin, dass die Kombina-
tionstherapie zur erhöhten NO Produktion durch iNOS führt. NO aktiviert die Tumo-
rendothelzellen und fördert damit die Einwanderung von T-Zellen, was letztlich zur Absto-
ßung der Tumore führt.  
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Darüber hinaus wurden bei einem Transfer peritonealer Makrophagen aus Niedrigdosis be-
strahlten wildtyp Mäusen in unbestrahlte RIP1-TAg5 Mäuse, gefolgt von einem adoptiven T-
Zell Transfer, Effekte beobachtet, die denen nach Kombinationstherapie entsprechen, 
wodurch die Bedeutung der Makrophagen in dem Mechanismus verdeutlicht wird. Genom-
weite Transkriptomanalysen bestrahlter peritonealer Makrophagen ermöglichte die Unter-
suchung genetischer und funktioneller Veränderungen, die durch die Niedrigdosisbestrah-
lung hervorgerufen wurden. Demnach zeigen bestrahlte Makrophagen eine Aktivierung des 
Interferon Signalwegs, sowie eine erhöhte Expression interferon-regulierter Gene. Durch 
Strahlung geschädigte und gestresste Zellen setzen so genannte „danger“ Signalmoleküle 
frei, die von Makrophagen erkannt werden. Die Detektion dieser Moleküle führt zur Aktivie-
rung der Makrophagen und schließlich zu einer Interferonantwort. Transkriptionsfaktoren 
wie die Interferon regulatorischen Faktoren (IRF), darunter IRF7, spielen bei der Signaltrans-
duktion und -amplifikation von Interferonantworten eine zentrale Rolle. Diese Transkripti-
onsfaktoren induzieren unter anderem die Expression von Nos2. Die Expression von Irf7 so-
wie Nos2 und von verschiedenen profinflammatorischen Genen wie Tumor-Nekrose-Faktor-
α (Tnfa) waren nach Niedrigdosisbestrahlung in den peritonealen Zellen erhöht. Da NO und 
TNF-α die Endothelaktivierung auslösen können, stellt diese Beobachtung eine Verbindung 
zwischen Niedrigdosisbestrahlung und der Makrophagen-vermittelten Aktivierung des Tu-
morendothels dar.  
Diese Arbeit verdeutlicht die Rolle proinflammatorischer Makrophagen bei der Aktivierung 
von Tumorendothelzellen, welche für die Infiltration von Immuneffektorzellen und somit für 
die Tumorimmunabwehr essentiell ist. Die Erkenntnisse aus dieser Arbeit sind daher von 
großer Bedeutung für zukünftige immuntherapeutische Ansätze bei der Behandlung von 
Krebspatienten. 
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1. INTRODUCTION 
 
1.1. Cancer and the tumour microenvironment 
 
Carcinogenesis is a multistep and often multifactorial process during which initially normal 
cells acquire genetic and epigenetic alterations, such as somatic point mutations in tumour 
suppressor genes and oncogenes, which provide them with growth and survival advantages 
over their neighbouring cells. In cells undergoing malignant transformation multiple genetic 
alterations accumulate that provide characteristics necessary for the development of cancer. 
Six crucial capabilities of tumour cells have been described in 2000 by Hanahan and Wein-
berg, the so-called hallmarks of cancer: ‘sustained proliferative signalling’, ‘evading growth 
suppression’, ‘resisting cell death’, ‘enabling replicative immortality’, ‘inducing angiogenesis’ 
and ‘activating invasion and metastasis’ (Hanahan and Weinberg, 2000). In 2011 two emerg-
ing hallmarks (‘deregulating cellular energetics’, ‘avoiding immune destruction’) and two 
enabling characteristics (‘genome instability and mutation’, ‘tumour-promoting inflamma-
tion’) were added (Hanahan and Weinberg, 2011). For a long time, the focus of cancer re-
search has been laid on the cancer cells themselves, despite the fact that tumours are com-
plex tissues with malignant cells embedded in a connective tissue framework. The tumour 
stroma is a conjunction of extracellular matrix-producing stromal cells (cancer associated 
fibroblasts and fat cells), immune cells and the tumour vasculature (endothelial cells, peri-
cytes). The complex of cancer cells and tumour stroma is called the tumour microenviron-
ment. The importance of the tumour microenvironment in cancer is stressed by the observa-
tions that it affects tumour progression (Hanahan and Weinberg, 2011), disease prognosis 
(Chen et al., 2015) and treatment outcome (Klemm and Joyce, 2015). Although the tumour 
stroma can have protective properties by restricting tumour growth (Burnet, 1967; Ozdemir 
et al., 2014; Proia and Kuperwasser, 2005; Quail and Joyce, 2013), it has mainly been de-
scribed to promote tumour progression and impair treatment outcome (Hanahan and 
Coussens, 2012; Mueller and Fusenig, 2004). In the course of tumour development, the can-
cer cells modulate the tumour microenvironment to sustain tumour progression and to sup-
port invasion and metastasis. In addition, some tumours are capable of recruiting cells that 
support their growth, invasion and metastasis (Hanahan and Coussens, 2012). In the next 
chapters I will focus on two components of the tumour microenvironment that are relevant 
in the context of this study: 1) The immune cells and 2) the tumour vasculature.  
 
1.1.1. Tumour immunity 
Leukocyte infiltrates were found in tumours as early as 1863 by Rudolf Virchow, who hy-
pothesised that chronic inflammation leads to tumourigenesis (Balkwill and Mantovani, 
2001). In the following decades the study of the interactions between the immune system 
and cancer has become a rapidly advancing field and provided a better understanding of the 
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complex cellular and molecular mechanisms involved. The ever-increasing knowledge is ap-
plied in the discovery of new cancer therapies which aim to harness the immune system to 
fight cancer. 
1.1.1.1. T cells 
For many years, it was unclear and has been a matter of controversial debate whether trans-
formed cells can be recognised by the immune system. Since tumour cells are derived from 
self, it was argued that recognition is suppressed by the immune system’s regulatory mech-
anisms. The first indication of the existence of tumour-specific antigens was found in 1953 
by Foley et al., who showed that mice cured of carcinogen-induced cancers resisted re-
challenge with the same tumour cells (Foley, 1953). However, it took five decades until it 
was unequivocally shown that the immune system can recognise transformed cells and that 
it is able to elicit an antitumour immune response (Parish, 2003). It is now commonly ac-
cepted that antitumour immune responses involve cells of the innate immune system, as 
well as cells of the adaptive immune system (Gajewski et al., 2013). For instance, many tu-
mours have been shown to be infiltrated by T cells, which can be associated with a better 
clinical outcome, depending on the specific type of T cells. In ovarian, colorectal and breast 
cancer, as well as in renal cell carcinoma, melanoma and gastrointestinal stromal tumours, 
increased numbers of CD8+ cytotoxic T cells (CTLs) correlate with improved survival (Azimi et 
al., 2012; Galon et al., 2006; Kreike et al., 2007; Mahmoud et al., 2011; Rusakiewicz et al., 
2013; Zhang  et al., 2003) Interestingly, CTLs are not only present, they have been shown to 
be tumour-specific since they recognise tumour-specific antigens and mediate spontaneous 
antitumour immune responses (Bonertz et al., 2009; Nagorsen et al., 2003; Schmitz-
Winnenthal et al., 2005). In the case of CD4+ T cell infiltration, the data regarding its prog-
nostic value is controversial. Unlike CD8+ T cells, CD4+ T cells differentiate into diverse T 
helper (TH) cell lineages (TH1, TH2, TH17 and Treg) upon antigen recognition, depending on the 
cytokines they encounter during antigen exposure. TH1 cells are induced by interferon (IFN)-
γ and interleukin (IL)-12, while TH2 cells are induced by IL-4. Differentiation into TH17 cells 
and regulatory T cells (Treg) is triggered by transforming growth factor (TGF)-β with IL-6, IL-21 
and IL-23 or IL-2, respectively. Upon differentiation, the T helper cell lineages exert distinct 
functions which are mediated by cytokine secretion. TH1 cells secrete IFN-γ, IL-12, as well as 
tumour necrosis factor (TNF)-α, and thereby mediate macrophage activation and elimination 
of intracellular pathogens. TH2 cells, on the other hand, produce IL-4, IL-5, IL-10 and IL-13. 
They are involved in the clearance of extracellular parasites, antibody-mediated immunity 
and allergic diseases. They also counteract TH1 responses. TH17 cells are characterized by the 
production of IL-17. Treg express FoxP3 (Forkhead-Box-Protein P3), secrete TGF-β, IL-35 and 
IL-10 and regulate immune responses by maintaining immunogenic tolerance (Luckheeram 
et al., 2012). The diverse functions (pro- and anti-inflammatory) of the distinct CD4+ T cell 
subsets could explain the controversial study reports on the prognostic value of intra-
tumoural CD4+ T cells. High Treg infiltrates are associated with poor prognosis in many cancer 
types (breast (Bates et al., 2006), ovarian (Curiel et al., 2004), hepatocellular (Gao et al., 
2007), lung (Petersen et al., 2006), gastric (Perrone et al., 2008) and cervical cancer (Shah et 
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al., 2011)). On the other hand, a high CD8+/Treg ratio is associated with improved clinical out-
come (Shang et al., 2015), highlighting the essential role of CD8+ T cells in tumour elimina-
tion. 
1.1.1.2. Macrophages 
A major component of tumour-infiltrating leukocytes are macrophages (mononuclear phag-
ocytes), which can make up 50 % of the tumour mass (Kelly et al., 1988; Tu et al., 2014; Van 
Overmeire et al., 2014). The literature concerning the prognostic value of intratumoural 
macrophages is controversial. Some studies report a correlation between high numbers of 
intratumoural macrophages and good prognosis (colorectal (Forssell et al., 2007) gastric 
(Ohno et al., 2003) endometrial (Ohno et al., 2004) non-small cell lung cancer (Kawai et al., 
2008; Kim et al., 2008; Welsh et al., 2005), prostate (Shimura et al., 2000)), whereas others 
showed either no effect of macrophage infiltration on prognosis (breast cancer (Kelly et al., 
1988)) or revealed an association with reduced survival (gastric, urogenital and head and 
neck cancer (Zhang et al., 2012)). This controversy might be due to differences in the tumour 
entities and tumour stages but it might also be attributed to distinct functional states of in-
tratumoural macrophages. Macrophages display large functional diversity and high plasticity 
meaning they are able to quickly adapt to changes in their environment by altering their 
functional phenotype. Of note, these phenotypical changes are reversible. As part of the first 
line of the host defence, tissue-resident macrophages constantly monitor their surroundings 
for pathogen infection and tissue damage. They detect pathogen and danger associated mo-
lecular patterns (PAMPs, DAMPs), which are displayed by microorganisms or released by 
infected and damaged cells, through pattern recognition receptors (PRRs). Membrane-
bound PRRs like the Toll-like receptors (TLRs) allow for the detection of extracellular patho-
gens such as gram-negative bacteria by the stimulation of TLR4 with lipopolysaccharide (LPS) 
but also intracellular microbial ligands such as double- or single-stranded RNA which activate 
TLR3 or TLR7/8, respectively. Cytosolic PRRs such as the RIG-I like receptors (RLRs) and AIM2-
like receptors (ALRs) identify intracellular microbial ligands such as foreign nucleic acids. The 
RLRs, RIG-I (retinoic acid-inducible gene-I) and MDA5 (melanoma differentiation gene 5), 
detect cytosolic RNAs, while the ALRs, AIM2 (absent in melanoma 2) and IFI (interferon 
gamma inducible protein) 16, detect intracellular DNA. PRR engagement leads the activation 
of enzymatic cascades via adaptor molecules, such as MyD88 (myeloid differentiation prima-
ry response 88) and TIRAP (TIR-containing adaptor protein) for TLRs, as well as MAVS (mito-
chondrial antiviral signalling protein) for RLRs, subsequently leading to the activation of NF-
κB and/or other transcription factors such as interferon regulatory factors (IRFs), which in-
duce the transcription of IFNs (Akira et al., 2001; Kawai and Akira, 2010; Loo and Gale Jr, 
2011). Overall, PRR signalling activates macrophages to initiate an inflammatory response. 
Activated macrophages produce proinflammatory cytokines like TNF-α and IL-1 that subse-
quently activate endothelial cells in surrounding blood vessels leading to the upregulation of 
adhesion molecules and thereby promoting leukocyte extravasation. By secretion of chemo-
attractants (e.g. chemokines), activated macrophages can also recruit other immune cells to 
the site of inflammation, first neutrophils and monocytes, later, when the stimuli persist, 
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eosinophils and lymphocytes. Additional cytokines such as IL-6, IL-12, IFNs and co-
stimulatory molecules are also upregulated in response to the above mentioned stimuli. This 
leads to the activation of different types of immune cells and the initiation of an adaptive 
immune response. In addition, macrophages are capable of directly killing pathogens by 
phagocytosis and the production of reactive oxygen and nitrogen species (ROS, RNS). Phago-
cytosis, as well as other non-transcriptional responses, can also be initiated by PRR signalling 
(Brubaker et al., 2015). After the infection is cleared, the macrophages are involved in the 
resolution of the inflammatory response and in the repair of the damaged tissue. To prevent 
secondary necrosis, macrophages phagocytose debris and apoptotic cells, especially neutro-
phils, which are abundant in early wounds as they are involved in pathogen clearance. It has 
been suggested that phagocytosis of neutrophils induces the transition from pro- to anti-
inflammatory, reparative macrophages (Ortega-Gómez et al., 2013). By producing anti-
inflammatory cytokines, such as IL-10 and IL-1Ra (interleukin-1 receptor antagonist), macro-
phages attenuate the inflammatory response. In addition, macrophages, as well as other cell 
types, produce growth factors to initiate and support the repair of tissue damage which was 
induced during inflammation by oxidative stress and protease degradation. The vascular-
endothelial growth factor (VEGF), a proangiogenic molecule, promotes revascularization 
(angiogenesis), while TGF-β and platelet-derived growth factor (PDGF) induce fibroblasts to 
differentiate, proliferate and produce extracellular matrix components (Koh and DiPietro, 
2011; Mantovani et al., 2013; Murray and Wynn, 2011). This shows that macrophages are 
able to exert a variety of functions during immune responses, which can be very specific de-
pending on the immunological context.  
 
The functional diversity of macrophages is reflected in their phenotypes. In the literature, 
macrophage phenotypes are classified using the M1/M2 polarization model. In analogy to 
the TH nomenclature, M1 macrophages describe inflammatory subtypes which are involved 
in pathogen clearance, whereas M2 macrophages, which are involved in immune regulation 
and wound healing, are associated with anti-inflammatory characteristics. However, it was 
soon recognized that this classification is oversimplified and does not cover the full extent of 
different activation states that were reported in related literature (Gordon, 2003; Mosser, 
2003). A standardized classification system was recently recommended by a consortium of 
macrophage biologists, in which the activation stimulus is reflected in the nomenclature, i.e. 
macrophages stimulated with IFN-γ or IL-4 are termed M(IFN-γ) and M(IL-4), respectively 
(Murray et al., 2014). In the new model, the different macrophage phenotypes are assigned 
to a spectrum of activation states with macrophages activated by IFN-γ, IFN-γ + LPS or LPS at 
the “M1” end of the spectrum and macrophages stimulated with IL-4, immune complexes 
(Ic), IL-10, glucocorticoids (GC) or TGF-β at the “M2” end, representing the fluent transition 
between the different phenotypes.  
 
Classical activation of macrophages with IFN-γ alone or in combination with microbial stimuli 
(e.g. LPS) or cytokines induces the M(IFN-γ) or M(LPS + IFN-γ) phenotype, formerly known as 
the M1 phenotype. This phenotype is characterised by high expression of IL-12 and IL-23. 
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Through their production of the TH1 chemokines CCL5, CXCL9, CXCL10 and CXCL11 they re-
cruit T cells, as well as monocytes, eosinophils and dendritic cells to the site of infection. 
These macrophages show increased expression of co-stimulatory molecules and production 
of inflammatory cytokines such as IL-1β, TNF-α and IL-6 thereby orchestrating TH1 (and TH17) 
responses. They also produce effector molecules such as reactive oxygen and nitrogen in-
termediates to clear microorganisms (Martinez and Gordon, 2014; Murray et al., 2014). An 
additional M1 phenotype was observed after activation through microbial stimuli (such as 
LPS) that signal via PRRs. In contrast to the classical activation with TH1 -derived IFN-γ, this 
activation is T cell-independent and antigen non-specific. This ‘Innate activation’ leads to the 
production of ROS, nitric oxide (NO) and type I IFNs. Thus activated cells display increased 
phagocytic and endocytic properties and show enhanced expression of co-stimulatory mole-
cules (Gordon, 2003; Martinez et al., 2008). 
 
Activation stimuli that shift macrophages to the ‘M2’ end of the spectrum induce a diversity 
of phenotypes that can be discriminated based on their cytokine, chemokine and receptor 
expression, as well as their effector functions. M2-like macrophages have in common that 
they are involved in attenuating inflammatory processes, while promoting anti-parasite im-
munity and TH2 responses. They scavenge debris, promote tissue remodelling and repair, in 
addition to supporting angiogenesis. For their phagocytic activities, they express mannose 
and galactose receptors such as CD163 and CD206. Furthermore, some secrete large 
amounts of IL-10 and TGF-β. The specific phenotypes can be divided as follows: stimulation 
with the TH2 derived cytokine IL-4 (and IL-13), formally known as ‘alternative activation’, 
leads to the production of CCL17, CCL18, CCL24 and CCL22, which attract Treg and TH2 cells. 
Stimulation with IL-10 or TGF-β and GC induces the secretion of CCL24, CLCL10, CXCL11 and 
CCL5. This shows that the different phenotypes attract distinct cell populations. M(Ic) mac-
rophages express Nos2 (nitric oxide synthase 2) and produce high levels of IL-10 but low lev-
els of IL-12. They recruit eosinophils, Treg and TH2 cells via CCL1 and mediate TH2 polarization 
of CD4+ T cells. In comparison to other M2 phenotypes, the arginase pathway does not dom-
inate in M(Ic) macrophages (Murray et al., 2014).  
 
It has to be taken into account that this classification system is predominantly based on find-
ings from in vitro studies that do not reflect the situation in complex organ systems as in 
inflammation or cancer where multiple stimuli simultaneously act on macrophages making 
the identification of distinct phenotypes challenging. Furthermore, the transition from one 
phenotype to another can be fluent and can even result in macrophages with mixed M1-and 
M2-like characteristics (Martinez and Gordon, 2014). In malignant tumours, macrophages 
are usually classified as M2-like macrophages since they mostly harbour tumour promoting 
properties. But, as in other situations like infection, tumour associated macrophages (TAM) 
can have dual effects. Apart from promoting tumour growth, invasion and immunosuppres-
sion, they are capable of killing tumour cells and induce antitumour immune responses. 
Whether they support or inhibit tumour growth largely depends on the signals they receive 
from their surroundings, the tumour microenvironment, and can differ depending on the 
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location in the tumour but also on the type and stage of the tumour (Van Overmeire et al., 
2014). It has been shown that especially in early carcinogenesis TAMs play a role in anti-
tumour resistance (O’Sullivan et al., 2012). In established tumours, on the other hand, TAMs 
usually display M2-like phenotypes and harbour tumour promoting characteristics 
(Mantovani and Locati, 2013). 
1.1.1.3. Immunoediting 
Tumours are infiltrated by various immune cell subsets which are capable of eliciting anti-
tumour immune responses. Although immune cells are able to recognise and eliminate 
transformed cells, cancer is diagnosed in approximately 39 % of all people at some point 
throughout their life (Howlader, 1975-2013), indicating that antitumour immune responses 
are insufficient and cannot fully eradicate tumours. At the same time, distinct immune cell 
subsets have been shown to promote tumour development. This dichotomy is illustrated by 
the two apparently opposing hallmarks of cancer ‘avoiding immune destruction’ and ‘tu-
mour-promoting inflammation’ (Hanahan and Weinberg, 2011) and can be explained by the 
‘Immunoediting hypothesis’, which describes the switch from initial antitumour immune 
responses towards tumour-promoting environments in three major steps (Figure 1).  
The Elimination phase is based on the ‘cancer immunosurveillance theory’ proposed in the 
1960s by Burnett & Thomas. This theory states that one of the immune system’s functions is 
the elimination of potentially dangerous mutant cells to protect the organism from carcino-
genesis (Burnet, 1970; Burnet, 1957; Thomas, 1982). This theory was later supported by the 
observation that wildtype (wt) mice are less prone to spontaneous and carcinogen-induced 
tumours than immunodeficient mice (Kaplan et al., 1998; Shankaran et al., 2001) but also by 
further evidence generated over the last years (reviewed in (Corthay, 2014)). The processes 
involved in the elimination of transformed cells are very similar to those observed during 
pathogen clearance and require the cooperation of the innate and the adaptive immune 
response. In early tumours, malignant cells produce stress-induced ligands and danger sig-
nals, such as calreticulin, that can be detected by cells of the innate immune system via PRRs. 
Upon ligand-binding to the PRRs, innate immune cells become activated and induce a tu-
mour-specific immune response (Schreiber et al., 2011). These early tumour cells also ex-
press tumour antigens presented by major histocompatibility complex (MHC) class I mole-
cules, which are recognised by tumour-specific CD8+ T effector cells. Together, these effector 
cells produce proinflammatory cytokines, type I and type II IFNs and co-stimulatory mole-
cules (CD28, CD137, OX-40), that further activate adjacent immune cells. Effector molecules 
like granzymes and perforin secreted by T cells can directly kill transformed cells. Another 
mechanism of T cell-induced apoptosis of tumour cells acts via activation of death receptors 
on tumour cells. The process of antitumour immunity also involves macrophages that se-
crete proinflammatory cytokines (TNF-α, IL-1, IL-12) and produce ROS and RNS. The elimina-
tion phase ends when all transformed cells are eliminated and tumour formation is prevent-
ed. However, if the elimination is incomplete and few tumour cell clones survive elimination, 
the tumour progresses to the equilibrium phase. 
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Figure 1 The three phases of Cancer immunoediting. 
When intrinsic mechanisms have failed to suppress tumour formation, the immune system, as an extrinsic 
tumour suppressing mechanism, can eliminate tumours or prevent their outgrowth. During the first phase 
(Elimination/Cancer Immunosurveillance), innate and adaptive immune cells cooperate to eliminate developing 
tumours. Tumour cells that survive enter the equilibrium phase, where immune control is in balance with tu-
mour growth and tumours appear dormant. When the balance tips and the immune system can no longer 
control the tumour cells the cancer progresses to clinically detectable malignancies. This figure is taken from 
(Vesely et al., 2011). 
 
During the Equilibrium phase, the surviving tumour cells are under constant selection pres-
sure induced by the ongoing immune response. Tumour cells that undergo unrestricted cell 
division continuously accumulate genetic modifications fostered by their genetic instability. 
This process leads to the positive selection of mutations by which tumour cells develop re-
sistances to immune recognition and elimination. In this way the immune system selects 
tumour variants that show reduced immunogenicity thereby supporting tumour progression 
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(Darwinian selection). As long as the immune control mechanisms are able to balance tu-
mour growth promoting mechanisms, the tumour appears dormant; a condition which can 
last for decades (Aguirre-Ghiso, 2007). It was found that in mice that did not develop pro-
gressively growing tumours in response to a low dose of the chemical carcinogen MCA (3′-
methylcholanthrene), depletion of CD8+ T cells, IFN-γ or IL-12 led to the outgrowth of occult 
cancer cells (Koebel et al., 2007), demonstrating that the adaptive immune system controls 
tumour growth and maintains dormancy. 
The Escape phase is defined by a dominance of immunosuppressive stimuli over proinflam-
matory signals and is characterized by re-expanding tumour cells that are no longer con-
strained by the immune system. When the immune system fails to eliminate or control can-
cerous cells, tumours grow out, resulting in clinically detectable disease. Many different es-
cape mechanisms contribute to the evasion of tumour cells from the immune system: in re-
sponse to immune pressure, tumour cells display reduced immune recognition and in-
creased resistance to immune-cytotoxicity. However, the tumours also change the immune 
system through immunosuppression. The diverse escape mechanisms will be discussed in 
the next chapter. 
1.1.1.4. Tumour immune evasion 
Successful antitumour immune responses require the interaction between innate and adap-
tive immune components. Dendritic cells (DCs) and macrophages are activated in early tu-
mours by danger signals and cellular stress. DCs take up tumour-associated antigens (TAA), 
migrate to draining lymph nodes and present the TAAs to T cells, thereby priming and acti-
vating them. These activated, tumour-specific T cells migrate to the tumour site where they 
eliminate tumour cells. However, tumours develop multiple mechanisms to circumvent 
these processes. Selected mechanisms that are relevant for the understanding of this re-
search project are listed below. 
Evading immune recognition and elimination. Tumour cells have been shown to avoid 
recognition and elimination by CTLs (Khong and Restifo, 2002). Reduced recognition can be 
caused by loss or downregulation of TAAs, by acquired defects in the antigen processing and 
loading mechanism or by the downregulation of MHC class I molecules (Vinay et al., 2015). A 
reduced response to IFN-γ by tumour cells can also lead to impaired TAA presentation, since 
antigen processing and presentation is regulated by IFNs. Furthermore, a lack or reduction of 
co-stimulatory molecules can impair tumour cell detection by CTLs (Ahmad et al., 2004). Tu-
mour cells avoid elimination by increased resistance to immune-cytotoxicity mechanisms. 
Decreased expression of death receptors (Stewart and Abrams, 2008) or upregulation of 
anti-apoptotic molecules facilitates escape from T cell-mediated apoptosis (Vesely et al., 
2011). Another way of evading recognition and elimination by immune cells is the expression 
of “don’t eat me” signals, which inhibit phagocytosis of tumour cells by macrophages 
(Willingham et al., 2012). 
Immunosuppression. Immunosuppressive cytokines like TGF-β and IL-10 which are present 
in the tumour microenvironment impede with effector functions of antitumouricidal im-
mune cells (Khong and Restifo, 2002). TGF-β acts on innate and adaptive immune cells by 
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affecting the differentiation, maturation and activation of macrophages, DCs and effector T 
cells. In CTLs for example TGF-β inhibits the production of perforin, granzymes, Fas ligand 
and IFN-γ, thereby suppressing their cytotoxic effects on tumour cells (Thomas and 
Massagué, 2005). In CD4+ T cells, TGF-β was shown to promote TH2 phenotypes and inhibit 
TH1 T cell responses (Maeda and Shiraishi, 1996). On the other hand, TGF-β induces the dif-
ferentiation and proliferation of Treg (Tu et al., 2014). Upon stimulation with TGF-β, macro-
phages were shown to adopt an anti-inflammatory phenotype with reduced TLR signalling. 
These macrophages lose the ability to produce proinflammatory cytokines in response to 
danger signals (Tu et al., 2014). IL-10 also suppresses DC differentiation, maturation and 
function. It inhibits antigen presentation and IL-12 production, thereby suppressing IL-12-
induced TH1 responses and skewing the T cell response towards TH2 (Sato et al., 2011). Fur-
thermore, it activates macrophages towards an anti-inflammatory phenotype. Tumour cells 
can further inhibit T cell function by the upregulation of PD-L1 (Programmed cell death 1 
ligand), an immunoinhibitory molecule which limits T cell activity, and by the recruitment, as 
well as the activation, of immunosuppressive cells such as Treg or myeloid-derived suppressor 
cells (MDSCs). Treg mainly inhibit CTL functions by producing IL-10 and TGF-β, but also other 
mechanisms have been suggested such as Treg-induced effector cell death (Schmidt et al., 
2012; Zou, 2006). Tumours recruit MDSCs, induce their expansion and polarize TAMs to an 
M2-like phenotype by the secretion of various anti-inflammatory cytokines and effector 
molecules (e.g. TGF-β, IL-10, Indoleamine-pyrrole 2,3-dioxygenase (IDO), VEGF). MDSCs are 
immunosuppressive immature myeloid cells that form a heterogeneous population including 
granulocytic and monocytic cells. In addition, TAMs stimulated with anti-inflammatory cyto-
kines are also able to adopt immunosuppressive phenotypes. Those cells produce immuno-
suppressive cytokines, such as IL-10 and TGF-β, thereby further contributing to the genera-
tion of an immunosuppressive tumour microenvironment. Increased expression of arginase 
1 and IDO suppresses T cell function and proliferation (Munn et al., 1999; Rodriguez et al., 
2004). By secretion of VEGF, they promote angiogenesis and by degrading the extracellular 
matrix, they stimulate tumour cell migration and metastasis (Engblom et al., 2016). 
Prevention of effector cell infiltration. Another way for tumours to escape immune re-
sponses is by restricting the access of immune effector cells to the tumour site. Tumours can 
generate a non-permissive microenvironment by specific chemokine profiles that favour 
infiltration of immunosuppressive cells rather than immune effector cells (Viola et al., 2012) 
and by an abnormal vasculature with reduced expression of adhesion molecules.  
 
1.1.2. Tumour vasculature 
As part of the tumour microenvironment, the tumour vasculature also affects tumour pro-
gression and treatment efficacies (Jain, 2013; Tanigawa et al., 1997). Tumour cells require 
large amounts of nutrients and oxygen for their uncontrolled proliferation. During tumour 
growth, hypoxic areas develop due to a lack of blood vessels. In response, tumour cells and 
stromal cells produce high levels of VEGF and other growth factors such as basic fibroblast 
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growth factor (bFGF), placental growth factor (PGF), TGF-α and PDGF (Baeriswyl and 
Christofori, 2009; Nagy et al., 2009; Weis and Cheresh, 2011). These growth factors induce 
angiogenesis by stimulating endothelial cells to proliferate, migrate and form new branches 
(sprouting of existing vessels). In tumours, production of VEGF is chronically upregulated and 
aberrantly high since it is not only induced by hypoxia but also by oncogene activation 
(Carmeliet, 2005). Prolonged and imbalanced angiogenesis leads to the formation of abnor-
mal blood vessels, which are tortuous and leaky and display erratic diameters with largely 
dilated segments. The leakiness is caused by oversized pores in the vessel wall formed by 
gaps in the endothelial barrier, low or lacking pericyte coverage and abnormal basement 
membranes. This allows plasma and erythrocytes to escape into the stroma. Microhaemor-
rhages (intratumoural blood lakes), haemoconcentration (increased concentration of cellular 
components in the blood) and increased interstitial pressure are the consequence (Baluk et 
al., 2005). The haemoconcentration, high interstitial pressure (by compression of vessels) 
and the heterogeneous spatial distribution of tumour blood vessels leads to a slow and ir-
regular blood flow. The reduced tumour perfusion not only impairs access of immune effec-
tor cells to the tumour site (Jain, 2013) but also causes hypoxia and an accumulation of met-
abolic waste which leads to the release of more proangiogenic factors, creating a vicious 
cycle. Additionally, the endothelium of tumour blood vessels shows reduced expression of 
adhesion molecules in response to VEGF and bFGF stimulation (Griffioen et al., 1996). This 
further inhibits tumour immunity since the expression of adhesion molecules on endothelial 
cells is required for the extravasation of T cells and other immune effector cells. Reduced 
expression of adhesion molecules leads to reduced leukocyte-endothelium interaction, as 
well as reduced adherence and diapedesis (Dirkx et al., 2003; Schmidt et al., 1999; Wu et al., 
1992). Consequently, the tumour vasculature forms a physical barrier to effector cell infiltra-
tion. 
 
1.2. Cancer immunotherapy 
 
The idea to treat cancer by directing and activating the immune system against tumours is 
not novel. About 110 years ago William Coley made the first attempts at cancer immuno-
therapy (CIT) by injecting streptococci into cancer patients with inoperable sarcoma. In over 
10 % of the cases, this treatment led to tumour regression (Parish, 2003). Today, the injec-
tion of mycobacteria (Bacillus Calmette-Guerin) is still successfully being used for the treat-
ment of superficial bladder cancer (Baselli and Greenberg, 2000). A lot has happened since 
then, especially in the last decades where several immunotherapeutics have been approved 
by the FDA as cancer therapies. Among them the most prominent is the use of monoclonal 
antibodies (mAb) directed against the immune-checkpoint inhibitors CTLA-4 (cytotoxic T-
lymphocyte-associated protein 4) and PD-1 (programmed cell death protein 1), which en-
hance endogenous antitumour T cell responses (Pardoll, 2012; Sharma and Allison, 2015). 
With the advent of these two inhibitors, CIT established itself among the main pillars of can-
cer therapy: surgery, chemotherapy and radiotherapy. As described before, clinically detect-
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able tumours are the ones that escaped immune surveillance and are either not immuno-
genic or have developed a tumour microenvironment which is not permissive for immune 
effector cells. Cancer immunotherapy aims to reverse the process of immunoediting by an-
tagonizing immunosuppressive processes in the tumour microenvironment and potentiating 
antitumour immune responses. The various immunotherapeutic approaches include cyto-
kine and interferon therapies (high-dose IL-2, IFN-α), TLR agonists (Imiquimod, Resiquimod), 
therapeutic mAb that are directed against targets expressed on tumour cells (Rituximab, 
Trastuzumab) or against immune checkpoint molecules (Ipilimumab, Nivolumab), cancer 
vaccines (recombinant viruses, bacteria, vector-DNA, peptides, whole tumour vaccines or DC 
based vaccines) and cellular immunotherapies such as the adoptive transfer of tumour-
specific T cells (Kazemi et al., 2016). 
 
1.2.1. Adoptive T cell therapy 
The adoptive transfer of T cells is a cell-based immunotherapy. Here, tumour infiltrating 
lymphocytes (TILs) are isolated from resected tumours and expanded ex vivo in very high 
concentrations of IL-2. This generates a mixed population of T cells that can be tested in vitro 
for tumour recognition. Selection and further expansion of tumour-specific TIL cultures, is 
followed by reinjection into the patient (Rosenberg and Restifo, 2015; Rosenberg et al., 
2008) (Figure 2). Initial studies in metastatic melanoma showed that the adoptive transfer of 
naturally occurring TILs led to objective tumour regression in metastatic melanoma patients 
with an overall response rate of 34 %, including some cases with complete response 
(Rosenberg et al., 1994). This treatment was combined with systemic high dose IL-2, which 
supports TIL survival and promotes TIL expansion in vivo (Rosenberg  et al., 1988). The 
treatment effects observed in these early studies could be further improved by lym-
phodepletion prior to cell transfer. Nonmyeloablative chemotherapy with or without total 
body irradiation (2 or 12 Gy (gray) TBI) improved the persistence of transferred T cells from 
days to months, which can be explained by the fact that transferred cells do not need to 
compete with host T cells for homeostatic cytokines like IL-7 and IL-15 (Wu et al., 2012). Fur-
thermore, the duration and incidence of clinical responses was strongly increased. Combin-
ing nonmyeloablative chemotherapy and 12 Gy TBI as a preparative regimen for adoptive T 
cell transfer in metastatic melanoma showed the best response rate with complete and du-
rable responses of around 20 % (Dudley, 2011; Rosenberg et al., 2011). However, due to the 
high toxicity, this pre-conditioning regimen is not widely applied. 
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Figure 2 Adoptive T cell therapy using autologous TILs in melanoma. 
Following tumour excision, the melanoma sample is divided into fragments which are cultured individually with 
with 6000 IU/ml IL-2. After 2-3 weeks, the tumour cells are destroyed and the pure lymphocyte cultures can be 
assayed for tumour reactivity. Only cultures that display high antitumour reactivity are rapidly expanded for 3 
weeks producing up to 10
11
 lymphocytes that are reinjected into the lymphodepleted cancer patient. This fig-
ure is taken from (Rosenberg and Restifo, 2015). 
 
TIL isolation and expansion from other cancer entities, though successful, rarely resulted in 
specific antitumour immune responses, since the TILs did not display antigen-specificity and 
did not specifically lyse autologous tumour cells (Yannelli et al., 1996). In order to overcome 
this obstacle and achieve application across other tumour entities, T cells, isolated from pe-
ripheral blood of cancer patients, were genetically engineered to express T cell receptors 
(TCR), that display high affinity for tumour antigens, or to express chimeric antigen receptors 
(CARs). CARs are recombinant proteins spanning the cell membrane with an extracellular 
antibody-derived single variable fragment for antigen recognition and an intracellular TCR-
derived signalling chain optionally modified with co-stimulatory domains (Dai et al., 2016). 
CARs enable the recognition of a wide range of unprocessed antigens which is independent 
of MHC restriction. The antibody variable fragment detects 3-dimensional structures, includ-
ing proteins and carbohydrates. Genetic modification of T cells for adoptive transfer allowed 
the expansion of the treatment to tumour entities other than melanoma: clinical responses 
were observed in colorectal cancer, multiple myeloma and synovial sarcoma trials with ge-
netically engineered TCR T cells, but also in studies testing CAR therapies in leukaemia and 
lymphoma, as well as in colorectal and prostate cancer (Houot et al., 2015; Kershaw et al., 
2013; Rosenberg and Restifo, 2015). 
Overall, these clinical studies showed impressive responses in some patients, however com-
plete clinical responses were found only in a subset of patients after adoptive T cell therapy 
(Lanitis et al., 2015; Melero et al., 2014). The limited success of adoptive T cell transfers in 
non-responders could be explained by therapy-induced immunoediting, functional suppres-
sion or restricted access of the transferred cells to the tumour site. Therapy-induced immu-
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noediting leads to the development of resistances to the treatment by the tumours (Holzel 
et al., 2013). Functional suppression or restricted access to the tumour site is mediated by an 
immunosuppressive tumour microenvironment, which is able to inhibit the functionality of 
the transferred T cells by providing “off signals” to T cells, or to prevent T cell infiltration due 
to an immunosuppressive chemokine milieu and an abnormal tumour vasculature (Lanitis et 
al., 2015; Wu et al., 2012). 
 
1.3. Radiotherapy 
 
In cancerous diseases radiotherapy (RT) is one of the most common treatments. It is based 
on the fact that ionizing radiation induces cell death in rapidly dividing cells and therefore 
primarily targets cancer cells. Direct damage caused by ionization of cellular macromolecules 
such as DNA, proteins and lipids is rare. The indirect, but more common way of radiation-
induced damage is by hydrolysis (radiolysis) of water (and other molecules) which leads to 
the formation of reactive oxygen and nitrogen species. The free radicals oxidize structural 
and functional proteins leading to impaired integrity of the cell membrane and impaired 
function of enzymes and cell cycle regulators (Corre et al., 2010; Daly, 2012; Mishra, 2004). 
Oxidation of DNA can induce double- and single-strand breaks (Desouky et al., 2015). The 
DNA breaks are sensed within seconds after the damaging event and initiate the DNA-
damage response (DDR) pathway resulting either in apoptosis or enforced cell cycle arrest 
(Ciccia and Elledge, 2010). Cell cycle arrest provides time for damage assessment and DNA 
repair. p53 plays a major role in the DDR by directly activating DNA repair mechanisms and 
regulators of cell-cycle, apoptosis or senescence depending on the extent of DNA damage 
(Ciccia and Elledge, 2010; Lauber et al., 2012). Other mechanisms induced by DDR include 
the activation of immune surveillance (Ciccia and Elledge, 2010). The effects of RT are not 
restricted to tumour cells, however. Ionizing radiation also affects untransformed cells with-
in the tumour microenvironment, like the cells of the immune system. Although, RT has ini-
tially been described to be immunosuppressive (Cole, 1986; James et al., 1989; Wasserman 
et al., 1989), today many reports describe its immunostimulatory effects. One of the major 
side effects in RT-treated patients is radiation-induced inflammation (Schaue et al., 2015). 
Moreover, the local (bystander effect) and distant (abscopal effect) out of field effects were 
found to be mediated by systemic antitumour immune responses (Demaria et al., 2004; 
Ehlers and Fridman, 1973; Ohba et al., 1998; Wersall et al., 2006). 
 
As part of the RT-induced DDR pathway, NF-κB signalling is activated (Wu and Miyamoto, 
2007), which leads to the expression of proinflammatory cytokines such as IL-1α, IL-1β, IL-6 
and TNF-α (Weichselbaum et al., 2012). Tumour endothelial cells have been shown to re-
spond to these cytokines by upregulation of cell adhesion molecules in the context of RT. 
This in turn promotes leukocyte extravasation and infiltration of the tumour, leading to RT-
mediated antitumour immunity (Hallahan et al., 1996; Handschel et al., 1999). In addition, 
radiation/ROS-induced cellular stress leads to immunogenic cell death which is characterized 
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by the exposure of danger signals that activate innate immune cells such as macrophages in 
the tumour microenvironment (Barker et al., 2015). Danger signals associated with irradiat-
ed cells include calreticulin, a chaperone from the endoplasmic reticulum (ER), which is ex-
posed on the cell surface of dying cells due to ER stress; HMGB1 (high-mobility group box 1), 
a chromatin protein that is passively released from dying cells (Apetoh et al., 2007); HSP70 
(heat shock protein 70), a chaperone and member of the stress-induced heat shock proteins; 
as well as nucleotides such as adenosine and uridine triphosphate (ATP, UTP), which are ac-
tively secreted by dying cells (Bezu et al., 2015; Derer et al., 2016; Frey et al., 2014). The nu-
cleotides act as chemoattractants for antigen presenting cells (APCs)(Elliott et al., 2009) and 
induce proinflammatory responses like phagocytosis, chemotaxis and the production of IL-1β 
(Di Virgilio et al., 1996; Weisman et al., 1998). HMGB1 is detected by TLR4 and HSP70 binds 
to TLR2/4 on APCs, while both induce the upregulation of co-stimulatory molecules and the 
secretion of proinflammatory chemokines and cytokines (Asea, 2008; Klune et al., 2008). 
Binding of calreticulin to lipoprotein receptor-related protein 1 (LRP1) promotes antigen 
uptake by APCs (Bezu et al., 2015; Vandenberk et al., 2015). Together, the interplay of cyto-
kines, chemokines, and co-stimulatory molecules triggers an adaptive immune response. 
Since RT provides tumour antigen presentation and co-stimulatory signalling at the same 
time, it has been referred to as an in situ antitumour vaccine (Demaria et al., 2014). In RT-
induced immune responses, danger signals trigger IFN responses in APCs, which are charac-
terized by type I IFN production, thereby forming an additional link between the innate and 
adaptive immune response (Deng et al.). Besides type I, also type II IFNs are induced by RT 
and together they enhance the cytolytic activity of CTLs (Lim et al., 2014). Through IFNs and 
chemokines, such as CXCL9 and CXCL10, as well as CXCL16, RT further promotes the recruit-
ment of circulating immune cells as demonstrated by the enhanced T cell infiltration in vari-
ous tumour mouse models (Draghiciu et al., 2014; Lim et al., 2014; Lugade et al., 2005). In 
tumour cells, radiation enhances the presentation of TAAs by an increased protein transla-
tion rate and by increased surface expression of MHC class I molecules, induced by type I 
and type II IFNs, as well as TNF-α. Increased TAA presentation enables tumour cell recogni-
tion by CTLs (Barker et al., 2015; Kalbasi et al., 2013; Soukup and Wang, 2015). Upregulation 
of death receptors by tumour cells, in response to RT, further exposes them to T cell-
mediated elimination (Chakraborty et al., 2003; Chakraborty et al., 2004). 
 
In contrast to the large amount of data supporting proinflammatory effects of RT, some re-
ports show that RT can also promote immune suppression: increased numbers of intra-
tumoural Treg were observed in a preclinical setting after high doses of irradiation (Schaue et 
al., 2012), as well as in colorectal and oesophageal cancer after radio-chemotherapy (Schaue 
et al., 2008; Vacchelli et al., 2015), which might be caused by a higher radioresistance dis-
played by Treg. Following high dose irradiation also an increase in PD-L1 expression was ob-
served on immune cells isolated from tumours of a mouse transplantation model (Deng et 
al.). Conversely, irradiation doses <1 Gy are commonly described to be immunosuppressive. 
Due to their anti-inflammatory and analgesic effects, these very low irradiation doses are 
used for the treatment of inflammatory diseases (Leroi et al., 2016). These data suggest a 
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window of radiation doses between 2 and 14 Gy that induce immunostimulatory rather than 
immunosuppressive effects. 
 
As a consequence of the nonspecific working mechanism of RT, one also has to consider RT-
induced modulation of other tumour microenvironment components such as fibroblasts and 
vascular cells. The majority of studies analysing the influence of RT on the tumour microenvi-
ronment report effects in favour of tumour resistance and disease recurrence (Barker et al., 
2015). In several studies (Baker and Krochak, 1989; Langley et al., 1997; Paris et al., 2001), it 
was demonstrated that conventional radiotherapy doses (>8 Gy) do not only kill tumour cells, 
but also induce apoptosis in endothelial cells thereby reducing blood vessel density and ag-
gravating the hypoxic conditions within the tumour. Hypoxia leads to the activation of HIF-1 
(Hypoxia-inducible factor 1), which is followed by increased levels of SDF-1 (stromal cell-
derived factor 1; CXCL12) which cause the recruitment of CD11b+ myeloid cells and endothe-
lial progenitor cells to the tumour site. The CD11b+ myeloid cells can either differentiate into 
macrophages or into endothelial cells which, together with the endothelial progenitor cells, 
reconstruct the tumour vasculature by de novo vessel formation (vasculogenesis). It has 
been demonstrated that this process promotes tumour recurrence and leads to the devel-
opment of radioresistance (Brown, 2014; Leroi et al., 2016; Russell and Brown, 2013). On the 
other hand, RT has been described to cause vascular normalization. Increased secretion of 
the antiangiogenic factors CXCL9 and CXCL10, in response to RT, promotes the remodelling 
of vessels and induces the expression of VCAM-1 (Ganss et al., 2002), as well as the infiltra-
tion of T cells and tumour regression.  
 
RT has effects on the tumour microenvironment that can support but also inhibit tumour 
growth. Even though the heterogeneity of study procedures (applied RT doses and fractiona-
tion, as well as distinct tumour entities) complicates the interpretation of the study results, 
regarding RT-induced effects on the tumour microenvironment, the majority of studies re-
port that RT induces immunostimulatory environments. Still, RT is not suitable to induce 
long-lasting immune response and tumour elimination due to therapy-induced resistance 
and cancer immunoediting. It has therefore been suggested to combine RT with CIT to take 
advantage of the inhibitory, but to prevent the stimulatory effects of RT on tumour growth 
and recurrence (Burnette and Weichselbaum, 2013; Derer et al., 2016; Frey et al., 2014; 
Kalbasi et al., 2013; Kershaw et al., 2013; Kwilas et al., 2012; Soukup and Wang, 2015). 
 
1.4. RIP1-TAg5 tumour mouse model and previous work 
 
Cancer immunotherapy, in particular adoptive transfer of tumour-specific T cells, has been 
shown to result in complete clinical responses in only a minority of patients. Radiotherapy 
has been shown to induce an initial but not long-lasting immune response. Therefore, the 
combination of CIT and RT has been proposed to achieve enhanced clinical response rates. In 
our group, the RIP1-TAg5 (RT5) tumour mouse model was used to study the effects of local 
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low dose irradiation in combination with adoptive T cell transfer on tumour progression. The 
RT5 mouse model is a genetically engineered mouse model of spontaneous and autochtho-
nous tumour growth. It was selected, as it very closely reflects the clinical situation of human 
tumour growth. In contrast to transplantation models, which tend to grow fast, are usually 
not orthotopically implanted and do not undergo the multistep process of tumourigenesis 
with the simultaneous development of a tumour microenvironment, mouse models with 
spontaneous tumours more closely resemble slower growing human tumours. Moreover, 
the study of cancer therapies in transplantation models has been suspected to be one cause 
of the increase in clinical trial failures, as treatment is frequently initiated at low tumour 
burdens or even simultaneously with tumour inoculation (Budhu et al., 2014; Denayer et al., 
2014; Fox et al., 2011; Talmadge et al., 2007). This is in contrast to the clinical setting where, 
at the time of diagnosis and treatment decision, cancers are fully established or even metas-
tasized, representing a condition where they have already escaped immune surveillance 
mechanisms.  
 
RT5 mice are transgenic for the hybrid RIP1-TAg gene. Expression of the oncogene SV40TAg 
(Simian Virus 40 large T-Antigen) starts at 10-12 weeks of age controlled by the rat insulin 
promotor-1 (RIP1) and is therefore restricted to β-cells in pancreatic islets. The oncoprotein 
SV40TAg binds to and inhibits the tumour suppressors p53 and Rb (retinoblastoma protein), 
thereby inducing β-cell transformation and hyperproliferation (Ahuja et al., 2005; Casanovas 
et al., 2005). In the early hyperplastic islets, before tumour formation, VEGF-mediated angi-
ogenesis leads to the formation of angiogenic islets that progress to invasive, insulin-
producing pancreatic islet carcinomas by 18-20 weeks. These insulinomas are highly vascu-
larized and display an abnormal vasculature which is characterized by an increased vessel 
density and heterogeneity, as well as irregular vessel diameters and increased leakiness of 
the tumour vessels. The leaky vessels lead to the formation of intratumoural haemorrhages, 
which are caused by extravascular erythrocytes (Ryschich et al., 2002). Due to the delayed 
onset of oncogene expression, SV40TAg is not recognized as ‘self’ by the immune system 
(Adams et al., 1987). Consequently, its expression elicits an immune response against the 
transformed cells (Grant et al., 1990), which is followed by the infiltration of B cells, macro-
phages and TAg-specific cytotoxic (CD8+) and helper (CD4+) T cells into premalignant hyper-
plastic islets (Förster et al., 1995; Skowronski et al., 1990). However, antitumour immunity 
does not lead to complete elimination of the tumour causing some hyperplastic islets to 
progress to insulin-secreting carcinomas. If left untreated RT5 mice die from hypoglycaemia 
at 30-35 weeks of age (Ganss and Hanahan, 1998). Of note, in the fully established tumours 
no infiltrating lymphocytes were observed indicating that the tumours evade the immune 
system by restricting the access of T cells. It has been shown that the angiogenic switch cor-
relates with reduced leucocyte adhesion (Ryschich et al., 2002), suggesting that the aberrant 
vasculature forms a barrier for immune effector cell infiltration and thereby promotes a non-
permissive tumour microenvironment that allows these tumours to escape immune surveil-
lance. The RT5 mouse model is therefore a suitable model to study the interactions between 
the immune system and cancer progression, as well as cancer therapies that target the tu-
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mour microenvironment, besides the tumour cells, since it resembles human tumours with 
regard to the abnormal tumour vasculature and tumour immune escape.  
 
The RT5 model was previously used to study adoptive T cell transfers (Ganss et al., 2002; 
Garbi et al., 2004; Klug et al., 2013; Sektioglu et al., 2016). However, these studies showed 
that the transfer of in vitro-activated tumour-specific T cells alone is unable to reject estab-
lished tumours. Combined with irradiation or systemic application of CpG (cytosine-
phosphorothioate-guanine), a TLR9 agonist, the same treatment could overcome the tu-
mours’ resistance of immune elimination. In our group it was found that the combination of 
adoptive T cell transfer with local low dose irradiation led to a massive infiltration of T cells 
into the tumours and long-term survival. A dose of 2 Gy was identified as most beneficial, as 
it induced the highest intratumoural CTL/Treg ratio (Klug et al., 2013). Both, the T cell infiltra-
tion and the prolonged survival, were dependent on macrophages as their depletion attenu-
ated the treatment effects. This was further supported by macrophage transfer experiments, 
where peritoneal exudate cells from irradiated syngeneic wt mice were transferred into oth-
erwise untreated 24-week old RT5 mice. In combination with adoptive T cell transfer this 
also led to increased numbers of intratumoural CD11b+ cells and T cells. It was further shown 
that the treatment-induced T cell infiltration was dependent on the activity of the inducible 
nitric oxide synthase (iNOS), which was expressed by intratumoural CD11b+ cells (Klug et al., 
2013).  
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1.5. Aim of the study 
 
A major challenge in cancer immunology is the development of new strategies to overcome 
tumour immune evasion and therapeutic resistance, the two main factors which limit the 
efficacy of cancer immunotherapies (CIT). The combination of CIT with specific treatment 
modalities that alter the tumour suppressive environment offers a promising approach to 
address these challenges. Radiation therapy has been shown to enhance the effects of CIT 
(Burnette and Weichselbaum, 2013). In our group, low dose irradiation was therefore com-
bined with the adoptive transfer of tumour-specific T cells in the treatment of RT5 tumours. 
The resulting increase in tumour infiltration of T cells turned out to be dependent on the 
activity of iNOS and macrophages, but the precise mechanism of T cell infiltration and the 
exact role of the macrophages and iNOS remain unclear. 
 
This thesis aims to investigate the therapeutic effects of low dose irradiation and adoptive T 
cell transfer and to elucidate the underlying molecular mechanisms. 
 
In the first part, the effects of low dose irradiation (LDI) and adoptive T cell therapy on tu-
mour regression and the tumour microenvironment will be investigated. In order to identify 
the cellular and molecular mechanisms, which lead to the increased T cell infiltration after 
combination therapy, the status of the tumour vasculature will be evaluated and the intra-
tumoural myeloid cell populations will be characterized. Furthermore, the influence of mac-
rophage depletion on tumour regression and survival in untreated mice will be examined. 
 
The second part will present a detailed analysis of the mediators of the therapeutic effects, 
namely, the peritoneal cells that were used for the transfer experiments. First, the distribu-
tion of the transferred cells in RT5 mice will be assessed, to identify possible site-specific 
accumulations. Next, the effects of LDI on global gene expression alterations in peritoneal 
cells will be investigated to explore LDI-induced functional changes. Finally, a characteriza-
tion of the polarization state of peritoneal macrophages will provide information on the spe-
cific macrophage phenotype that is stimulated by LDI.  
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2. RESULTS 
 
Studies in spontaneous and xenograft tumour mouse models demonstrate that adoptive T 
cell therapy alone is insufficient to cause full rejection of established tumours, while the 
combination of T cell transfer with irradiation (Ganss et al., 2002; Klug et al., 2013) or im-
munostimulatory agents, such as CpG (Garbi et al., 2004; Sektioglu et al., 2016), can cure 
mice from established tumours. Combined local LDI (2 Gy) and CD8 T cell transfer was shown 
to induce massive T cell infiltration in solid tumours, resulting in long-term survival. These 
effects were dependent on macrophages and the activity of iNOS (Klug et al., 2013). Howev-
er, the precise mechanism underlying increased T cell infiltration is not fully understood. 
Therefore, the aim of this study is to investigate the molecular mechanisms that drive the 
tumour modifications, which lead to a more permissive environment for increased T cell in-
filtration. 
 
2.1. Tumour-suppressive effects of LDI and adoptive T cell transfer  
 
For a detailed investigation of the effects of LDI in combination with adoptive T cell transfer 
on the tumour microenvironment, RT5 mice were treated as previously described (Klug et al., 
2013). Briefly, 24-week old RT5 mice were irradiated locally with a single dose of 2 Gy. After 
10 days, they received 5x106 in vitro-activated tumour-specific CD8+ T cells from TCR trans-
genic (TCRtg) TCR8 mice. On day 17, the tumours were excised for analysis (Figure 3 A). iNOS 
was described to be necessary for T cell infiltration after combination therapy. To investigate 
how iNOS facilitates T cell infiltration and to assess the influence of iNOS on the tumour mi-
croenvironment, in connection with the treatment effects, the enzyme was selectively inhib-
ited with the iNOS inhibitor 1400w. Systemic iNOS inhibition was achieved by subcutaneous-
ly implanting an osmotic pump, containing 1400w, one day before local LDI. The inhibitor 
was slowly released from the pump over 2 weeks. Since the treatment effects of local LDI 
and adoptive T cell transfer were demonstrated to be dependent on macrophages, their role 
was examined more closely by performing macrophage transfer experiments. Here, unirra-
diated RT5 mice received thioglycolate-elicited peritoneal exudate cells (PECs) from 
C3HeB/Fe (C3H) wt mice that had been subjected to 2 Gy total body irradiation, instead of 
local LDI. On day 10, the RT5 mice also received tumour-specific CD8+ T cells and tumours 
were excised for analysis one week later (Figure 3 B). 
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Figure 3 Schematic representation of experimental design 
Tumour development in RT5 mice after adoptive T cell transfer of in vitro-activated TCRtg CD8
+
 T cells com-
bined either with local LDI (A) or with adoptive transfer of irradiated PECs (B). A) 2 Gy + CD8: the pancreatic 
region of 24-week old RT5 mice was irradiated locally with a single dose of 2 Gy, followed by adoptive transfer 
of 5x10
6
 CD8
+
 T cells 10 days later. On day 17, the tumours were excised and analysed. B) irr M + CD8: 24-week 
old RT5 mice received 5x10
6
 thioglycolate-elicited peritoneal cells from C3H wt mice, that were subjected to 
2 Gy TBI. This was followed by adoptive transfer of 5x10
6
 CD8
+
 T cells 6 days later. On day 17 the tumours were 
excised and analysed. (irradiated (irr) unirradiated (unirr)). 
 
2.1.1. Composition of peritoneal exudate cells  
Thioglycolate is widely used to elicit naïve tissue resident macrophages in the peritoneum 
for macrophage research (Gallily et al., 1964). More recent studies demonstrated that thio-
glycolate elicits multiple populations of leukocytes in the peritoneal cavity (Ghosn et al., 
2010; Schleicher et al., 2005). To ascertain the composition of the thioglycolate-elicited PECs 
from irradiated and unirradiated C3H wt mice, the cells were analysed by flow cytometry. 
The results show that 60-80 % of the freshly isolated PECs are macrophages (CD11bhi F4/80+). 
It further shows minute numbers of T cells in the exudate; less than 1 % of the PECs are posi-
tive for CD3+. Between 5.8 and 10.5 % of the cells are positive for CD11c, indicating the pres-
ence of dendritic cells. Also Gr-1+ cells were observed; 7 % in the PECs from unirradiated 
mice and 20.3 % in the PECs from irradiated mice (Figure 4). The results demonstrate that a 
high percentage of the freshly isolated PECs are macrophages, however it has to be taken 
into account that the contaminating cell populations also affect the studied processes. 
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Figure 4 Immune cell composition of PECs after in vivo irradiation 
Flow cytometric analysis of thioglycolate-elicited PECs from unirradiated C3H wt mice or C3H wt mice subjected 
to 2 Gy TBI. Shown are the percentages of macrophages (CD11b
hi 
F4/80
+
), CD11c
+
, Gr-1
+
 cells and T cells. Only 
single, viable cells were included in the analysis. Data shown as mean ± SEM (n=8 mice per group; two-tailed 
Mann-Whitney test).  
 
2.1.2. in vitro activation of TCRtg T cells  
For adoptive T cell transfer, splenocytes from TCRtg TCR8 mice were cultured with IL-2 and 
SV40TAg peptide for 72 hrs, to activate and expand the CD8+ T cells. 5x106 activated tumour-
specific T cells were subsequently injected into RT5 mice. The activation state of the T cells 
was confirmed by detection of IFN-γ production using flow cytometry. IFN-γ secretion was 
assessed in T cells stimulated with IL-2, SV40TAg peptide, or a combination of both. As a con-
trol, splenocytes were cultured in medium only. This experiment was carried out by L. Nögel 
and was published in his master thesis. Activation with IL-2 and the SV40TAg peptide or the 
peptide alone resulted in increased IFN-γ secretion by 50 % of the T cell population, while 
less than 10 % of the T cells showed an increased IFN-γ secretion upon stimulation with IL-2 
alone. IFN-γ secretion was not detected in unstimulated control T cells (Figure 5). These re-
sults indicate that the CD8+ T cells that were used for transfer into RT5 mice are highly acti-
vated. 
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Figure 5 Increased IFN-γ production by CD8
+
 T cells upon antigen-specific activation in vitro 
Splenocytes from TCR8 mice were activated in vitro with IL-2, SV40TAg peptide or IL-2 and SV40TAg peptide. 
Control cells were cultured in medium only. After 72 hrs in culture, IFN-γ secretion of CD8
+
 T cells was analysed 
by flow cytometry. Only single, viable, CD11c
-
, CD3
+
 cells were included in the analysis. A) Histogram showing 
the level of IFN-γ secretion by CD8
+
 T cells after stimulation. B) Quantification of IFN-γ
+
 T cells. Data shown as 
mean + SEM (n=2). The experiment was performed by L. Nögel, figure published in L. Nögel`s master thesis. 
 
2.1.3. The combination of LDI and adoptive T cell transfer leads to tumour immune rejec-
tion 
Local LDI combined with adoptive T cell transfer led to long-term survival in RT5 mice (Klug 
et al., 2013). This suggests that the treatment causes tumour regression. To test if the com-
bination therapy affects tumour development, RT5 tumours were excised and inspected 
macroscopically. Insulinomas from untreated RT5 mice appear dark red with a granular sur-
face. In contrast, tumours from RT5 mice treated with local LDI and CD8 T cell transfer, as 
well as the tumours treated with irradiated PECs and CD8 T cell transfer, are smaller in size 
and milky white with a smooth even surface (Figure 6 A). 
The dark red appearance of the untreated tumours is caused by haemorrhages resulting 
from leaky tumour blood vessels, a characteristic of an abnormal tumour vasculature (Jain, 
2013). Therefore, tumour haemorrhages are an indicator of an abnormal tumour vasculature. 
Relative quantification of non-haemorrhagic tumours between treated and untreated mice 
reveals a significant increase of non-haemorrhagic tumours in treated mice (Figure 6 B), sug-
gesting a normalization of the aberrant tumour vasculature after combination therapy. Tu-
mour diameters ranged between 1.0 and 2.8 mm in mice treated with local LDI or transfer of 
irradiated PECs combined with CD8 T cell transfer, displaying a more than 2-fold size reduc-
tion compared to tumour diameters of 1.7 to 8.3 mm in untreated RT5 mice. Interestingly, 
iNOS inhibition in mice treated with local LDI and tumour-specific T cells suppressed the 
treatment-specific effect on tumour size (Figure 6 C).  
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Figure 6 The impact of combined LDI and adoptive T cell transfer on tumour size and phenotype in RT5 mice 
A) Representative RT5 tumours from untreated mice, mice treated with local LDI (2 Gy) and CD8
+
 T cells or with 
irradiated PECs and CD8
+
 T cells. B) Percentage of non-haemorrhagic tumours in the different treatment groups. 
(n=3-4 mice per group). C) Tumour diameter before therapy (24-week old) or after therapy (27-week old) of 
untreated mice and of mice treated with local LDI (2 Gy) and CD8
+
 T cells, with irradiated PECs and CD8
+
 T cells 
or with local LDI (2 Gy), CD8
+
 T cells and 1400w (iNOS inhibitor) (n=2-11 tumours per group, with 2-3 mice per 
group). Data is shown as mean + SEM; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 (unpaired two-tailed 
Student's t-test) 
 
Taken together, these results confirm that the combination of local LDI and adoptive T cell 
transfer leads to the rejection of established tumours in an iNOS-dependent manner. They 
further suggest that the treatment leads to a normalization of the tumour vasculature. 
  
RESULTS 
 
| 24  
2.2. Vessel normalization after combination therapy 
2.2.1. Normalization of vessel morphology 
In the previous section, it was shown that local LDI and T cell transfer induce changes in the 
macroscopic characteristics of the tumour, suggesting a normalization of the tumour vascu-
lature after combination therapy. Abnormal tumour vasculature is characterised by uncon-
trolled and chaotic outgrowth of existing blood vessels, resulting in irregularly enlarged and 
tortuous blood vessels (Jain, 2013). To test whether the aberrant tumour vasculature of RT5 
mice is affected by the treatment with local LDI and tumour-specific CD8+ T cells, the tumour 
vessel morphology was analysed at a microscopic level. Tumour sections were stained for 
the endothelial cell marker CD31 and for SV40TAg, which labels tumour cells. Subsequently, 
the sections were evaluated by immunofluorescence (IF) microscopy. The IF microscopy im-
ages show that tumour vessels of untreated RT5 mice are enlarged and dilated. In contrast, 
the tumour vasculature of mice that received local LDI and CD8+ T cells, is characterized by 
smaller and less dilated vessels (Figure 7 A). Quantitative analysis of the tumour sections 
revealed that the average vessel size is significantly decreased after combination therapy, as 
is the total vessel area (Figure 7 B).  
Similar effects on the tumour vasculature were observed when adoptive T cell transfer was 
combined with the transfer of irradiated PECs instead of local LDI, as the average vessel size 
and total vessel area were significantly reduced. In mice in which iNOS activity was inhibited, 
the average vessel size remained unchanged after local LDI and CD8 T cell transfer. The total 
vessel area on the other hand was increased in comparison to mice with normal iNOS activi-
ty, but it was still lower than in the untreated group, suggesting that the changes in vessel 
morphology, induced by combination therapy, are not solely dependent on the activity of 
iNOS. 
 
2.2.2. Endothelial activation caused by combination therapy is dependent on iNOS  
In addition to abnormal morphological features, the aberrant tumour vasculature is further 
characterised by low expression levels of adhesion molecules thereby forming a barrier to 
lymphocyte infiltration (Griffioen, 2008). Normalization of aberrant tumour vasculature is 
accompanied by the activation of the endothelium, which is characterised by the upregula-
tion of adhesion molecules such as VCAM-1 (vascular cell adhesion protein 1) and ICAM-1 
(intercellular adhesion molecule 1)(Lanitis et al., 2015). 
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Figure 7 Normalized tumour vasculature after low dose irradiation combined with adoptive T cell transfer 
Morphological characteristics (average vessel size, total vessel area) of the tumour vasculature in untreated 
RT5 mice compared to mice treated with adoptive T cell transfer following local LDI or adoptive transfer of 
irradiated PECs. A) Representative IF microscopy images of RT5 tumours from untreated mice or mice treated 
with local LDI (2 Gy) and CD8
+
 T cells, showing blood vessels in red (anti-CD31, marking endothelial cells) and 
tumour cells in green (anti-SV40TAg). Scale bar, 50 µm. B) Quantitative analysis of the tumour vasculature: 
average vessel size and CD31
+
 area [mm
2
]/mm
2
 in RT5 mice treated with local LDI (2 Gy) and CD8
+
 T cells, with 
irradiated PECs and CD8
+
 T cells or with local LDI (2 Gy), CD8
+
 T cells and 1400w (iNOS inhibitor). Data shown as 
mean ± SEM; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 (n=5-9 tumours per group of 3-5 mice; two-
tailed Mann-Whitney test). 
 
To assess if the tumour endothelium of RT5 mice was activated after combination therapy, 
tumour sections were stained for CD31 and VCAM-1 and analysed for endothelial cells that 
expressed VCAM-1. Tumour vessels in untreated RT5 mice show no or very low levels of 
VCAM-1 expression (Figure 8 A). Conversely, in mice treated with local LDI and adoptive T 
cell transfer, VCAM-1 expression on endothelial cells is strongly increased. An average of 
47.1 % (range 17 to 73 %) of the CD31+ area was positive for VCAM-1. When treated with 
irradiated PECs instead of local LDI, the level of colocalized VCAM-1 and CD31 expression in 
RT5 tumours even further increased to 81 % on average (range 65 to 92 %)(Figure 8 B). This 
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demonstrates that the transfer of irradiated PECs in combination with tumour-specific T cells 
has a greater effect on endothelial activation than local LDI and CD8+ T cells. Interestingly, 
iNOS inhibition almost completely abrogates the effect of combination therapy on endothe-
lial activation. VCAM-1 expression was greatly reduced with an average of 15 % colocalized 
area (Figure 8). Yet, the levels are not as low as in untreated tumours, suggesting that iNOS 
activity is not the only factor responsible for endothelial activity after combination therapy. 
 
Figure 8 Endothelial activation in RT5 tumours after combination therapy 
Adhesion molecule (VCAM-1) expression on tumour endothelial cells in untreated RT5 tumours compared to 
tumours after treatment with local LDI or adoptive transfer of irradiated PECs prior to adoptive T cell transfer, 
or local LDI combined with adoptive T cell transfer under iNOS inhibition. A) Representative IF images of RT5 
tumour sections from untreated mice, mice treated with local LDI (2 Gy) and CD8
+
 T cells, with irradiated PECs 
and CD8
+
 T cells or with local LDI (2 Gy), CD8
+
 T cells and 1400w (iNOS inhibitor), were immunolablelled with 
antibodies against CD31 (red) marking endothelial cells and VCAM-1 (green). The colocalized areas (yellow) 
show activated endothelium. Scale bar, 50 µm. B) Quantitative analysis of the VCAM-1
+
/CD31
+
 colocalized area 
for the indicated treatment groups. Data shown as mean ± SEM; *** p<0.001; **** p<0.0001 (n=9-13 tumours 
of 2 mice per group; two-tailed Mann-Whitney test).  
 
Taken together, these results demonstrate that combination therapy leads to vessel normal-
ization in RT5 tumours which is partly dependent on the enzymatic activity of iNOS. Since 
iNOS produces NO it can be hypothesized that NO might be one of the factors responsible 
for endothelial activation in this setting. 
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2.2.3. Direct endothelial activation by nitric oxide 
In RT5 tumours we could show that the upregulation of adhesion molecules on endothelial 
cells is partly dependent on the activity of iNOS. However its product NO has been predomi-
nantly described to inhibit cytokine-induced expression of adhesion molecules. Khan et al. 
showed that the NO donor DETA-NO (=DETA NONOate) decreases ICAM-1 and VCAM-1 lev-
els on HUVECs (human umbilical vein endothelial cells) at concentrations between 50 µM to 
1000 µM. Of note, 10 µM induced a slight but not significant increase of VCAM-1 and ICAM-1 
levels and lower concentrations of DETA-NO were not tested (Khan et al., 1996). We hypoth-
esized that NO concentrations below 10 µM might have a different effect on endothelial 
cells. To investigate the effects of NO on endothelial activation, the expression of distinct 
adhesion molecules was assessed on HUVECs treated with DETA NONOate (in cooperation 
with I. Sektioglu). Therefore, HUVECs were incubated for 18 hrs with different concentra-
tions (0.098 µM to 50 µM) of DETA NONOate and subsequently analysed by flow cytometry. 
Levels of VCAM-1 and ICAM-1 increased at a concentration of 0.195 µM, showing a peak at 
3.125 µM. Increasing levels of E-selectin expression were observed at 0.781 µM of DETA 
NONOate, reaching a peak at 3.125 µM. Higher concentrations than 3.125 µM did not fur-
ther increase the expression levels of the adhesion molecules. Interestingly, higher doses 
seemed to block adhesion molecule expression completely, as MFIs for VCAM-1, ICAM-1 and 
E-selecting were as low as in untreated HUVECs (Figure 9 A).  
 
Figure 9 Dose-dependent induction of adhesion molecules on HUVECs stimulated with NO 
Surface expression of adhesion molecules on HUVECs treated with the NO donor, DETA NONOate, with or 
without TNF-α. HUVECs were analysed by flow cytometry after 18 hrs culture with the indicated concentrations 
of A) DETA NONOate alone or B) DETA NONOate with 10 ng/ml TNF-α. Quantification of VCAM-1, ICAM-1 and 
E-Selectin surface expression (mean fluorescent intensity (MFI)) in CD31
+
 single, viable HUVECs. Data is shown 
as mean + SEM of triplicate wells from two independent experiments. The experiment was performed in coop-
eration with I. Sektioglu. 
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A well described inducer of adhesion molecules on vascular endothelial cells is TNF-α (Bernot 
et al., 2005; Dhawan et al., 1997; Mattila et al., 1992; Xia et al., 1998). To test whether TNF-α 
and low concentrations of NO can synergistically enhance the expression levels of the se-
lected adhesion molecules, HUVECs were treated with 10 ng/ml TNF-α and increasing con-
centrations of DETA NONOate (0.098 µM to 50 µM). TNF-α-induced expression levels of E-
selectin and to a lesser extent ICAM-1 are further increased by low concentrations of DETA 
NONOate. Furthermore, we observed that concentrations of DETA NONOate, higher than 
3.125 µM supress TNF-α induced expression of the three adhesion molecules (Figure 9 B). 
Together these findings show that low concentrations of NO are able to induce expression of 
the adhesion molecules VCAM-1, ICAM-1, and E-selectin in HUVECs, while high concentra-
tions lead to a reduction of their expression, even when induced by TNF-α. 
 
2.3. iNOS dependent macrophage infiltration induced by combination therapy 
 
Previous work has demonstrated that local LDI in combination with CD8 T cell transfer leads 
to the infiltration of T cells into RT5 tumours, as well as to the infiltration of CD11b+ cells, 
which are thought to migrate from the periphery into tumour tissue (Klug et al., 2013). How-
ever, the infiltration of macrophages can be reduced in large tumours (Zhang et al., 1997), 
suggesting that the tumour size can affect the infiltration of macrophages. To analyse 
whether infiltration of CD11b+ cells is reduced in larger tumours, the number of intra-
tumoural CD11b+ cells was analysed with respect to the size of the corresponding tumour. In 
untreated RT5 mice, as well as in RT5 mice treated with local LDI and tumour-specific T cells, 
the number of intratumoural CD11b+ cells negatively correlates with tumour size (Figure 10 
A). Of note, mice receiving the combination therapy depict a higher absolute number of in-
tratumoural CD11b+ cells, irrespective of the cell/size ratio, confirming that local LDI com-
bined with tumour-specific CD8 T cell transfer leads to the infiltration of CD11b+ cells regard-
less of the tumour size. 
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Figure 10 Combination therapy affects myeloid cell populations in insulinomas 
Intratumoural myeloid cell populations (CD11b
+
, CD68
+
, Gr-1
+
 cells) in untreated RT5 mice or after treatment 
with local LDI and adoptive T cell transfer with or without iNOS inhibition. A) Number of CD11b
+
 cells/0.5mm
2
 
in RT5 tumours of untreated mice or mice treated with local LDI (2 Gy) and CD8
+
 T cells in relation to the total 
tumour area (n=12-16 tumours per group with 2 mice per group; Spearman´s rank correlation coefficient test). 
B, C) IF analysis of myeloid cell markers in RT5 tumours from untreated mice, mice treated with local LDI (2 Gy) 
and CD8
+
 T cells or local LDI (2 Gy), CD8
+
 T cells and 1400w. B) Representative IF microscopy images of RT5 
tumour sections from the indicated treatment groups, stained for CD11b (green), CD68 (green) or Gr-1 (red). 
Outlined are tumour areas. Scale bar, 50 µm. C) Quantitative analysis of IF microscopy images: number of 
CD11b
+
, CD68
+
 or Gr-1
+
 cells per 0.5mm
2
 for the indicated treatment groups. Data shown as mean ± SEM; *** 
p<0.001; **** p<0.0001 (n=8-16 tumours of 2 mice per group; two-tailed Mann-Whitney test). 
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Since CD11b has been shown to be expressed on various myeloid cells, including MDSCs and 
granulocytes (Murdoch et al., 2008), the intratumoural myeloid cell population was further 
characterised by IF microscopy analysis. RT5 tumour sections were stained for CD11b, as 
well as for CD68, a macrophage marker (Murray and Wynn, 2011), and Gr-1 which is ex-
pressed on MDSCs (Youn and Gabrilovich, 2010) and granulocytes (Murdoch et al., 2008). 
Here we show that in response to local LDI and CD8 T cell transfer, the tumour infiltrating 
myeloid cell population in RT5 tumours consists mainly of macrophages. Representative IF 
microscopy images (Figure 10 B) and quantitative analysis (Figure 10 C) show, that combina-
tion therapy leads to an increased number of CD11b+ and CD68+ cells and a decrease in Gr-1+ 
cells in the tumour tissue. Of note, the inhibition of iNOS suppresses macrophage infiltration. 
Mice treated with 1400w in addition to local LDI and CD8+ T cells show reduced numbers of 
CD11b+ and CD68+ cells in the tumour, the number of Gr-1+ cells, on the other hand, was 
higher under iNOS inhibition. These findings demonstrate that macrophage accumulation in 
insulinomas after local LDI and CD8 T cell transfer is dependent on the activity of iNOS. 
 
2.4. Macrophages are essential for the effects of local LDI and T cell transfer 
2.4.1. Clodrosome depletes intratumoural macrophages 
Tumour associated macrophages are known to promote tumour progression (Noy and 
Pollard, 2014). The observed increase of intratumoural macrophages after combination 
therapy led to the question whether these macrophages influenced the treatment outcome. 
To study the function of macrophages in RT5 tumours, they were depleted by intraperitone-
al (i.p.) injections of clodronate disodium salt encapsulated in liposomes (Clodrosome; 
5 mg/ml). These liposomes are recognised and taken up by macrophages. The toxic clodro-
nate is released into the macrophages’ cytosol causing their death. Flow cytometric analysis 
of RT5 tumours and pancreata revealed a considerably reduced number of macrophages 
(CD11bhi F4/80+ cells) in pancreatic (3-fold decrease) and tumour tissues (6-fold decrease) of 
mice treated with Clodrosome over 3 weeks compared to untreated mice (Figure 11). The 
dot plots show that not only CD11bhi F4/80+ cells were considerably reduced, but all CD11b+ 
and all F4/80+ cells.  
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Figure 11 Macrophage depletion in tumour and pancreatic tissue following Clodrosome treatment 
Flow cytometric analysis of tumours and pancreata from untreated RT5 mice or after a 3 week Clodrosome 
treatment (100 µl of 5 mg/ml i.p injections every 5 days, with an initial injection of 200 µl). 
A) Representative dot plots showing intratumoural macrophages (CD11b
hi 
F4/80
+
) in untreated or Clodrosome-
treated mice. B) Quantitative analysis: results presented are % CD11b
hi 
F4/80
+
 of viable, single, CD45
+
 cells in 
tumour or pancreatic tissue of untreated or Clodrosome treated mice. Data shown as mean + SEM (from 2 
independent experiments; n=2-5 mice per group). 
 
2.4.2. Macrophage depletion affects survival or tumour rejection only after combination 
therapy  
After macrophage depletion, RT5 tumours exhibit a similar phenotype compared to tumours 
from untreated mice, characterised by a dark red appearance and a tumour size that is com-
parable to untreated control tumours (Figure 12 A). Based on cumulative data, the percent-
age of non-haemorrhagic tumours is only marginally higher (5 % compared to 0 %) and the 
size only slightly decreased (3.3 mm compared to 4.3 mm) (Figure 12 B, C). Furthermore, 
depletion of macrophages in RT5 mice that were otherwise untreated had no beneficial or 
detrimental effect on survival (Figure 12 D). These results indicate that the depletion of mac-
rophages in untreated mice does not affect tumour rejection, vascular normalization or im-
prove their survival. It further shows that Clodrosome is not systemically toxic since the sur-
vival of the RT5 mice is not impaired by Clodrosome alone. 
As has been shown before (Klug et al., 2013; Seibel, 2010), depletion of macrophages in 
treated RT5 mice significantly attenuates their survival. Mice treated with Clodrosome in 
addition to 2 Gy local LDI and repeated CD8 T cell transfers showed a median survival of 40 
weeks. In comparison, mice that received Encapsome (empty liposomes) depicted long-term 
survival, showing that prolonged survival in response to combination therapy is impaired by 
macrophage depletion (Figure 12 D). Furthermore, macrophage depletion by Clodrosome 
treatment was previously shown to impair T cell infiltration into RT5 tumours (Klug et al., 
2013). Overall, these results demonstrate that macrophages are required for the treatment 
effects of combination therapy (Klug et al., 2013). 
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Figure 12 Effects of macrophage depletion on tumour rejection and survival 
A, B, C) Haemorrhagic phenotype and size of RT5 tumours from untreated mice, mice treated with LDI (2 Gy) 
and CD8
+
 T cells or mice treated with Clodrosome. A) Representative images of RT5 tumours B) Percentage of 
non-haemorrhagic tumours in the different treatment groups (n=3-8 mice per group). C) Tumour diameter in 
the different treatment groups (n=5-15 tumours per group with 3-8 mice). Data is shown as mean + SEM; * 
p<0.05; *** p<0.001; **** p<0.0001 (unpaired two-tailed t-test) D) Survival of RT5 mice after macrophage 
depletion: 24-week old RT5 mice were treated with a single dose of local LDI (2 Gy) combined with CD8 T cell 
transfers starting on day 10 (weekly during the first 5 weeks, then biweekly). In addition, they received clodro-
nate loaded or empty liposomes (Clodrosome/Encapsome) every 5 days, starting one week before irradiation. 
Control mice were untreated or received Clodrosome. ** p<0.01 for survival in the 2 Gy + CD8 + Encapsome 
group compared to the untreated or the 2 Gy + CD8 + Clodrosome group (n=4-6 mice per group; Mantel-Cox 
test). Experiments were performed together with F. Klug. 
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2.5. More macrophages but fewer MDSCs infiltrate RT5 tumours after transfer of 
irradiated PECs 
 
As demonstrated in chapter 2.3, combination treatment of RT5 mice leads to the infiltration 
of macrophages but not MDSCs into tumour tissue (Figure 10 B, C). Klug et al. further 
showed that the number of intratumoural CD11b+ cells is increased after transfer of irradiat-
ed PECs when combined with CD8 T cell transfer (Klug et al., 2013). 
To ascertain the identity of these CD11b+ myeloid cells, tumour sections of RT5 mice that 
received no, irradiated or unirradiated PECs prior to a CD8 T cell transfer were stained for 
F4/80 or Gr-1 (Figure 13). After the transfer of irradiated PECs and CD8+ T cells, the number 
of F4/80+ cells in RT5 tumours was increased indicating an increased number of intra-
tumoural macrophages. This effect could not be observed in tumours of mice that received 
no or unirradiated PECs in combination with T cell transfer. Notably, only few Gr-1+ cells 
were found in RT5 tumours after transfer of irradiated PECs, but they were abundant when 
the mice only received CD8+ T cells or unirradiated PECs and CD8+ T cells. These findings im-
ply that the transfer of irradiated PECs in combination with CD8+ T cells leads to an increase 
in macrophages and a reduction of MDSCs in the tumour tissue. 
 
 
Figure 13 The impact of adoptively transferred irradiated PECs on myeloid cell infiltration into RT5 tumours 
Intratumoural myeloid cell populations in RT5 mice after adoptive transfer of PECs from unirradiated or irradi-
ated wt mice combined with adoptive T cell transfer. IF microscopy images of RT5 tumours from mice that 
received no, irradiated (irr) or unirradiated (unirr) PECs and CD8
+
 T cells, showing macrophages (F4/80
+
) or 
MDSCs/Granulocytes (Gr-1
+
) in red and nuclei in blue. Outlined are tumour areas (T). Scale bar, 50 µm. 
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2.6. Transferred macrophages infiltrate RT5 tumours 
 
In the next step, we wanted to identify the origin of the macrophages observed after the 
transfer of irradiated PECs and CD8+ T cells in RT5 tumours. The intratumoural macrophages 
either stem from the wt donor mice or they originate from the host and are recruited into 
the tumour tissue. To ascertain the source of the intratumoural macrophages, PECs were 
labelled with PKH26 before they were transferred into tumour bearing RT5 mice. The estab-
lishment of the staining protocol was performed by L. Nögel in the course of his master the-
sis and is published therein. Briefly, after isolating the thioglycolate-elicited PECs from irradi-
ated (2 Gy TBI) or unirradiated C3H wt mice, they were labelled ex vivo with micro-
aggregates of PKH26. These aggregates are selectively taken up by phagocytes. 5x106 la-
belled cells were then transferred into otherwise untreated, 24-week old RT5 mice. On day 
10, some of the mice received CD8+ T cells. On day 10 and on day 17 after the PEC transfer, 
tumours and additional organs (lung, pancreas, tumour, peritoneum and spleen) were ana-
lysed by flow cytometry to study the visceral distribution of PECs after transfer in RT5 mice.  
The analysis revealed that the transferred PECs do migrate into RT5 tumours, as PKH26+ cells 
were detectable in tumour tissue on day 10, as well as on day 17 after the transfer (Figure 14 
A). In the lung, tumour and spleen, more PKH26+ cells were detected on day 10 in mice that 
received irradiated PECs compared to mice that received unirradiated PECs (lung: 0.106 % vs. 
0.050 %; tumour 0.010 % vs. 0.003 %; spleen 0.216 % vs. 0.126 %). On day 17 however, fewer 
PKH26+ cells were found in these organs after transfer of irradiated cells when combined 
with CD8 T cell transfer (lung: 0.022 % vs. 0.046 %; tumour 0.001 % vs. 0.018 %; spleen 
0.020 % vs. 0.049 %). Without the transfer of CD8+ T cells, the percentages of PKH26+ cells 
were also lower after transfer of irradiated cells but only in the tumour and spleen (tumour 
0.002 % vs. 0.008 %; spleen 0.103 % vs. 0.220 %). On day 10, the percentages of PKH26+ cells 
in the pancreas and peritoneum do not differ between the two treatment groups. For the 
pancreatic tissue the same observation was made on day 17. In the peritoneum, the number 
of PKH26+ cells in mice treated with irradiated PECs was reduced (0.053 vs. 0.081 %), com-
pared to unirradiated PECs. However, an increased number (0.114 %) of PKH26+ cells were 
detected in mice that received CD8+ T cells in addition to irradiated macrophages (vs. 
0.072 % in the unirr PEC+TC group) (Figure 14 B). The differences between the treatment 
groups are not consistent over time, indicating that LDI does not affect the distribution of 
PKH26+ cells in RT5 mice. Furthermore, the numbers of intratumoural PKH26+ cells are very 
low. Therefore, the transfer of irradiated PECs does not contribute greatly to the massive 
accumulation of macrophages in tumour tissue after the combination of irradiated PECs and 
CD8+ T cells. However, the results do show that a small fraction of irradiated PECs infiltrate 
the tumour tissue, suggesting that irradiated PECs affect macrophage accumulation by alter-
native mechanisms.  
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Figure 14 Distribution and tumour infiltration of transferred PECs in RT5 mice 
24-week old RT5 mice received 5x10
6
 PKH26 labelled PECs from total body irradiated (2 Gy) or unirradiated 
C3H wt mice. 7 days later (d10) mice in the indicated groups received TCRtg CD8
+
 T cells. Flow cytometric anal-
ysis was performed on day 10 (left) and day 17 (right). A) Representative dot plots showing viable PKH26
+
 cells 
in RT5 tumours after transfer with unlabelled or labelled PECs. B) Percentage of PKH26
+
 cells in the lung, pan-
creas, tumour, peritoneum or spleen of RT5 mice after transfer of unirradiated or irradiated PECs with or with-
out T cell transfer (TC). Results presented are % PKH26
+
 of single, viable cells as means + SEM (n=2-4 mice per 
group, from 2 independent experiments). The experiments were performed by L. Nögel and N. Bender. 
 
2.7. Low dose irradiation causes transcriptomic changes in PECs  
2.7.1. Whole transcriptome analysis of peritoneal macrophages reveals effects of LDI on 
gene expression 
Macrophages can be considered as a crucial component in the mechanisms underlying the 
effects of the combination therapy, demonstrated by the fact that macrophage depletion 
supressed these effects. This is further supported by the transfer of peritoneal cells from 
irradiated wt donor mice into unirradiated RT5 mice combined with a T cell transfer which 
has equivalent effects on vascular normalization, T cell and macrophage infiltration as the 
application of the combination therapy. Since no difference in the relative number of intra-
tumoural PKH26+ cells could be observed after transfer of irradiated and unirradiated cells, 
we hypothesized that the treatment effects are likely due to functional changes induced by 
low dose irradiation. 
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To investigate LDI-induced global gene expression changes, whole transcriptome analysis 
(RNA sequencing) of PECs from low dose irradiated as well as from unirradiated control mice 
was performed. PECs were either irradiated in vivo or ex vivo, to examine whether LDI either 
directly affects the gene expression profile in macrophages or indirectly causes changes in 
macrophages through damaged and apoptotic tissue cells. For in vivo irradiation, C3H wt 
mice were subjected to 2 Gy TBI on day 0, followed by thioglycolate injection on the next day. 
72 hrs later, PECs were collected by peritoneal lavage for RNA isolation. For in vitro irradia-
tion, thioglycolate-elicited PECs from C3H wt mice were isolated by peritoneal lavage on day 
0, irradiated ex vivo on the same day and kept in culture for 72 hrs before RNA isolation. 
RNA sequencing of the isolated RNA from unirradiated, in vivo or in vitro irradiated PECs was 
followed by count-based differential gene expression analysis (Anders et al., 2013) which 
was performed by T. Michels (Figure 15).  
 
 
Figure 15 Schematic overview of experimental design and RNA sequencing workflow 
Whole transcriptome analysis of thioglycolate-elicited PECs after in vitro or in vivo irradiation. For in vivo irradi-
ation, C3H wt mice received 2 Gy TBI on day 0, followed by thioglycolate injection on the next day. 3 days later, 
PECs were collected by peritoneal lavage. For in vitro irradiation, thioglycolate-elicited PECs from C3H wt mice 
were isolated by peritoneal lavage on day 0, irradiated ex vivo on the same day and cultured for 72 hrs at 37°C. 
The isolated RNA from unirradiated, in vivo or in vivo irradiated PECs was submitted to the DKFZ GPCF or GATC 
Biotech for RNA sequencing. Count-based differential gene expression analysis (Anders et al., 2013) of the raw 
data, performed by T. Michels, was followed by pathway and Gene Ontology (GO) analysis of the differentially 
expressed genes (DEGs) (n=4 mice per group). 
 
The PECs used for the RNA Sequencing were either freshly isolated (in vivo) or cultured fol-
lowing irradiation (in vitro). Since culturing thioglycolate-elicited peritoneal cells causes an 
enrichment of macrophage populations (Zhang et al., 2001), the in vivo and in vitro irradiat-
ed PECs were analysed by flow cytometry for macrophage content. The freshly isolated PECs 
contained 60-80 % macrophages (Figure 16 A) whereas 90-96 % of the cultured PECs were 
found to be macrophages which did not change over time in culture. Of note, LDI slightly 
increased the amount of macrophages by 1-2 % (Figure 16 B). The difference in macrophage 
content in in vivo versus in vitro irradiated PECs might affect downstream analyses.  
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Figure 16 Adherence-mediated macrophage enrichment in PECs 
Flow cytometric analysis of in vivo (A) or in vitro (B) irradiated thioglycolate-elicited PECs showing the percent-
age of macrophages (CD11b
hi 
F4/80
+
) in all single, viable cells. A) % CD11b
hi 
F4/80
+ 
in PECs from unirradiated 
C3H wt mice or C3H wt mice subjected to 2 Gy TBI (n=8 mice per group; two-tailed Mann-Whitney test). B) % 
CD11b
hi 
F4/80
+
in PECs from C3H wt mice that were irradiated ex vivo with 2 Gy. Flow cytometric analysis was 
performed after 24, 48 and 72 hrs in culture. Data shown as mean ± SEM; ** p<0.01; *** p<0.001 (n=5; with 
cells pooled from 2 mice per sample; Paired two-tailed t-test (SAS)). 
 
The whole transcriptome analysis of in vivo and in vitro irradiated PECs produced large and 
complex datasets. To generate an overview of the gene expression changes induced by LDI, 
the count-based differential gene expression analysis workflow included a `Principal-
Component-Analysis´ (PCA) and produced a `Minus-Average´ (MA) plot, to visualize the gene 
expression data. The PCA examines the variance of gene expression between the samples 
and identifies subgroups that display similar gene expression patterns. This is illustrated in 
the PCA plot (Figure 17 A). In vivo: in the first principal component, a high similarity was ob-
served between the control samples and between the irradiated samples, respectively. Fur-
thermore, the PCA plot illustrates that the sex of the mice has an effect on the gene expres-
sion similarity of the samples. PECs from sex-matched mice show similarity with respect to 
the second principal component. This, however, is unlikely to affect downstream analyses 
since the first principal component accounts for the largest part of the variance in the da-
taset (Jolliffe, 2014). The second principal component only accounts for the second largest 
part of the variance. Moreover, the differences resulting from different sexes were not ob-
served in the hierarchical clustering analysis (Figure 18) and were therefore not considered 
in subsequent analyses. For the in vitro studies only female animals were used to prevent 
influences of the sex. Here, the unirradiated (CTL) samples form a cluster, displaying high 
similarities regarding the first and second principal component, demonstrating their high 
similarity in gene expression. The irradiated samples are scattered in the PCA plot. Samples 1 
and 4 and samples 2 and 3 display similarities with regard to the first principal component, 
respectively. Samples 2 and 3 show a higher similarity to the unirradiated samples than to 
the other irradiated samples (1 and 4).  
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Figure 17 Overview of LDI-mediated gene expression changes in PECs 
Transcriptomic data of in vivo (upper panel) and in vitro (lower panel) irradiated PECs in comparison to unirra-
diated control PECs, visualized by PCA plots (A), MA plots (B) and pie charts (C). A) PCA plots illustrate the rela-
tions among all samples of each dataset. Irradiated samples (IRR) are shown in blue, unirradiated control sam-
ples (CTL) in green. B) The MA plots show the distribution of all sequenced genes regarding their log2 fold 
change values (irradiated vs. unirradiated) plotted against the average standardized read counts, displayed as 
Average log10 counts per million (CPM). Each dot represents a gene; in red, genes with an FDR<0.05; in orange, 
condition-unique points C) Pie charts present the percentage of up- (red) and downregulated (blue) DEGs (de-
fined as, FDR <0.05, FC ≥ |1.5|) of all sequenced transcripts in the in vivo and in vitro dataset. (n=4 mice per 
group) 
 
2.7.2. Identification of DEGs 
The MA-plots in Figure 17 B display all transcripts determined by the RNA sequencing analy-
sis. The log2 fold change value of each identified transcript (gene) is plotted against the av-
erage read counts (Average logCPM), thereby visualizing the level of expression and the level 
of regulation after LDI of each transcript. The plots show the significantly up- or downregu-
lated genes in red. Significance is defined by a False Discovery Rate (FDR) < 0.05. Many of the 
genes with low average counts display FDR values below 0.05, even with high fold change 
values. Of the significantly regulated genes those with a Fold Change (FC) ≥ |1.5| were se-
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lected for subsequent analyses and herein referred to as differentially expressed genes 
(DEGs). Shown in orange are the genes with no detectable reads in a large proportion of 
samples in one or both conditions; the so called condition-unique points. They were not in-
cluded in downstream analyses. In the in vivo dataset significantly up- and downregulated 
genes seem to be equally distributed. 165 (1.3 %) of all transcripts were significantly down-
regulated and 245 (1.9 %) were significantly upregulated. After in vitro irradiation, only 43 
genes were significantly downregulated (0.4 %) while 466 of the DEGs were upregulated 
(4.0 %) (Figure 17 C). For closer examination of this bias, the DEGs were analysed by hierar-
chical clustering, illustrated in heat maps (Figure 18). Clusters are grouped together based on 
similarity of gene expression, thereby revealing two main clusters. One encompasses the 
genes that show decreased expression and the other includes all genes with increased ex-
pression after LDI. After in vitro irradiation, the majority of the DEGs are upregulated, while 
in the in vivo dataset almost two thirds of the DEGs are upregulated, thereby confirming the 
results from Figure 17. 
The heat maps also show dendrograms visualizing the unsupervised hierarchical clustering of 
the samples (above the heat map). The height of the branches indicates the similarity be-
tween 2 samples, thus larger distances represent larger dissimilarities. In vivo: the control 
samples and the irradiated samples respectively form clusters. This analysis did not reveal 
differences in gene expression related to the sex of the mice, as seen in the PCA plot (Figure 
17 A). In vitro: the control samples show high similarities in gene expression, shown by the 
small distances of the dendrogram branches. The irradiated samples 2 and 3 form a cluster 
with the unirradiated samples, while the irradiated samples 1 and 4 form a separate cluster. 
This confirms the results of the PCA plot. Together, these results demonstrate that low dose 
irradiation (in vivo, as well as in vitro) leads to gene expression changes in PECs. 
 
For a more detailed analysis, the top 25 DEGs up- or downregulated after in vivo or in vitro 
LDI were explored. This revealed that several genes, whose expression is associated with 
M2-like macrophages, were downregulated in response to LDI: RetnIa (resistin like alpha; 
synonym Found in inflammatory zone (Fizz)-1) (Murray et al., 2014), CD163 (Martinez and 
Gordon, 2014), CD163l1, Fcrls (Fc receptor-like S, scavenger receptor; synonym macrophage 
scavenger receptor (Msr)2 (Cai et al., 2012), Cx3cr1 (chemokine (C-X3-C motif) receptor 1) 
(Lee et al., 2013)) (Table 2, Table 4). In contrast, Flt1 (FMS-like tyrosine kinase 1) which is 
associated with M1-like macrophages (Lee et al., 2013) and Nos2 an important M1 marker 
(Martinez and Gordon, 2014; Murray et al., 2014) are among the top 25 DEGs upregulated 
after in vivo and in vitro LDI, respectively. Furthermore, several IFN-associated genes were 
upregulated after LDI: Igigp (interferon inducible GTPase) 1, Ifit (interferon-induced protein 
with tetratricopeptide repeats) 1, Ifit1bl, Ifit2 and Ifit3, as well as Oas (2'-5'-oligoadenylate 
synthetase 3, 100kDa) 3 (Table 1, Table 3). These observations suggest an LDI-mediated M2 
to M1 shift in peritoneal macrophages and an involvement of IFN signalling.  
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Figure 18 Effects of LDI on gene expression of PECs 
Heat maps and unsupervised hierarchical clustering of all DEGs from the A) in vivo or B) in vitro dataset. The 
columns represent the samples: irradiated PECs (IRR 1-4) compared to unirradiated control PECs (CTL 1-4) 
(male; female). Each row represents one DEG and depicts the expression level for each sample. The colour 
intensity indicates the level of gene expression (normalized read counts as CPM) with tones of red representing 
high and tones of blue low expression values within a row. The up- and downregulated DEGs are clustered 
(increased; decreased, respectively) FDR <0.05, FC ≥ |1.5|. Heat maps were generated and clustering of DEGs 
was performed by Gene-e. 
Table 1 Top 25 DEGs significantly upregulated after in vivo irradiation. 
Gene FC FDR Description 
Pou3f1 32.45 0.0034 POU domain, class 3, transcription factor 1 
Stfa2l1 30.76 0.0145 stefin A2 
Ifit3 27.57 0.0000 interferon-induced protein with tetratricopeptide repeats 3 
Pdgfrb 26.19 0.0154 platelet-derived growth factor receptor, beta polypeptide 
Tnc 25.58 0.0336 tenascin C 
Rarres1 24.74 0.0297 retinoic acid receptor responder (tazarotene induced) 1 
Gzmb 24.50 0.0001 granzyme B 
Wwc1 22.01 0.0418 WW and C2 domain containing 1 
Ifit2 17.44 0.0000 interferon-induced protein with tetratricopeptide repeats 2 
Ifit1bl1 12.59 0.0020 interferon-induced protein with tetratricopeptide repeats 1 
Ccl2 10.79 0.0000 chemokine (C-C motif) ligand 2 
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Ifit1 10.03 0.0000 interferon-induced protein with tetratricopeptide repeats 1B 
Ccl7 9.69 0.0000 chemokine (C-C motif) ligand 7 
Ly6c2 8.06 0.0000 lymphocyte antigen 6 complex, locus A 
Samd3 7.62 0.0200 sterile alpha motif domain containing 3 
Ly6c1 7.52 0.0000 lymphocyte antigen 6 complex, locus A 
Iigp1 7.17 0.0356 interferon inducible GTPase 1 
Rab15 6.18 0.0031 RAB15, member RAS oncogene family 
Spire2 6.13 0.0000 spire-type actin nucleation factor 2 
Rsad2 5.97 0.0000 radical S-adenosyl methionine domain containing 2 
Klrb1f 5.74 0.0191 killer cell lectin-like receptor subfamily B member 1F 
Flt1 5.61 0.0128 fms-related tyrosine kinase 1 
Oas3 5.37 0.0000 2'-5'-oligoadenylate synthetase 3, 100kDa 
Usp18 5.33 0.0000 ubiquitin specific peptidase 18 
Ccl24 5.22 0.0143 chemokine (C-C motif) ligand 24 
Table 2 Top 25 DEGs significantly downregulated after in vivo irradiation. 
Gene FC FDR Description 
Sult1a1 -21.99 0.0250 sulfotransferase family 1A, phenol-preferring, member 1 
Igha -8.94 0.0250 immunoglobulin heavy constant alpha 
Pkmyt1 -7.90 0.0051 protein kinase, membrane associated tyrosine/threonine 1 
Slc36a2 -7.53 0.0083 solute carrier family 36 (proton/amino acid symporter), member 2 
Blk -6.87 0.0000 BLK proto-oncogene, Src family tyrosine kinase 
Fcrls -5.22 0.0027 Fc receptor-like S, scavenger receptor 
Klrg2 -4.73 0.0074 killer cell lectin-like receptor subfamily G, member 2 
Cd163 -4.40 0.0038 CD163 molecule 
Rltpr -4.36 0.0379 RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing 
Retnla -4.18 0.0000 resistin like alpha 
St8sia6 -4.10 0.0062 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 
Cd163l1 -3.87 0.0120 CD163 molecule-like 1 
Cd209a -3.87 0.0001 C-type lectin domain family 4, member M 
Ighd -3.72 0.0000 immunoglobulin heavy constant delta 
C1qb -3.63 0.0000 complement component 1, q subcomponent, B chain 
Mgl2 -3.62 0.0242 C-type lectin domain family 10, member A 
Fcrla -3.50 0.0003 Fc receptor-like A 
Siglech -3.41 0.0175 sialic acid binding Ig-like lectin H 
H2-Ob -3.30 0.0000 major histocompatibility complex, class II, DO beta 
Fcmr -3.25 0.0191 Fc fragment of IgM receptor 
Rcn3 -3.25 0.0000 reticulocalbin 3, EF-hand calcium binding domain 
Tmem176a -3.24 0.0108 transmembrane protein 176A 
Nynrin -3.22 0.0105 NYN domain and retroviral integrase containing 
C1qc -3.18 0.0000 complement component 1, q subcomponent, C chain 
Pou2af1 -3.15 0.0000 POU class 2 associating factor 1 
Table 3 Top 25 DEGs significantly upregulated after in vitro irradiation. 
Gene FC FDR Description 
Serpina3f 1050.60 0.0008 serine (or cysteine) peptidase inhibitor, clade A, member 3G 
Ubd 869.47 0.0008 ubiquitin D 
Lcn2 651.67 0.0008 lipocalin 2 
Iigp1 448.20 0.0015 interferon inducible GTPase 1 
Htr7 429.35 0.0008 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled 
RESULTS 
 
| 42  
Gm4951 405.34 0.0008 predicted gene 4951 
Ly6i 355.08 0.0015 lymphocyte antigen 6 complex, locus A 
Gbp8 334.30 0.0015 guanylate-binding protein 8 
Cxcl3 265.03 0.0015 chemokine (C-X-C motif) ligand 3 
Ly6a 121.26 0.0008 lymphocyte antigen 6 complex, locus A 
Gbp4 96.80 0.0008 guanylate binding protein family, member 6 
Cfb 93.64 0.0010 complement factor B 
Il23r 87.49 0.0027 interleukin 23 receptor 
Ly6c1 87.12 0.0015 lymphocyte antigen 6 complex, locus A 
Marco 80.90 0.0009 macrophage receptor with collagenous structure 
Spon1 80.62 0.0062 spondin 1, extracellular matrix protein 
U90926 76.16 0.0043 cDNA sequence U90926 
Ly6c2 64.58 0.0023 lymphocyte antigen 6 complex, locus A 
Fpr1 62.55 0.0015 formyl peptide receptor 1 
Irg1 61.35 0.0010 immunoresponsive 1 homolog (mouse) 
Trim30c 57.44 0.0010 tripartite motif-containing 30C 
Nos2 55.56 0.0011 nitric oxide synthase 2, inducible 
Fpr2 53.41 0.0008 formyl peptide receptor 2 
Tnfaip8l3 50.18 0.0071 tumor necrosis factor, alpha-induced protein 8-like 3 
Ctgf 49.80 0.0079 connective tissue growth factor 
Table 4 Top 25 DEGs significantly downregulated after in vitro irradiation. 
Gene FC FDR Description 
Cyp2s1 -8.62 0.0008 cytochrome P450, family 2, subfamily S, polypeptide 1 
Cx3cr1 -5.95 0.0008 chemokine (C-X3-C motif) receptor 1 
Fcrls -5.47 0.0110 Fc receptor-like S, scavenger receptor 
Cited4 -5.25 0.0008 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 
Apln -5.10 0.0026 apelin 
Cdkn3 -4.39 0.0375 cyclin-dependent kinase inhibitor 3 
Fads2 -4.05 0.0008 fatty acid desaturase 2 
H1fx -3.91 0.0083 H1 histone family, member X 
Ube2c -3.69 0.0380 ubiquitin-conjugating enzyme E2C 
Cd200r3 -3.38 0.0458 CD200 receptor 3 
Cdc20 -3.36 0.0425 cell division cycle 20 
Cdca3 -3.36 0.0424 cell division cycle associated 3 
Cd34 -3.27 0.0377 CD34 molecule 
Gpr183 -3.08 0.0083 G protein-coupled receptor 183 
Acap1 -3.06 0.0084 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 
Kif2c -2.99 0.0488 kinesin family member 2C 
Tsc22d1 -2.96 0.0010 TSC22 domain family, member 1 
Rasal1 -2.95 0.0495 RAS protein activator like 1 (GAP1 like) 
Atg9b -2.83 0.0194 autophagy related 9B 
Traip -2.82 0.0313 TRAF interacting protein 
Pttg1 -2.78 0.0467 pituitary tumor-transforming 1 
Dlgap5 -2.78 0.0450 discs, large (Drosophila) homolog-associated protein 5 
Lmnb1 -2.74 0.0231 lamin B1 
Ncapd2 -2.74 0.0269 non-SMC condensin I complex, subunit D2 
Kif22 -2.73 0.0334 kinesin family member 22 
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2.7.3. Overlapping DEGs after in vivo and in vitro irradiation 
The whole transcriptome analysis was performed on in vivo and in vitro irradiated PECs with 
the aim to discern whether LDI exerts its effects directly on macrophages or whether the 
effects are indirectly induced through surrounding damaged tissues. To assess whether in 
vivo and in vitro irradiation cause similar effects on gene expression in PECs, the DEGs from 
the two datasets were compared and genes unique to, as well as genes shared by, the two 
datasets were identified (Figure 19). Transcriptome analysis of irradiated and unirradiated 
PECs identified a total of 410 (in vivo) and 509 (in vitro) DEGs. Ninety-eight (11.9 %) of these 
DEGs are found in both datasets (Figure 19 A). In order to account for the direction of al-
tered gene expression, up- and downregulated genes of the in vivo and in vitro datasets 
were analysed separately, thereby revealing genes which are commonly up- or downregu-
lated and genes which are conversely regulated. After in vivo irradiation 245 genes and after 
in vitro irradiation 466 genes were upregulated. Of note, the upregulated genes showed an 
overlap of 92 genes (14.9 %) between in vivo and in vitro irradiation, indicating that tran-
scriptional modulation of these commonly regulated genes is a direct effect of LDI. Hence, 
these genes were included in further analyses. Surprisingly, only two genes were commonly 
downregulated after in vivo and in vitro irradiation (Cx3cr1 and Fcrls) (Figure 19 A). 
A small fraction of genes was inversely regulated, as depicted by the lower Venn diagrams in 
Figure 19 B. There was no overlap between the 245 upregulated genes of the in vivo dataset 
and the 43 downregulated genes of the in vitro dataset which further supports the specific 
upregulation of the above identified set of 92 genes by LDI. Furthermore, only 4 genes were 
found to be downregulated after in vivo and upregulated after in vitro irradiation. The identi-
fied DEGs of the in vivo (n=410) and the in vitro (n=509) data sets, as well as the 92 common-
ly upregulated genes in both datasets, were further studied by Gene Ontology and pathway 
analyses.  
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Figure 19 Overlap of differentially expressed genes in PECs upon in vivo versus in vitro LDI 
Overlap between the in vivo and in vitro dataset of upregulated and/or downregulated genes. Scaled Venn 
diagrams identifying shared DEGs after in vivo and in vitro irradiation: A) Comparison of all DEGs from the in 
vivo and in vitro dataset. B) Comparison of genes upregulated (red) or downregulated (blue) by in vivo or in 
vitro irradiation: upper Venn diagrams depict shared upregulated (left) or shared downregulated (right) DEGs. 
Lower Venn diagrams show overlap in DEGs which are inversely regulated after in vivo and in vitro irradiation. 
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2.7.4. DEGs are associated with immune system processes 
The previous experiments demonstrated that LDI induces gene expression changes in PECs. 
To analyse their implications on macrophage characteristics, the downstream effects of 
these transcriptional changes, as well as the biological functions and processes associated 
with the DEGs, were identified by linking the gene lists of DEGs to gene ontologies using the 
databases of the online annotation tool STRING 10.0 and the Ingenuity® Pathway Analysis 
software (IPA®, QIAGEN, Redwood City). The STRING Gene Ontology (GO) enrichment analy-
sis allows for the functional interpretation of the transcriptomic data, since the GO terms 
describe gene product (protein) properties. Analysis of genes up- or downregulated after in 
vivo or in vitro irradiation, revealed GO terms that were overrepresented to a significant de-
gree in the respective gene sets. Genes upregulated after in vivo irradiation are associated 
with the biological processes of ‘Immune response’, ‘Response to other organism’, ‘Innate 
immune response’, ‘Defence response’ and ‘Immune system process’ (Table 5). Genes down-
regulated after in vivo irradiation are associated with ‘Antigen processing and presentation 
of exogenous peptide antigen via MHC class II’, ‘Immune system process’, ‘Regulation of 
immune system process’, ‘Regulation of immune response’ and ‘Antigen processing and 
presentation’ (Table 5). Overall, the GO terms, associated with altered gene expression after 
in vivo irradiation, are related to processes of the immune system, suggesting that in vivo 
irradiation affects immune responses.  
 
Table 5 Top 5 overrepresented GO biological process terms (in vivo up (red) and down (blue)) 
Biological Process observed 
gene count FDR  
Biological Process observed 
gene count FDR 
Immune response 43 1.14e-17 
 
Ag processing and presentation 
of exogenous peptide Ag via 
MHC class II 
7 7.65e-09 
Response to other organ-
ism 40 2.16e-17  
Immune system process 33 4.28e-07 
Innate immune response 32 4.94e-17 
 
Regulation of immune system 
process 27 7.1e-07 
Defence response 44 5.22e-16 
 
Regulation of immune response 17 5.7e-06 
Immune system process 54 1.64e-14 
 
Ag processing and presentation 8 1.44e-05 
GO biological processes significantly overrepresented in the up- (red) and downregulated (blue) gene sets after 
in vivo irradiation, generated with the STRING database. 
 
Biological processes associated with genes upregulated after in vitro irradiation are analo-
gous to the terms overrepresented after in vivo irradiation: ‘Immune response’, ‘Immune 
system process’, ‘Defence response’, ‘Innate immune response’ and ‘Response to cytokine’ 
(Table 6), indicating that in vitro irradiation affects immune responses as well. STRING analy-
sis of the 43 genes downregulated after in vitro irradiation revealed alterations of cell cycle 
functions, as was evident from the top 5 GO terms shown in Table 6. It has to be considered 
that this analysis does not take into account which effect (activating or inhibiting) a single 
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gene has on the associated biological process, therefore this analysis does not show whether 
low dose irradiation suppresses or stimulates immune responses.  
Table 6 Top 5 overrepresented GO biological process terms (in vitro up (red) and down (blue)) 
Biological Process observed 
gene count FDR  
Biological Process observed 
gene count FDR 
Immune response 86 2.71e-41 
 
Nuclear division 11 1.12e-06 
Immune system process 114 3.74e-38 
 
Cell cycle 15 1.12e-06 
Defence response 83 1.98e-32 
 
Mitotic nuclear division 10 1.12e-06 
Innate immune response 56 1.79e-30 
 
Cell cycle process 13 1.5e-06 
Response to cytokine 59 6.78e-27 
 
Mitotic cell cycle process 11 2.64e-06 
GO biological processes significantly overrepresented in the up- (red) and downregulated (blue) gene sets after 
in vitro irradiation, generated with the STRING database. 
 
To further assess the impact of LDI on immune responses, the list of 92 genes, commonly 
upregulated after in vivo and in vitro irradiation, was also analysed using STRING. Indeed, the 
top 10 GO biological processes significantly overrepresented in this gene set included ‘Innate 
immune response’, ‘Immune response’, ‘Defence response’, ‘Response to other organism’, 
‘Defence response to other organism’, ‘Defence response to virus’, ‘Immune effector pro-
cess’, ‘Response to interferon-beta’, ‘Immune system process’, and ‘Response to cytokine’ as 
summarised in Table 7.  
Table 7 Top 10 overrepresented GO biological process terms (in vivo and in vitro up)  
Biological Process 
observed 
gene count 
FDR 
Innate immune response 22 3.01e-16 
Immune response 26 2.9e-15 
Defence response 27 2.02e-14 
Response to other organism 23 1.92e-13 
Defence response to other organism 18 5.69e-13 
Defence response to virus 13 2.43e-12 
Immune effector process 16 9.1e-11 
Response to interferon-beta 7 7.45e-09 
Immune system process 26 8.17e-09 
Response to cytokine 16 4.9e-08 
GO biological processes associated with the 92 genes upregulated after in vivo and in 
vitro irradiation, generated with the STRING database. 
 
STRING analysis further generated a protein interaction network showing the proteins en-
coded by the 92 genes upregulated by in vivo and in vitro irradiation (Figure 20). This over-
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view visualizes the relations between the 92 proteins. The network comprises a significant 
enrichment of interactions, as calculated by STRING, signifying the functional linkage of 
these proteins. Using the MCL (Markov Cluster Algorithm) cluster function, protein clusters 
were associated to GO terms. The yellow shaded area highlights the proteins in cluster A, 
which are mainly associated with the GO term ‘Innate immune response’. Proteins in cluster 
B (green shaded area) are mainly associated with the biological process term ‘Cell migration’. 
The specific proteins forming cluster A and B, respectively, are shown in the supplemental 
Figure S33. 
 
 
Figure 20 Protein interaction network of genes upregulated in PECs in response to LDI 
Protein-protein interactions of the proteins encoded by the 92 genes upregulated after both in vivo and in vitro 
irradiation, visualized by STRING. The nodes represent proteins, the edges (841) represent physical and func-
tional connections between the proteins, with the line colour indicating the action type and the line shape 
indicating the action effect (detailed description, see legend). The coloured areas highlight protein clusters 
which predominantly comprise proteins involved in an innate immune response (yellow) or cell migration 
(green). 
 
As an additional finding, the dataset of commonly upregulated genes (n=92), as well as the in 
vivo and in vitro dataset, revealed a statistical enrichment for the GO term ‘Response to 
stress’ (Table 8). Figure 21shows the 92 genes upregulated after in vivo and in vitro irradia-
tion with the 31 genes associated with the GO term ‘Response to stress’ highlighted in red. 
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In summary, these results suggest that in vivo and in vitro LDI lead to a stress response in 
PECs, to an increase in cell migration and an innate immune response of these cells. 
Table 8 GO biological process term ‘Response to Stress’  
Response to stress 
observed 
gene count 
FDR 
In vivo up 68 1.61e-11 
In vitro up 123 6.27e-21 
In vivo & in vitro up 31 1.05e-06 
Enrichment of the GO term ‘Response to Stress’ in genes upregulated after in vivo and/or in vitro irradiation, 
generated with the STRING database. Shown is the number of genes annotated with the (GO) Biological pro-
cess term ‘Response to Stress’ in the indicated gene sets. 
 
 
Figure 21 Network of stress response-associated proteins induced in PECs upon LDI 
STRING protein interaction network of the 92 genes upregulated after in vivo and in vitro irradiation with pro-
teins associated with a stress response highlighted in red. The nodes represent proteins, the edges represent 
physical and functional associations between the proteins, with the line colour indicating the action type and 
the line shape indicating the action effect. 
Subsequently, the in vivo and in vitro datasets were analysed with the Ingenuity® Pathway 
Analysis software. Only significantly regulated genes with an FDR <0.05 and FC values ≥ |1.5| 
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were included in the analysis (in vivo n=410; in vitro n=509). The software mapped the da-
tasets to the Ingenuity® Knowledge Base, thereby creating causal networks, identifying up-
stream regulators, as well as overrepresented biological functions and canonical pathways. 
In these analyses, the direction of change, that is whether a gene is up- or downregulated, is 
taken into account.  
Table 9 IPA Diseases and biological functions  
Diseases and activation z-score 
Bio Functions in vivo in vitro 
   
Innate immune response 1.94 3.44 
   
Activation of leukocytes 2.76 4.42 
Activation of myeloid cells 1.39 4.24 
Activation of phagocytes 1.17 3.56 
Activation of macrophages 0.74 3.77 
   
Cell movement 2.32 6.25 
Cell movement of myeloid cells 2.26 3.92 
Cell movement of phagocytes 1.97 4.01 
Cell movement of macrophages 1.09 2.90 
   
Viral Infection -2.39 -2.50 
Diseases and functions predicted by IPA to be increased (red) or decreased (blue) after in vivo or in vitro irradi-
ation. Activation z-score ≥ |2|; p-value <0.0001 considered significant. Insignificant values shown in black. Ta-
ble 29 lists the DEGs of the two datasets for each Disease and biological function. 
 
The IPA Downstream Effects Analysis identified which downstream biological processes were 
predicted to be increased or decreased after in vivo or in vitro irradiation. Several biological 
functions in the categories ‘Cellular Movement’, ‘Inflammatory Response’ as well as in other 
categories were predicted to be activated; a selection is listed in Table 9. The sub functions 
‘Innate immune response’ and ‘Activation of leukocytes’ of the category ‘Inflammatory Re-
sponse’ were predicted to increase after LDI. ‘Activation of myeloid cells, phagocytes and 
macrophages’ were predicted to be activated after in vitro but not after in vivo irradiation. 
‘Cell movement’ in general, and ‘Cell movement of myeloid cells, phagocytes or macrophag-
es’ in particular, were all predicted to be increased after in vitro irradiation; the first two also 
after in vivo irradiation. In the category ‘Infectious Diseases’, ‘Viral infection’ was one of the 
diseases predicted to decrease after in vivo and in vitro LDI. The IPA Downstream Effects 
Analysis confirmed the results of the GO enrichment analysis generated by STRING. Moreo-
ver, it gives additional information about the activity of the biological functions signifying 
whether the gene expression changes lead to an activation or inhibition of the process. In 
summary, LDI seems to activate the peritoneal macrophages, stimulate their migration and 
promote an (innate) immune response.  
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As described above, IPA also identified enriched canonical signalling pathways in the in vivo 
and in vitro gene sets. To determine which pathways are affected by a certain gene set, IPA 
calculates whether the overlap between the genes in the pathway and the DEGs of the da-
taset is statistically significant. This is described by the overlap p-value (-log(p-value)). On the 
basis of the expression data, IPA additionally ascertains the activation state of the affected 
pathway. IPA Pathway analysis of the targets that were differentially regulated by in vivo or 
in vitro irradiation revealed that ‘Interferon Signalling’, ‘Activation of IRF by Cytosolic Pattern 
Recognition Receptors’ and ‘Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses’ are predicted to be activated by both, in vivo and in vitro irradiation (Figure 22 A, 
B).  
Due to its role in the mechanism of combination therapy-induced endothelial activation and 
T cell infiltration, we were interested in the expression of iNOS in peritoneal macrophages 
after LDI. Also, it is known that iNOS can be induced by IFN stimulation (Blanchette et al., 
2003). Therefore, the subsequent analyses focussed on the IFN signalling pathway. In short, 
the pathway is initiated by the binding of type I (IFN-α/IFN-β) or type II (IFN-γ) interferons to 
their respective receptors. This induces the activation of the Jak/Stat signalling pathway and 
leads to the expression of interferon regulated genes (IRGs). After in vivo irradiation Stat1 
(signal transducer and activator of transcription 1) is significantly upregulated, as well as the 
interferon regulated genes Ifit1bl1, Oas1a, Isg15 and Ifit3 (Der et al., 1998; Fensterl and Sen, 
2015; Pulit-Penaloza et al., 2012; Zhang and Zhang, 2011) (Figure 22 C). In vitro irradiation 
leads to an upregulation of Stat1, Stat2, Irf1 and the interferon regulated genes Tap1, 
Ifit1bl1, Oas1a, Isg15 and Ifit3 (Min et al., 1998) (Figure 22 D). The canonical signalling path-
ways are designed by IPA on the basis of literature findings. However, they do not cover all 
interactions of each molecule but rather show a selection of well-described interactions. 
Therefore, not all genes which are regulated by IFNs are displayed in this figure. But since 
the results indicate that LDI activates the IFN signalling pathway and induces IRG expression, 
the identification of IRGs in the in vivo and in vitro datasets was subject of the following 
analyses. 
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Figure legend on the next page 
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Figure 22 Canonical pathways predicted to be activated by LDI 
Top 5 canonical pathways, predicted to be activated by A) in vivo or B) in vitro irradiation with an activation z-
score ≥ 0.9 and an overlap p-value <0.001. The colour intensity of the bars indicates the activation z-score (0.9 - 
4); the height of the bars represents the overlap p-value (upper axis; -log(p-value)) which was calculated by IPA 
using the right-tailed Fisher`s Exact test. The threshold line represents the p-value cut-off set at 0.05. (IPA de-
fault setting); the second line represents the ratio between the DEGs from the dataset that map to the pathway 
and the total number of genes in the pathway (lower axis labelled; ‘Ratio’). C, D) Interferon signalling pathway 
with DEGs from the C) in vivo or D) in vitro dataset highlighted by coloured fillings. The colour intensity indi-
cates the level of gene expression, with tones of red representing increased and tones of blue decreased gene 
expression (FC values). In grey, genes that did not pass the threshold of FDR <0.05, FC ≥ |1.5|; in white, genes 
that were not present in the dataset. Relationships between molecules are denoted by solid (direct) or dashed 
lines (indirect); Molecule types are described in the legend. A-D) Generated by analysis of all DEGs using IPA. 
 
2.7.5. Effect of LDI on the expression of IRGs 
Pathway analysis of the DEGs revealed a role of IFN signalling in irradiated peritoneal macro-
phages. This indicates that LDI induces the expression of IRGs. To identify IRGs in the in vivo 
and in vitro dataset, the Interferome database was employed. Interferome is a searchable 
database, containing published datasets with expression data of genes differentially ex-
pressed after treatment with different types and concentrations of IFNs allowing the retriev-
al and comparison of IFN-specific transcriptional modulation. To obtain further information 
about the direction of gene expression regulation in the in vivo and in vitro dataset, up- and 
downregulated genes were analysed separately (Figure 23). Comparison analysis with the 
Interferome database aimed to identify genes that are commonly regulated by IFN as well as 
by in vivo and/or in vitro irradiation. Therefore, the database was searched for the genes up 
(Figure 23 A) or downregulated (Figure 23 B) after in vivo and/or in vitro irradiation.  
Of the 245 genes significantly upregulated after in vivo irradiation, more than half (54.7 %) 
were identified as IRGs. 48.2 % were reported to be upregulated by IFN treatment according 
to the Interferome database, revealing a high consistency between IFN stimulation and in 
vivo irradiation. Similarly, of the genes significantly upregulated after in vitro irradiation 
(n=466), 48.7 % have been identified as IRGs, and 42.3 % are positively regulated by IFN. The 
overlap between IFN-induced gene expression and in vivo or in vitro irradiation-induced 
gene expression was even higher in the commonly upregulated gene set. Here, 72.8 % of the 
92 genes were identified as IRGs, the majority (71.7 %) being upregulated by IFN. Less than a 
third (27.2 %) of the shared upregulated genes is not regulated by IFNs. The proportion of 
IRGs in the genes downregulated after in vivo or in vitro irradiation is lower compared to the 
relative number of IRGs found in the upregulated gene sets. 35.8 % of the genes downregu-
lated by in vivo irradiation are considered IRGs, according to the Interferome database. 
27.9 % are reported to be downregulated by IFNs, while 7.9 % are upregulated by IFNs. In 
vitro irradiation led to 43 significantly downregulated genes (Figure 23 B), the vast majority 
of which (76.7 %) are not affected by IFN treatment. 6.98 % of these genes show higher and 
16.3 % lower expression after IFN treatment. In summary, many genes were identified that 
are transcriptionally regulated in the same direction by LDI and IFN stimulation with a very 
high target overlap between LDI and IFN treatment, demonstrating that LDI and IFNs similar-
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ly affect gene expression. This strongly suggests that LDI-induced gene expression changes in 
macrophages are (at least in part) mediated through IFN signalling.  
 
 
Figure 23 LDI-mediated increase in interferon regulated genes among the DEGs in PECs 
Identification of interferon regulated genes (IRGs) in in vivo or in vitro up- or downregulated DEGs using the 
Interferome database. Upper panel: Venn diagrams showing the overlap in A) upregulated B) downregulated 
genes after in vivo and in vitro irradiation. Lower panel: A) Percentages of IRGs in genes upregulated after in 
vivo, after in vivo and in vitro, after in vitro irradiation (from left to right). B) Percentage of IRGs in all DEGs 
downregulated after in vivo, after in vivo and in vitro, after in vitro irradiation (from left to right). The light 
red/blue shaded segments represent genes not regulated by interferons. The dark red/blue segments show the 
percentage of genes identified as IRGs. In dark red, genes upregulated and in dark blue, genes downregulated 
after IFN treatment. FC ≥ |1.5|, FDR <0.05 
 
2.7.6. Activation of the iNOS signalling pathway in irradiated PECs 
As shown previously, iNOS activity is essential for endothelial activation, T cell and macro-
phage infiltration, as well as tumour rejection in RT5 mice following local LDI and adoptive T 
cell transfer. It is further known that the expression of Nos2, the gene encoding iNOS, is up-
regulated in macrophages by type I or type II IFNs (Diefenbach et al., 1998; Farlik et al., 2010) 
through Jak/Stat-mediated upregulation of Irf1, a transcription factor that induces Nos2 ex-
pression (Figure 24) (Kamijo et al., 1994). Based on the findings that several of the genes 
upregulated by LDI could be linked to an activated IFN signalling pathway (Figure 24) and 
since IFN signalling can induce Nos2 gene expression it was assumed that irradiation could 
also affect expression levels of Nos2. Analysis of the transcriptome data further strength-
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ened this hypothesis. A 55.6-fold upregulation of Nos2 was observed after in vitro irradiation. 
Additional evidence was provided by significant upregulation of the IFN signalling-associated 
genes: Jak1 (FC: 1.8) and Jak2 (FC: 2.3) (FDR>0.05), as well as Stat1 (FC: 4.1), Stat2 (FC: 4.99) 
and Irf1 (FC: 6.2). After in vivo irradiation Stat1 (FC: 1.6) and Stat2 (FC: 1.7) were significantly 
upregulated (Table 10). Figure 24 shows the iNOS signalling pathway with the DEGs from the 
in vivo (A) and the in vitro (B) dataset highlighted in red. 
 
 
Figure 24 LDI-induced upregulation of iNOS signalling pathway- associated genes in PECs 
iNOS signalling pathway, with genes highlighted in red that were significantly upregulated after A) in vivo or B) 
in vitro irradiation. The colour intensity corresponds to the degree of differential expression. In grey, genes that 
did not pass the threshold of FDR <0.05, FC ≥ |1.5|; in white, genes that were not present in the dataset. Rela-
tionships between molecules are represented by solid (direct) or dashed lines (indirect); Molecule types and 
functions are described in the legend. Generated by analysis of all DEGs using IPA. 
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Table 10 LDI-induced expression changes in iNOS signalling-associated genes.  
Gene 
Symbol 
FC 
(in vivo) 
FDR 
(in vivo) 
FC 
(in vitro) 
FDR 
(in vitro) 
Description 
Ifng NA NA NA NA Interferon gamma 
Jak1 1.078 0.701 1.778 0.172 Janus kinase 1 
Jak2 1.069 0.951 2.302 0.089 Janus kinase 2 
Stat1 1.628 0.043 4.073 0.009 signal transducer and activator of transcription 1 
Stat2 1.715 0.000 4.993 0.008 signal transducer and activator of transcription 2 
Irf1 1.357 0.367 6.229 0.011 interferon regulatory factor 1 
Nos2 NA NA  55.561 0.001 nitric oxide synthase 2, inducible 
Presented are the FC and FDR values from the in vivo and in vitro dataset. Significantly upregulated genes (FDR 
<0.05, FC ≥ |1.5|) are highlighted in tones of red, with the colour intensity indicating the level of gene expres-
sion. 
 
To further examine the role of LDI in the activation of the IFN-γ signalling pathway and sub-
sequent induction of Nos2 gene expression, mRNA expression levels of Ifng, Jak1, Stat1, Irf1 
and Nos2 were analysed by RT-qPCR in PECs from C3H mice that received the same treat-
ment protocol as in previous experiments (Figure 15). Briefly, C3H wt mice received 2 Gy TBI 
on day 0, followed by thioglycolate injection on the next day. 3 days later, PECs were collect-
ed by peritoneal lavage (in vivo). Thioglycolate-elicited PECs from C3H wt mice were isolated 
by peritoneal lavage on day 0, irradiated ex vivo on the same day and cultured for 72 hrs at 
37°C (in vitro). RNA was isolated from the collected PECs and analysed by RT-qPCR. Though it 
was not detected by RNA Sequencing, Ifng was included in the following experiments, as 
RNA sequencing can be less sensitive compared to RT-qPCR, especially at low read depths 
(Consortium, 2014). Ifng, Stat1 and Nos2 were significantly upregulated after in vivo and in 
vitro irradiation. Irf1 was found to be upregulated only after in vitro irradiation, but not after 
in vivo irradiation, whereas Jak1 expression levels were not affected by LDI (Figure 25 B). 
Together, these results confirm that LDI leads to the upregulation of Nos2 gene expression 
and suggest that this is mediated by IFN-γ signalling. 
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Figure 25 The effect of LDI on the expression of IFN-γ/iNOS signalling pathway-genes 
A) IFN-γ/iNOS signalling pathway, with genes that were significantly upregulated after in vivo or in vitro LDI 
highlighted in red, as determined by RNA Sequencing. B) RT-qPCR validation of selected genes from the IFN-
γ/iNOS signalling pathway. In vivo: thioglycolate-elicited PECs were derived from C3H mice that were subjected 
to 2 Gy TBI. In vitro: thioglycolate-elicited PECs were irradiated ex vivo with 2 Gy and cultured for 72 hrs. RNA 
isolated from the peritoneal cells was analysed by RT-qPCR. The graphs show Ifng, Jak1, Stat1, Irf1 and Nos2 
gene expression levels, relative to an unirradiated control sample. The gene expression values were normalized 
to a reference gene (Hprt (hypoxanthine guanine phosphoribosyl transferase)) according to the ΔΔCt method. 
Data is shown as mean ± SEM; * p<0.05; ** p<0.01; *** p<0.001 (n=8 mice per group; in vivo: two-tailed Mann-
Whitney test; in vitro: paired, two-tailed t-test (SAS)) 
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To assess whether the underlying mechanism of LDI-induced Nos2 expression is dependent 
on IFN-γ signalling, Nos2 mRNA levels were measured in ex vivo irradiated PECs under IFN-γ 
blockage (Figure 26 A). Since Nos2 gene expression can also be induced by type I IFNs 
(Mattner et al., 2000), the effect of blocking IFN-β alone or in combination with IFN-γ inhibi-
tion on LDI-induced gene expression was analysed as well. PECs from C3H wt mice were irra-
diated ex vivo in medium containing neutralizing antibodies against IFN-γ, IFN-β or both. 
After culture for 48 or 72 hrs, the samples were analysed for Ifng, Jak1, Stat1, Irf1 and Nos2 
gene expression (Figure 26 A). As a positive control, unirradiated PECs were treated with 
20 ng/ml IFN-γ. Ifng, Irf1 and Nos2 mRNA levels were found to be increased by LDI after 
48 hrs and 72 hrs. Stat1 expression was also induced by LDI after 72 hrs and inhibition by 
anti-IFN-γ or anti-IFN-β clearly attenuated the effect of LDI as compared to the unirradiated 
control. Jak1 gene expression was neither affected by LDI, the neutralizing antibodies or IFN-
γ stimulation, indicating that it is regulated at a translational rather than the transcriptional 
level (Figure 26 C). Together, these results demonstrate that LDI-induced gene regulation of 
Ifng, Jak1, Stat1, Irf1 and Nos2 in peritoneal macrophages is dependent on IFN signalling. 
This indicates that the effects of LDI on peritoneal macrophages are (at least partly) mediat-
ed by IFNs.  
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Figure 26 The impact of IFN signalling blockade on gene expression in low dose irradiated PECs  
Gene expression in in vivo or in vitro irradiated PECs under blockade of IFN-γ or IFN-β. A) Experimental setup: 
thioglycolate-elicited PECs were collected from C3H wt mice by peritoneal lavage, irradiated ex vivo and cul-
tured at 37°C in medium only, in medium containing anti-IFN-γ mAb, anti-IFN-β mAb or both for the indicated 
times. Control samples were not irradiated and cultured in medium only or medium containing IFN-γ 
(20 ng/ml). RNA was isolated for RT-qPCR analysis. B) Proposed effect: antibody neutralization of IFN-γ is ex-
pected to inhibit LDI-induced upregulation of genes in the IFN-γ/iNOS signalling pathway. C) RT-qPCR analysis 
of genes in the IFN-γ/iNOS signalling pathway: Ifng, Jak1, Stat1, Irf1 and Nos2 gene expression levels, relative to 
an unirradiated control sample. The gene expression values are normalized to Hprt, according to the ΔΔCt 
method. Data shown as mean ± SEM; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 (n=8 mice per group; 
Paired, two-tailed t-test (SAS)) 
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2.7.7. LDI affects macrophage polarization 
Since Nos2 expression is induced by LDI, it seemed likely that iNOS protein levels were in-
creased as well. To examine whether the upregulation in gene expression is accompanied by 
an increase in iNOS protein levels, in vivo and in vitro irradiated PECs were analysed for iNOS 
by flow cytometry. As reviewed in the introduction, M1-like macrophages have been shown 
to exert antitumouricidal effects while M2-like macrophages are capable to promote tumour 
progression. To ascertain the effect of LDI on the polarization state of the peritoneal macro-
phages, which were used for the transfer experiments, PECs were stained for the polariza-
tion markers iNOS, MHC class II, and CD206. iNOS and MHC class II have been described to 
be M1 and CD206 has been describe to be an M2 marker (Lawrence and Natoli, 2011). As 
before, in vivo irradiated PECs were derived from C3H wt mice subjected to 2 Gy TBI. In vitro 
irradiated PECs were derived from unirradiated C3H wt mice, irradiated ex vivo and cultured 
for 24, 48 or 72 hrs (Figure 27 A).  
 
 
Figure continues on the next page  
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Figure 27 Effects of LDI on macrophage polarization 
Flow cytometric analysis of in vivo or in vitro irradiated peritoneal macrophages for macrophage polarization 
markers (iNOS, MHC class II, CD206). A) Experimental setup In vivo: thioglycolate-elicited peritoneal macro-
phages from unirradiated C3H wt mice or C3H wt mice, subjected to 2 Gy TBI, were collected for flow cytome-
try on day 4 by peritoneal lavage. In vitro: thioglycolate-elicited peritoneal macrophages from C3H wt mice 
were harvested on day 0 by peritoneal lavage, irradiated ex vivo with 2 Gy and analysed after 24, 48 and 72 hrs 
in culture. Unirradiated PECs were cultured in medium only or in medium containing 20 ng/ml IFN-γ. Repre-
sentative dot plots and quantitative analysis of B) iNOS
+
, C) CD206
+
 and D) MHC class II
+
 macrophages 
(CD11b
hi
F4/80
+
). Only single, viable cells were included in the analysis. Data shown as mean ± SEM; * p<0.05; 
** p<0.01; *** p<0.001; **** p<0.0001 (in vivo: n=8 mice per group, two-tailed Mann-Whitney test; in vitro: 
n=5 with cells pooled from 2 mice per sample, Paired two-tailed t-test (SAS)). 
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After in vivo irradiation, a significantly increased number of macrophages was positive for 
iNOS (0.05 versus 1.3 %), representing a 2.6-fold increase in irradiated PECs (Figure 27 B). In 
vitro irradiation did not lead to an increase in iNOS+ macrophages. However, IFN-γ stimula-
tion of unirradiated PECs strongly induced iNOS expression in macrophages demonstrating 
that peritoneal macrophages are capable of iNOS expression by direct IFN-γ stimulation 
(Figure 27 B). Flow cytometric analysis of CD206 expression revealed a significantly smaller 
fraction of CD206+ (M2-like) macrophages after in vivo irradiation (13 % versus 20 %). In vitro 
irradiation reduced the number of CD206+ cells already after 24 hrs (45 % versus 37 %), and 
further after 48 hrs (37 % versus 31 %). This effect was further sustained throughout 72 hrs 
(29 % versus 26 %) in culture, but the relative difference in CD206 protein expression de-
creased. IFN-γ stimulation also reduced CD206 expression (20 % CD206+ macrophages). 
Overall, the levels of CD206 in cultured PECs are higher compared to freshly isolated PECs 
(Figure 27 C), but irrespective of the treatment conditions, LDI consistently reduced CD206 
expression on peritoneal macrophages.  
 
Interestingly, the MHC class II expression level on macrophages was slightly but significantly 
reduced after in vivo (1.4 % versus 0.7 %) and in vitro irradiation (3 % versus 2 %) (Figure 27 
D). IFN-γ stimulation, on the other hand, induced the expression of MHC class II which is in 
agreement with the literature (Giroux et al., 2003). Also, at the mRNA level it was observed 
that LDI causes the downregulation of MHC class II genes. RNA sequencing results revealed 
that most MHC class II genes were significantly downregulated in peritoneal cells after in 
vivo irradiation (Table 11). In vitro irradiation did not induce significant gene expression 
changes of MHC class II genes. All in all, these results indicate that LDI does affect macro-
phage polarization. However, it does not induce a clear shift towards an M1 or M2-like phe-
notype.  
Table 11 Gene expression changes of MHC class II genes after in vivo or in vitro irradiation.  
Gene 
Symbol 
FC 
(in vivo) 
FDR 
(in vivo) 
FC 
(in vitro) 
FDR 
(in vitro) 
Description 
H2-Aa -2.84 0.000 1.03 0.984 histocompatibility 2, class II antigen A, alpha 
H2-Ab1 -2.45 0.000 1.99 0.465 histocompatibility 2, class II antigen A, beta 1 
H2-Ea-ps -2.41 0.000 1.77 0.564 
histocompatibility 2, class II antigen E alpha, 
pseudogene 
H2-Eb1 -2.49 0.000 1.10 0.934 histocompatibility 2, class II antigen E beta 
H2-Eb2 -2.75 0.777 NA NA histocompatibility 2, class II antigen E beta2 
H2-DMa -2.01 0.000 1.83 0.390 histocompatibility 2, class II, locus Dma 
H2-DMb1 -1.71 0.005 1.31 0.638 histocompatibility 2, class II, locus Mb1 
H2-DMb2 -1.68 0.045 1.32 0.654 histocompatibility 2, class II, locus Mb2  
H2-Oa -2.07 0.421 5.18 0.148 histocompatibility 2, O region alpha locus 
H2-Ob -3.30 0.000 NA NA histocompatibility 2, O region beta locus 
Ciita -1.81 0.027 4.51 0.169 class II transactivator 
Presented are the FC and FDR values from the in vivo and in vitro dataset. Significantly downregulated genes 
(FDR <0.05, FC ≥ |1.5|) are highlighted in tones of blue, with the colour intensity indicating the level of gene 
expression. 
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2.7.8. IFN-dependent upregulation of Tnf after LDI  
One major factor responsible for failure of adoptive T cell therapy is the aberrant tumour 
vasculature. Although normalization of the tumour blood vessels in RT5 tumours after com-
bination therapy was partly dependent on iNOS activity (Figure 7, Figure 8), it is unclear 
which additional factors might be involved. TNF-α is a known activator of endothelial cells 
(McHale et al., 1999) and it is produced by activated macrophages (Flynn et al., 1995) and 
CD8+ T cells (Vassalli, 1992). According to the RNA sequencing results, in vivo irradiation led 
to a 2.43-fold increase in Tnf gene expression, while in vitro irradiation resulted in a 1.45-fold 
increase. These changes were not considered to be significant, since the FDR values were 
>0.05. Nevertheless, this trend was further investigated, because RT-qPCR is can be more 
sensitive than RNA sequencing. A 1.7-fold increase in Tnf mRNA levels was observed after in 
vivo irradiation (Figure 28 A). In vitro irradiation, as well as IFN-γ stimulation, also induced 
Tnf expression. Here, the upregulation of Tnf was more pronounced 48 hrs after irradiation 
compared to 72 hrs. Furthermore, blocking IFN-γ, IFN-β or both abrogates the upregulation 
of Tnf induced by LDI after 48 hrs, demonstrating that LDI induces Tnf expression in an IFN-
dependent manner (Figure 28 B). These results suggest that TNF-α, together with NO, medi-
ates LDI-induced endothelial activation in RT5 tumours. 
 
 
Figure 28 The role of IFNs on LDI-induced Tnf gene expression in PECs 
Tnf gene expression in PECs after A) in vivo irradiation or B) in vitro irradiation under blockade of IFN-γ, IFN-β or 
both (experimental setup, see Figure 26 A) based on RT-qPCR analysis. The graphs show Tnf gene expression 
levels for the indicated treatment groups, relative to the respective unirradiated control samples. The gene 
expression values were normalized to Hprt, according to the ΔΔCt method. Data shown as mean ± SEM; * 
p<0.05; ** p<0.01; *** p<0.001 (n=8 mice per group; in vivo (A): two-tailed Mann-Whitney test; in vitro (B): 
Paired, two-tailed t-test (SAS)). 
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2.7.9. Upstream regulators of low dose irradiation in PECs 
After assessing the downstream processes induced by LDI, next we wanted to investigate the 
factors which are responsible for the gene expression changes following LDI, to further elu-
cidate the underlying mechanisms. To this end, the Upstream Regulator Analysis by IPA was 
employed. By calculating the overlap between all the target genes regulated by a particular 
molecule and the genes of a dataset, IPA identifies potential upstream regulators (IPA). 
Based on the expression data, IPA additionally predicts the activation state of the transcrip-
tional regulators, indicated by the activation z-score. Upstream regulators predicted to be 
activated by in vivo and in vitro LDI included IFN-associated proteins and proteins involved in 
the detection of danger signals, as well as their ligands (Table 12, Table 13, Table 14) 
2.7.9.1. IFN-response molecules predicted to be upstream regulators 
Corresponding to the finding that the effects of LDI are mediated by IFN signalling, the Up-
stream Regulator Analysis by IPA identified several proteins which are associated with IFN 
signalling to be upstream regulators, including type I (IFN-α and IFN-β1) and type II (IFN-γ) 
interferons, as well as the IFN regulating factors IRF3, 5 and 7 and STAT1 (Table 12). To visu-
alize the relationships between the upstream regulator and the downstream target genes, 
IPA generates interaction networks. As an example, Figure 29 displays the upstream regula-
tor network of IRF7. Some of the upstream regulators, like IRF7 and STAT1, were identified 
to be upregulated in PECs after LDI by RNA Sequencing. Irf7 expression was 3.76-fold in-
creased after in vivo irradiation and 14.1-fold after in vitro irradiation. Independent RT-qPCR 
experiments confirmed LDI-mediated upregulation of Stat1 (Figure 25) and Irf7 (Figure 30). 
Irf7 expression was strongly induced by in vivo irradiation, with a fold change of 3.5, while 
the effects of in vitro irradiation on Irf7 expression were less pronounced with a modest up-
regulation after 72 hrs. Inhibition of IFN-γ, IFN-β or both suppressed the upregulation of Irf7 
expression induced by LDI after 72 hrs, showing that the increased Irf7 expression in PECs 
after LDI is dependent on IFNs. Taken together, these results further support previous ob-
servations that LDI induces IFN-responses and thereby exerts its effects.  
 
Table 12 IPA Upstream regulators (IFN signalling) 
Upstream regulator in vivo in vitro 
IRF3 5.63 6.01 
IRF7 5.47 5.73 
IRF5 4.17 3.93 
IFN-γ 4.09 7.67 
IFN-α 4.95 5.88 
IFN-β1 3.76 5.16 
STAT1 3.50 4.47 
Upstream regulators, associated with IFN signalling, predicted by IPA to be activated in PECs after in vivo or in 
vitro LDI. Activation z-score ≥ |2|; p-value <0.0001 considered significant.Table 29 lists the DEGs of the two 
datasets for each Upstream regulator. 
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Figure 29 IRF7 – Upstream regulator network of DEGs 
Interaction network displaying IRF7 with its downstream target genes from the A) in vivo or B) in vitro irradia-
tion dataset. Upregulated DEGs are highlighted in tones of red with the colour intensity corresponding to the 
degree of differential expression. Relationships between molecules are represented by solid lines (direct) with 
the colour indicating the predicted action: orange - activation; grey -not predicted. Networks generated by IPA. 
 
 
Figure 30 IFN-dependent upregulation of Irf7 expression in low dose irradiated PECs 
Irf7 gene expression in PECs after A) in vivo irradiation or B) in vitro irradiation under blockade of IFN-γ, IFN-β 
or both (experimental setup, see Figure 26 A) based on RT-qPCR analysis. All graphs show Irf7 gene expression 
levels for the indicated treatment groups, relative to the respective unirradiated control samples. The gene 
expression values are normalized to Hprt, according to the ΔΔCt method. Data shown as mean ± SEM; * p<0.05; 
** p<0.01; *** p<0.001; **** p<0.0001 (n=8 mice per group; in vivo (A): two-tailed Mann-Whitney test; in vitro 
(B): paired, two-tailed t-test (SAS)). 
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2.7.9.2. DNA damage response molecules predicted to be upstream regulators 
Besides the upstream regulators associated with IFN signalling, two other groups of up-
stream regulators were prominent. Table 13 shows TLR agonists like LPS, poly I:C (Polyinosin-
ic:polycytidylic acid), CpG oligonucleotides and Resiquimod, which were identified to be po-
tential upstream activators. In line with that, the upstream regulators shown in Table 14 are 
proteins involved in the detection of danger and pattern associated molecular patterns 
(DAMPs and PAMPs) like the Toll-like receptors (TLR) 3, 7 and 9 which are sensors of endo-
somal nucleic acids. But also other pattern recognition receptors like the RLRs DDX58 (DEAD 
(Asp-Glu-Ala-Asp) box polypeptide 58; synonym RIG-1), IFIH1 (interferon induced with hel-
icase C domain 1; synonym MDA5) and their adaptor molecules MAVS, TBK1 (TANK-binding 
kinase 1) and MYD88 were predicted to be transcriptional activators (Table 14). These re-
sults show that many of the predicted upstream regulators are involved in sensing cytosolic 
nucleic acids. Further analysis of the in vivo and in vitro datasets revealed that genes coding 
for sensors of cytosolic RNA or DNA are significantly upregulated after low dose irradiation: 
Ifi204 (synonym Ifi16), Zbp-1 (Z-DNA binding protein; synonym Dai (DNA-dependent activa-
tor of IRFs), Dhx58 (DEXH (Asp-Glu-X-His) box polypeptide 58), Ddx58, Ifih1, Ifit1bl1 (IFN-
induced protein with tetratricpeptide repeats 1B like 1) a sensor of viral ssRNAs, and Ifit3b 
(adapter bridging TBK1 and MAVS) (Table 15).  
Table 13 IPA Upstream regulators (TLR agonists) 
Upstream regulator in vivo in vitro 
LPS 6.31 9.65 
poly I:C 5.65 7.02 
CpG oligonucleotide 1.24 4.45 
Resiquimod 1.83 3.39 
TLR agonist upstream regulators predicted by IPA to be activated in PECs after in vivo or in vitro LDI. Activation 
z-score ≥ |2|; p-value <0.0001 considered significant. Grey shaded values are below the threshold. Table 31lists 
the DEGs of the two datasets for each Upstream regulator. 
Table 14 IPA Upstream regulators (PRR signalling) 
Upstream regulator in vivo in vitro 
DDX58 3.05 4.02 
MAVS 4.23 4.07 
TBK1 2.81 4.08 
IFIH1 2.75 2.76 
TLR3 4.94 6.16 
TLR7 2.22 3.13 
TLR9 4.53 6.01 
MYD88 4.16 6.80 
TICAM1 4.41 6.48 
Upstream regulators, associated with PRR signalling, predicted by IPA to be activated in PECs after in vivo or in 
vitro LDI. Activation z-score ≥ |2|; p-value <0.0001 considered significant. Table 32 lists the DEGs of the two 
datasets for each Upstream regulator. 
 
RESULTS 
 
| 66  
Of note, IPA analysis predicted an activation of the canonical pathways ‘Activation of IRF by 
Cytosolic Pattern Recognition Receptors’ and ‘Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses’ by LDI (Figure 22 A). Together, these results strongly 
suggest that LDI leads to IFN signalling via the activation of Pattern Recognition Receptors. 
Table 15 LDI-induced expression changes in PRR signalling-associated genes  
Gene 
Symbol 
FC 
(in vivo) 
FDR 
(in vivo) 
FC 
(in vitro) 
FDR 
(in vitro) 
Description 
Ddx58 1.970 0.000 4.263 0.009 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58  
Dhx58 2.097 0.000 2.860 0.050 DEXH (Asp-Glu-X-His) box polypeptide 58 
Ifi204 2.382 0.000 3.792 0.013 interferon activated gene 204 
Ifih1 2.081 0.000 3.620 0.013 interferon induced with helicase C domain 1 
Ifit1bl1 12.588 0.002 10.021 0.027 
IFN induced protein with tetratricpeptide repeats 1B 
like 1  
Ifit3b 9.553 0.072 13.473 0.001 IFN-induced protein with tetratricopeptide repeats 3B 
Zbp1 4.569 0.000 25.246 0.001 Z-DNA binding protein 1 
Presented are the FC and FDR values from the in vivo and in vitro dataset. Significantly upregulated genes (FDR 
<0.05, FC ≥ |1.5|) are highlighted in tones of red, with the colour intensity indicating the level of gene expres-
sion.  
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3. DISCUSSION  
 
The efficacy of cancer immunotherapies is inhibited by the immunosuppressive characteris-
tics of the tumour microenvironment. In therapies based on the adoptive transfer of T cells, 
complete responses are restricted to a subset of patients. The limited success of adoptive T 
cell therapy can be attributed to a non-permissive tumour microenvironment that restricts 
their access to the tumour site but also impairs T cell function. The process of T cell extrava-
sation requires an activated endothelium which shows high expression levels of adhesion 
molecules. In many tumour entities, however, the vasculature is abnormal regarding its 
structure and function. For example, tumour endothelial cells express low levels of adhesion 
molecules, thereby forming a physical barrier to effector cell infiltration. On the other hand, 
the normalization of the tumour vasculature has been shown to enhance T cell infiltration 
(Huang et al., 2013) and, consequently, the efficacy of adoptive T cell therapy (Hamzah et al., 
2008; Johansson et al., 2012). On this basis, it was suggested to combine adoptive T cell 
therapy with additional treatment modalities that reprogram the tumour microenvironment 
and overcome the tumour’s intrinsic resistance mechanisms that interfere with T cell infiltra-
tion and function. Among them, radiotherapy represents a suitable candidate, as it stimu-
lates antitumour immune responses, is capable of breaking the endothelial barrier and re-
duces immunosuppressive processes within tumours (Burnette and Weichselbaum, 2013; 
Soukup and Wang, 2015). The combination of irradiation with various cancer immunothera-
pies has already shown promising results in preclinical, as well as clinical studies (Kalbasi et 
al., 2013; Kwilas et al., 2012).  
 
Previous work has investigated the combinatorial effects of radiotherapy and adoptive T cell 
transfer in the RT5 tumour mouse model, as the transfer of tumour-specific, in vitro-
activated T cells alone was revealed to be insufficient to induce tumour immune rejection 
(Ganss et al., 2002; Klug et al., 2013). Moreover, adoptive T cell therapy may even reinforce 
immunosuppression as it was shown to induce intratumoural TH2 cytokines when it was not 
combined with irradiation (Klug et al., 2013). On the other hand, in this, but also in other 
tumour mouse models, radiation was shown to enhance the efficacy of adoptively trans-
ferred T cells to reject solid tumours (Chakraborty et al., 2003; Ganss et al., 2002; Reits et al., 
2006; Zhang et al., 2007). The doses used in these studies, however, were high (8-10 Gy) 
rendering the translation into a clinical setting problematic, since high radiation doses cause 
organ toxicities and, in severe cases, require bone marrow transplantation. As published by 
our group, low dose irradiation (2 Gy; LDI) combined with adoptive T cell therapy induced 
massive T cell infiltration and resulted in long-term survival in RT5 mice (Klug et al., 2013), 
suggesting that LDI offers a better approach for clinical translation as a neoadjuvant therapy 
prior to adoptive T cell transfer. This study presents an analysis of the underlying mecha-
nisms of increased T cell infiltration following LDI in combination with adoptive T cell trans-
fer and focusses on the cross-talk between LDI and the tumour microenvironment. 
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3.1. Combination therapy reprograms the tumour microenvironment 
 
The first part of this work demonstrated that the combination of local LDI and adoptive T cell 
transfer leads to a normalization of the aberrant tumour vasculature, to an increase in intra-
tumoural macrophages and a reduction in intratumoural MDSCs, which is indicative of a less 
immunosuppressive tumour microenvironment after treatment. This is further supported by 
Klug et al. who showed that combination therapy promotes a shift of the tumours’ cytokine 
profile in favour of a TH1 cytokine response (Klug et al., 2013). The less immunosuppressive 
tumour microenvironment, together with the normalized tumour vasculature and activated 
endothelium, renders tumours more accessible to the infiltration of T cells and supports 
their antitumour functions, thereby enhancing the rejection of established RT5 insulinomas. 
Tumour rejection induced by combination therapy was demonstrated by the reduction in 
tumour size but also by normalized blood glucose levels, which indicate tumour regression 
(Klug et al., 2013; Seibel, 2010). Insulinomas are pancreatic islet carcinomas, which constant-
ly produce insulin and thus cause chronically reduced blood glucose levels (hypoglycaemia). 
Therefore, blood glucose levels provide an indirect measurement of the tumour burden in 
RT5 mice. Notably, tumour growth could merely be delayed in mice that received a single 
injection of CD8+ T cells, while repetitive T cell transfers, following a single low dose of radia-
tion, were able to provoke complete macroscopic regression of established tumours and led 
to long-term survival (Klug et al., 2013). Since highly activated T cells display only a short 
lifespan of approximately 7-20 days after in vivo expansion (Ganss et al., 2002; Nayar et al., 
2015), repeated transfers guarantee consistently high levels of tumour-specific T cells, in 
contrast to a single infusion. 
 
In 2008, Quezada et al. published similar findings in a transplantable melanoma mouse 
model. They combined 4.5 Gy irradiation with the transfer of tumour antigen-reactive T cells 
and found that this treatment leads to the infiltration of T cells, delayed tumour growth and 
prolonged survival, as well as an upregulation of VCAM-1 and ICAM-1 on tumour endothelial 
cells (Quezada et al., 2008). In their study, as in our model, LDI alone did not cause vessel 
normalization, endothelial activation or T cell infiltration. Moreover, T cell transfer alone had 
only minor effects on vessel normalization and slightly increased T cell infiltration (Klug et al., 
2013; Quezada et al., 2008)(data not shown). This demonstrates that full vascular normaliza-
tion requires the synergy of LDI and T cell transfer, indicating that the in vitro-activated 
transferred T cells substantially contribute to endothelial activation and vessel normalization. 
 
The massive infiltration of macrophages into RT5 tumours after combination therapy raised 
the question of their role in the treatment effects. Systemic depletion of macrophages pre-
vented treatment-induced T cell infiltration and reduced the prolonged survival (Klug et al., 
2013; Seibel, 2010). In this study, clodrosome-mediated depletion of TAMs in otherwise un-
treated RT5 mice did not suppress tumour growth, nor did it affect the aberrant tumour vas-
culature or survival compared to untreated control mice. Together these findings demon-
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strate that macrophages are necessary for the effects of LDI and adoptive T cell transfer. 
They further suggest that these macrophages exert proinflammatory functions as they are 
required to overcome the immunosuppressive tumour microenvironment and enable tu-
mour immune rejection. An important characteristic of proinflammatory macrophages is the 
production of iNOS. Expression of Nos2, the gene encoding iNOS, can be induced in response 
to various inflammatory stimuli during pathogenic infections, but also during radiation-
induced inflammation (Lorimore et al., 2001). In RT5 tumours, iNOS was shown to be ex-
pressed by macrophages after combination therapy (Klug et al., 2013), demonstrating their 
proinflammatory phenotype. On the other hand, iNOS can also be associated with tumour 
immune suppression. The enzyme is expressed by intratumoural MDSCs and its product NO 
has been shown to inhibit T cell function by nitrating T cell receptors, CD8 molecules and 
various proteins involved in TCR signalling (Monu and Frey, 2012). Here we show that the 
inhibition of iNOS in RT5 mice, treated with local LDI and adoptive T cell transfer, prevents 
tumour rejection. These findings suggest that in our setting, T cell function is not impaired by 
iNOS and that iNOS promotes tumour immune rejection in response to the treatment. 
Treatment-mediated activation of the tumour endothelium, as well as increased T cell and 
macrophage infiltration were dependent on the enzymatic activity of iNOS. As iNOS synthe-
sizes NO, these findings further imply that NO is directly involved in the activation of the 
tumour endothelium. We tested this assumption by treating HUVECs with increasing doses 
of the NO donor DETA NONOate, which revealed a dose-dependent dichotomy in the func-
tions of NO: high doses of NO inhibited the expression of adhesion molecules on endothelial 
cells, even after cytokine stimulation, whereas low concentrations of NO activated the HU-
VECs to upregulate adhesion molecules. These results also explain the frequently reported 
finding that NO suppresses the expression of VCAM-1 and other adhesion molecules on en-
dothelial cells, since these studies used high concentrations of NO (De Caterina et al., 1995; 
Khan et al., 1996). Interestingly, it was recently shown that the endothelial upregulation of 
adhesion molecules, mediated by low doses of NO, is dependent on NF-κB signalling 
(Sektioglu et al., 2016). Together, these data demonstrate that by inducing iNOS activity in 
macrophages, the combination of local LDI and adoptive T cell transfer leads to the activa-
tion of tumour endothelial cells, which upregulate adhesion molecules and thereby promote 
tumour infiltration of T cells and macrophages. Our findings, thus, confirm the observations 
of an in vitro study in which irradiated macrophages were shown to induce VCAM-1 expres-
sion in HUVECs in an iNOS/NO dependent manner (Xiao et al., 2014). Since iNOS inhibition 
did not fully abrogate the effects of combination therapy on the vessel phenotype or adhe-
sion molecule expression, we presume that additional factors are involved in regulating the 
vessel characteristics in response to the treatment. 
 
Radiation is used as a localized therapy for solid tumours. As abscopal effects, where distant 
metastases are affected by the treatment, are rare (Demaria and Formenti, 2016), radiation 
therapy is not suitable for the treatment of disseminated disease, thereby limiting its range 
of application considerably. Since we found that the combination of local LDI and adoptive T 
cell transfer is mediated by iNOS-producing macrophages, we examined whether the trans-
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fer of peritoneal macrophages from irradiated wt donor mice, together with adoptive T cell 
transfer, had similar effects. The combined transfers would allow the treatment of metasta-
sized cancer patients and haematological malignancies. Peritoneal macrophages were there-
fore elicited by thioglycolate-induced sterile peritonitis, followed by isolation of peritoneal 
exudate cells (PECs), a protocol widely used in macrophage research (Gallily et al., 1964; Li et 
al., 1997). Analysis of freshly isolated PECs revealed that the majority were macrophages 
(60-80 %), while very few T cells, some dendritic and granulocytic cells were also detected. In 
agreement with these findings, it was recently shown that thioglycolate-elicited peritoneal 
exudates comprise a heterogeneous mix of several cell types including B and T lymphocytes, 
as well as NK cells, DCs, neutrophils, eosinophils and macrophages, which make up the ma-
jority of PECs (Misharin et al., 2012). In vivo LDI of peritoneal cells led to an increase in Gr-1+ 
cells. Gr-1 can be expressed by granulocytes (neutrophils, eosinophils (Ghosn et al., 2010; 
Misharin et al., 2012)), monocytes (Geissmann et al., 2003) and by rare subsets of peritoneal 
macrophages (Ghosn et al., 2010). Gr-1 expression is therefore not suitable for the discrimi-
nation between different types of myeloid cells and a more detailed analysis is required. 
Granulocytes, accounted for the largest fraction of non-macrophages in the peritoneal exu-
date, which is in line with the literature where eosinophils are described to be a major 
source of contamination in thioglycolate-elicited macrophages (Carretero et al., 2015; 
Misharin et al., 2012). Of note, in transplantable tumour mouse models, activated eosino-
phils have recently been shown to enhance T cell infiltration into tumours by modulating the 
tumour microenvironment. The eosinophils induced the normalization of the aberrant tu-
mour vasculature and the polarization of TAMs to an M1-like phenotype (Carretero et al., 
2015). Neutrophils were also reported to exhibit antitumour potential and to suppress tu-
mour growth (Di Carlo et al., 2001; Noffz et al., 1998; Sionov et al., 2015). Furthermore, eo-
sinophils and neutrophils become activated by danger signals released after irradiation 
(Dalal et al., 1992; Lorimore et al., 2001; Takeshima et al., 2016). Therefore, the eosinophils 
and neutrophils could further support the treatment effects on RT5 tumours by skewing per-
itoneal macrophages to M1-like phenotypes, thereby further promoting the reprogramming 
of the tumour microenvironment. 
 
Following the transfer of irradiated PECs and CD8+ T cells, the aberrant tumour vasculature 
was normalized and the endothelium was activated, thereby facilitating leukocyte infiltration. 
During tumour development, abnormally high levels of intratumoural VEGF result in uncon-
trolled angiogenesis and the development of an aberrant tumour vasculature. Tumour ves-
sels are characterized by reduced perfusion, which aggravates hypoxia and further promotes 
the production of VEGF. Anti-angiogenic therapies can break this vicious cycle and, by target-
ing VEGF, transiently normalize the vasculature which can improve the efficacy of anticancer 
therapies (Jain, 2013). Similarly, the transfer of irradiated PECs combined with adoptive T 
cell transfer reduced intratumoural VEGF levels that were increased after LDI or transfer of 
CD8+ T cells alone (Klug et al., 2013). The vascular normalization, as well as the endothelial 
upregulation of adhesion molecules, can be explained by a combination therapy-induced 
shift from M2-like TAMs, which are characterized by the production of high levels of VEGF 
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and other proangiogenic factors, to M1-like macrophages that generate NO via increased 
expression of iNOS. The reduced levels of the proangiogenic factors may account for vascular 
normalization, while NO-mediated activation may result in the upregulation of adhesion 
molecules on the endothelium. Of note, endothelial activation in RT5 tumours was even 
more pronounced after transfer of irradiated PECs and CD8+ T cells compared with local LDI 
and T cell transfer, indicating that the transfer of irradiated macrophages has a stronger ef-
fect on endothelial activation than local LDI. Possibly, fewer macrophages are stimulated by 
local LDI, due to the restricted field of radiation, compared to the number of macrophages 
stimulated by TBI in wt mice, which are transferred to RT5 mice. Hence, the transfer of irra-
diated macrophages may provide more stimulatory factors for endothelial cells in RT5 tu-
mours, causing a stronger activation and upregulation of adhesion molecules. Alternatively, 
macrophage phenotypes might be part of the cause. Macrophages in RT5 tumours are influ-
enced by the immunosuppressive microenvironment and may therefore be polarized to-
wards M2-like phenotypes, whereas macrophages which are transferred from wt mice were 
not exposed to pro- or anti-inflammatory stimuli and might therefore display a more naïve 
phenotype. The effects of radiation on the distinct phenotypes could differ and induce 
stronger activation towards M1-like phenotypes in the more naïve macrophages. Of course, 
further investigations are required to clarify the observations.  
 
The normalization of the tumour vasculature and the activation of the tumour endothelium 
correlated with an increased number of intratumoural T cells and macrophages, as well as 
with a reduced tumour size, suggesting that the transferred tumour-specific T cells, which 
were enabled to infiltrate the tumour tissue by the normalized tumour vasculature, exert 
their antitumour functions, thereby mediating tumour immune rejection. After transfer of 
irradiated but not unirradiated PECs, T cell infiltration was accompanied by the infiltration of 
macrophages, indicating that the transferred PECs migrate to the tumour site and accumu-
late therein. However, only few endogenous intratumoural macrophages were observed in 
untreated RT5 mice, suggesting that macrophages, just like T cells, are hindered from infil-
trating the tumour tissue by the tumour endothelial barrier. Consequently, the aberrant tu-
mour vasculature may impair tumour infiltration by irradiated PECs which are injected into 
untreated RT5 mice. Furthermore, PEC infiltration may be influenced by the yet undefined 
mechanisms of tumour vasculature normalization induced by adoptive T cell transfer. To 
investigate whether the transferred irradiated PECs are capable of infiltrating untreated tu-
mours, labelled PECs were tracked in vivo and RT5 tumours were analysed for labelled PECs 
before and after T cell transfer (day 10). Transferred PECs could be detected on day 10 and 
day 17 following PEC injection, demonstrating that macrophages are able to infiltrate RT5 
tumours with or without T cell transfer and that the infiltration was not affected by the aber-
rant tumour vasculature. This implies that macrophages can overcome the endothelial barri-
er or circumvent it and migrate into tumours via surrounding tissues (Dandekar et al., 2011; 
Lamagna et al., 2006). Of note, macrophage migration is not a directed process, as the ma-
jority of transferred PECs drained in the lung, liver, and spleen and only a small number of 
peritoneal macrophages reached the tumour site. The numbers of labelled PECs within tu-
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mours were too low to account for the vast accumulation of intratumoural macrophages 
observed after the transfer of irradiated PECs and T cells. An alternative explanation for the 
increased number of TAMs after treatment could be the recruitment of endogenous macro-
phages to the tumour site from the surrounding tissues (Klug et al., 2013) or from the blood 
but also the proliferation of intratumoural macrophages (Campbell et al., 2011; Tymoszuk et 
al., 2014; Van Overmeire et al., 2014). However, it remains unclear how the irradiated PECs 
instigate the reprogramming of the tumour microenvironment. As no treatment-specific 
differences in PEC infiltration were observed, we assumed that LDI affects PEC effector func-
tions rather than the migration to and infiltration into RT5 tumours. 
 
3.2. LDI primes peritoneal macrophages 
 
Ionizing radiation can induce macrophage activation through the release of danger signals 
from damaged tissues (Schaue et al., 2015). To gain insight in gene expression and functional 
changes induced by LDI in peritoneal macrophages, whole transcriptome analysis was per-
formed of in vivo and in vitro irradiated PECs. RNA sequencing revealed that in vivo, as well 
as in vitro (ex vivo), LDI affects gene expression in PECs. After in vivo and in vitro irradiation, 
410 and 509 genes, respectively, were significantly differentially expressed. By unsupervised 
hierarchical clustering, the samples of the in vivo dataset clustered together according to 
their treatment. In the in vitro dataset however, two of the irradiated samples displayed a 
higher similarity to the controls than to the other irradiated samples, which showed distinct 
expression patterns compared to the unirradiated samples. Since independent experiments 
with in vitro irradiated PECs clearly showed that irradiated samples differed from control 
samples in their gene expression, we assume that irradiation might have failed in the two 
unresponsive samples of the first experiment. 
Comparison of the datasets revealed that 94 of the differentially expressed genes (DEGs) 
were commonly regulated after in vivo and in vitro irradiation, demonstrating a strong over-
lap between the different experimental setups. It was presumed that these DEGs represent 
the genes whose expression is directly affected by LDI. Due to the different experimental 
conditions, however, it was expected that the majority of DEGs shows no overlap between in 
vivo and in vitro treatment. In the in vivo setting, wt mice received total body irradiation and 
so whole tissues were affected, resulting in cell damage and stress responses in immune 
cells, as well as non-immune cells, causing the release of various factors that activate com-
ponents of the immune system. In vitro irradiation, on the other hand, affects only cells in 
the peritoneal exudate, thereby restricting the effects to immune cells. Furthermore, in this 
setting the cells were cultured after isolation, which affects the composition of the different 
cell subsets. As described earlier, freshly isolated, thioglycolate-elicited PECs are a heteroge-
neous mix of many cell types with the majority (60-80 %) being macrophages. Culturing the 
PECs led to an enrichment of macrophages (90-95 %). Misharin et al. described that adher-
ence considerably reduces the contamination with dead cells, lymphocytes, dendritic cells, 
neutrophils and, although to a lesser extent, eosinophils (Misharin et al., 2012). In addition, 
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isolation procedures and culture conditions can influence the functional phenotype of mac-
rophages (Chiang et al., 2008). But despite the differences between the two setups, the 
DEGs of both datasets were associated with similar biological functions, namely immune 
system processes, cell migration and stress response. GO enrichment analysis indicated that 
LDI increases the migration of PECs and promotes PEC-induced cell movement of other cells. 
The former is supported by changes in chemokine receptor or adhesion molecule expression 
(Cx3cr1; integrins) and the latter by the upregulation of chemokines such as Ccl2, Ccl7 and 
Cxcl2 in response to in vivo LDI and Ccl5, Ccl6, Ccl12, Cxcl1, Cxcl2, Cxcl3 and Cxcl16 after in 
vitro LDI, as well as other chemoattractive proteins, such as components of the complement 
system. These changes enable irradiated PECs to migrate and infiltrate various organs, in-
cluding tumours, and to recruit other leukocytes to their location, such as T cells or macro-
phages to the tumour site after their infiltration. Furthermore, ‘innate immune response’ 
was identified as a GO term enriched in the datasets, and leukocytes, such as myeloid cells, 
phagocytes and macrophages were predicted to be activated by LDI. Interestingly, the IFN 
signalling pathway was enriched and a high abundance of IFN regulated genes (IRGs) was 
identified among the DEGs, demonstrating that LDI leads to the upregulation of IRGs through 
the activation of IFN signalling. It is well described that type I but also type II IFNs are pro-
duced in response to irradiation, thereby initiating IFN signalling (Deng et al., 2014; Lim et al., 
2014; Lugade et al., 2005; Sugihara et al., 2011). Type I IFNs have been shown to be upregu-
lated in tumours early after radiation and subsequently induced the production of IFN-γ (Lim 
et al., 2014).  
 
During viral infections, the presence of foreign nucleic acids initiates an innate immune re-
sponse through the activation of the interferon regulatory factors, IRF3 and IRF7, which in-
duce the transcription of type I IFNs. Secreted IFN-α and β bind to type I IFN receptors in an 
autocrine and paracrine manner and thereby induce the transcription of IRGs, including Irf7. 
This initiates a positive feedback loop which amplifies the signal and ensures a quick re-
sponse to infectious viruses (Honda and Taniguchi, 2006). Here we show that LDI induces the 
upregulation of Irf7 in PECs, which was dependent on type I and type II IFNs, suggesting that 
LDI activates processes similar to the ones induced by viral infections. Using IPA, IRF7 was 
identified as an upstream regulator of the DEGs. Through the amplification of IFN signalling, 
IRF7 promotes the upregulation of IRGs, suggesting that LDI acts via the IRF7 and IFN ampli-
fication loop to mediate its effects. Prior to that, IRF7 becomes activated by cytosolic nucleic 
acids, danger signals that are generated during viral infections, but also during cellular stress 
which can be induced by irradiation-generated radicals. Cytosolic DNA, as well as certain 
cytosolic RNAs, are sensed by PRRs which activate signalling cascades that lead to the ex-
pression of effector genes, thereby shifting the irradiated cells to an activated (anti-viral) 
state. In the in vivo and in vitro dataset, PRRs that sense cytosolic DNA, as well as their lig-
ands and adaptor molecules, were identified as upstream regulators. Furthermore, the sig-
nalling pathways ‘Activation of IRF by Cytosolic Pattern Recognition Receptors’ and ‘Role of 
Pattern Recognition Receptors in Recognition of Bacteria and Viruses’ were predicted to be 
activated. In this line, genes encoding sensors of cytosolic nucleic acids were highly upregu-
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lated after LDI. The DExH/D box helicases encoded by Ddx58 and Ifih1 detect ds and ssRNA 
and signal via the adaptor protein MAVS. MAVS activates TBK-1 and IKK (IκB kinase), thereby 
initiating IRF3/IRF7 and NF-κB signalling, which culminates in the expression of type I and 
type II IFNs and IRGs, as well as proinflammatory cytokines (Brubaker et al., 2015). IFIT1bl1 is 
a sensor of viral ssRNAs and IFIT3b is an adaptor bridging TBK1 and MAVS. IFI204, is induced 
by IFN signalling and an inducer of Ifnb transcription. Its human homolog IFI16 is involved in 
the DNA damage response. ZBP-1, also called DAI, activates IRF3 and NF-κB upon sensing 
cytosolic DNA (Unterholzner, 2013). In summary, the genes Ddx58, Dhx58, Ifi204, Ifih1, 
Ifit1bl1, Ifit3b and Zbp1 were upregulated after LDI and together, this demonstrates that LDI 
leads to a stress response in PECs and, through the detection of cytosolic nucleic acids, in-
duces IFN signalling. 
 
In peritoneal macrophages, LDI leads to the activation of IFN signalling and to the expression 
of Irf7 which both strongly upregulate the expression of Irf1 (Sgarbanti et al., 2007). IRF1 is a 
transcription factor and direct inducer of Nos2 expression (Kamijo et al., 1994). In accord-
ance, LDI led to the upregulation of Nos2 in PECs which was dependent on IFN-γ and IFN-β. 
Moreover, the IFN-γ signalling pathway genes Ifng, as well as Stat1 and Irf1, displayed in-
creased expression levels after LDI, which was also dependent on IFN-γ and IFN-β. We 
thereby show that LDI leads to the upregulation of iNOS through the induction of an IFN re-
sponse. The release of NO from iNOS+ macrophages can then induce the expression of adhe-
sion molecules on tumour endothelial cells, thereby promoting leukocyte infiltration.  
 
TNF-α and IL-1β are the most important mediators of endothelial activation during inflam-
mation. They stimulate increased expression of adhesion molecules on endothelial cells 
(Mako et al., 2010) and have been shown to be upregulated in macrophages in response to 
irradiation (Iwamoto and McBride, 1994; Nemoto et al., 1995; Ray et al., 2013). In this study, 
gene expression analysis of irradiated PECs revealed that Tnfa was upregulated after LDI in 
an IFN-γ- and IFN-β-dependent manner, suggesting that it synergizes with NO in the activa-
tion of endothelial cells in RT5 tumours. IL-1ß was also strongly upregulated after in vitro LDI 
as determined by RNA Sequencing and might contribute to endothelial activation, in addi-
tion to NO and TNF-α. 
 
Taken together, the results obtained in the course of this study point to an LDI-induced M2 
to M1 shift in the peritoneal macrophages. The literature reports contradictory findings re-
garding the effects of radiation on the polarization of macrophages. Intramuscular or intra-
cranial murine tumours treated with 25 or 8 Gy, respectively, developed hypoxic areas that 
were associated with an accumulation of M2 macrophages. Another study showed that phe-
notypic changes following irradiation were dependent on the mouse strain: murine-derived 
BMDMs from CBA/Ca and C57/BL/6 mice displayed M1- and M2-like phenotypes, respective-
ly, after in vivo, as well as in vitro irradiation, with 4 Gy (Coates et al., 2008). A recent study 
describes a shift towards pro-inflammatory M1-like phenotypes in human blood monocyte-
derived macrophages after ionizing radiation (5x2 Gy), however, these macrophages re-
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tained some tumour promoting abilities (Teresa Pinto et al., 2016). In 2007 Shan et al. 
showed that 2 Gy TBI induced the production of proinfilammatory cytokines in murine peri-
toneal macrophages (Shan et al., 2007). In the present study, gene expression analysis of 
irradiated peritoneal macrophages revealed that several genes, associated with M2-like 
phenotypes were downregulated (i.e. Cd163, RetnIa, Fcrls), whereas genes associated with 
M1-like phenotypes were upregulated (Nos2, Isg15, Ifi44, Ifit1) (Jablonski et al., 2015). Fur-
thermore, the surface expression of the M2 marker CD206 (Chávez-Galán et al., 2015; 
Martinez et al., 2008) was decreased after in vivo and in vitro irradiation. Surprisingly, gene 
expression of MHC class II, which is generally described to be an M1 marker (Biswas and 
Mantovani, 2010), was downregulated after in vivo irradiation. Also the number of MHC 
class II+ macrophages was decreased after in vivo as well as in vitro LDI. Stimulation with IFN-
γ (but not LPS), on the other hand, induced the upregulation of MHC class II surface expres-
sion on peritoneal macrophages (Figure S34). Interestingly, IFN-γ-induced MHC class II ex-
pression can be suppressed by the TLR9 and 7 ligands CpG ODN and Resiquimod (Celhar et 
al., 2016; Chu et al., 1999), by TNF-α (Watanabe and Jacob, 1991) and by type I IFNs (Heise 
et al., 1998), all of which are proinflammatory stimuli that skew macrophages towards M1- 
rather than M2-like phenotypes (Kratochvill et al., 2015; Lee et al., 2014; Sica and Mantovani, 
2012; Wang et al., 2015; Wu et al., 2016; Xie et al., 2016). As described earlier, irradiation 
mediates its effects via type I IFN responses. Therefore, we assume that irradiation inhibits 
MHC class II expression by means of type I IFN induction. Overall, MHC class II might not be 
the ideal M1 marker, as it is also expressed on M2 macrophages (Martinez and Gordon, 
2014) and therefore does not clearly characterize macrophage polarization states. iNOS, on 
the other hand, is an established marker of M1-like macrophages (Murray et al., 2014) and 
in our setting Nos2 expression was upregulated after in vivo and in vitro LDI. However, flow 
cytometric evaluation of iNOS protein levels revealed only low expression intensities on peri-
toneal macrophages and in vivo but not in vitro irradiation led to a slight increase in iNOS+ 
macrophages. The reported controversy in the literature regarding macrophage polarization 
in response to irradiation might be attributable to divergent effects of different doses and 
dose fractionations. However, another reason might be that the macrophage polarization 
paradigm, which is applied, is oversimplified. The M1/M2 polarization model describes iso-
lated in vitro activation of macrophages with a limited number of stimuli and does not take 
into account the complex networks of pro- and anti-inflammatory factors that are present in 
inflammatory or tumour tissues. These -often conflicting- stimuli influence the activation 
state of macrophages and produce mixed populations including different polarization states 
where M1 and M2 represent the extremes in a spectrum of phenotypes (Martinez and 
Gordon, 2014; Murray et al., 2014). Therefore, it is unlikely that macrophages isolated from 
tissues of living organisms display a clear-cut activation status as it is described by the 
M1/M2 paradigm. According to the newly proposed nomenclature by Murray et al, the irra-
diated peritoneal macrophages in our setting most closely resemble M(LPS) macrophages, 
which express low levels of Nos2 and are not fully activated unless they receive additional 
stimuli, such as IFN-γ. In addition, the thioglycolate-induced PECs might also comprise mac-
rophages that are not fully differentiated and still display monocytic features, such as lower 
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surface expression of MHC class II. In monocytes, MHC class II molecules are retained in en-
dosomal compartments until macrophages become fully activated (Roche and Furuta, 2015). 
In contrast, the macrophages observed in RT5 tumours after the treatment with either LDI or 
irradiated PECs in combination with adoptive T cell transfer display a more fully activated 
phenotype, as they express higher levels of iNOS (Klug et al., 2013). A possible explanation 
may be that these macrophages are exposed to the adoptively transferred T cells, which in-
filtrate the tumour and produce IFN-γ, which can fully activate the macrophages to a proin-
flammatory M1 phenotype. 
 
3.3. Conclusion 
 
Combining cancer immunotherapies with treatment modalities that break tumour-induced 
immune suppression can synergistically potentiate their efficacy and enhance clinical re-
sponses (Drake, 2012; Kalbasi et al., 2013). However, the complex interactions between the 
different therapeutic approaches are not well understood. The present study demonstrates 
how low dose irradiation in combination with adoptive T cell transfer augments tumour im-
mune rejection through the manipulation of the tumour microenvironment. It thereby con-
tributes to the understanding of the interactions between radiation therapy, the immune 
system and cancer. Based on the findings of this study we propose the following model of 
the mechanism of action: 
LDI, locally applied to the tumour tissue or systemically applied to wt mice, primes macro-
phages through the induction of DNA damage and the release of danger signals, which are 
sensed by macrophages through PRRs. PRR signalling then induces IFN responses that lead 
to the expression of IRGs, amongst others, Nos2 and Tnfa. Primed macrophages produce low 
levels of iNOS and TNF-α, which lead to an initial and modest activation of endothelial cells 
in tumour tissues. The upregulation of adhesion molecules allows the infiltration of small 
numbers of leukocytes, including in vitro-activated IFN-γ producing T cells that are injected 
into tumour-bearing mice, as adoptive T cell therapy. The T cell-derived IFN-γ provides the 
required stimulus to fully activate intratumoural, primed macrophages which in turn in-
crease their production of iNOS and other proinflammatory cytokines, as well as chemokines, 
and become fully activated. The increased expression of iNOS and TNF-α further activates 
the endothelium and the secreted proinflammatory cytokines and chemokines reprogram 
the tumour microenvironment. Together, this leads to the recruitment and the infiltration of 
increasing numbers of immune effector cells. The initiated positive feedback loop can be 
maintained by repeated T cell transfers. Finally, the infiltrating, tumour-specific T cells exert 
their antitumour functions and mediate tumour eradication, leading to long-term survival 
(Figure 31). 
 
The present study demonstrates the benefits of the combination of adoptive T cell therapy 
with neoadjuvant local low dose irradiation over the monotherapy. It further implies the 
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huge potential of this treatment strategy in clinical settings. We therefore suggest that these 
findings should be tested in a clinical trial.  
 
 
Figure 31 Proposed mechanism of action 
LDI primes TAMs through the generation of danger signals in irradiated tissues. Primed macrophages downreg-
ulate M2-markers and induce low levels of iNOS and TNF-α, which modestly activate the tumour endothelium. 
Infiltrating in vitro-activated, IFN-γ producing T cells further activate the primed macrophages through IFN-γ, 
thereby increasing the expression of iNOS, TNF-α and initiating a positive feedback response. Similar models 
have been proposed by (Lee and Biswas, 2016; Sektioglu et al., 2016). 
 
 
MATERIALS AND METHODS 
 
| 78  
4. MATERIALS AND METHODS 
 
4.1. Materials 
4.1.1. Assay kits 
 
4.1.2. Antibodies 
4.1.2.1. Flow Cytometry 
Antibodies for flow cytometry directed against human epitopes  
 
Antibodies for flow cytometry directed against murine epitopes 
Product Supplier 
Agilent RNA 6000 Nano Kit Agilent Technologies 
ArC™ Amine Reactive Compensation Bead Kit Molecular Probes, Invitrogen 
Clodrosome Macrophage Depletion Kit Encapsula NanoSciences 
Foxp3/Transcription Factor Staining Buffer Set eBioscience 
LIVE/DEAD® Fixable Yellow Dead Cell Staining Kit Molecular Probes, Invitrogen 
Mouse IFN-γ Secretion Assay - Detection Kit (PE) Miltenyi Biotec  
Mouse IL-2 Secretion Assay - Detection Kit (APC)  Miltenyi Biotec  
PKH26 Red Fluorescent Cell Linker Kit for Phagocytic Cell Labelling Sigma-Aldrich 
RevertAid H Minus First Strand cDNA Synthesis Kit Thermo Scientific 
RNase-Free DNase Set (50) QIAGEN 
RNeasy Mini Kit (50) QIAGEN 
Zombie NIR™ Fixable Viability Kit Biolegend 
Specificity Conjugation Species Isotype Clone Supplier 
CD31 BV421 Mouse IgG1,κ WM59 Biolegend 
ICAM-1 
(CD54) 
FITC Mouse IgG1 O1 Sino Biological 
VCAM-1 
(CD106) 
APC Mouse IgG1,κ STA Biolegend 
E-Selectin 
(CD62E) 
PE Mouse IgG2a,κ HCD62E Biolegend 
Specificity Conjugation Species Isotype Clone Supplier 
CD11b BV510  Rat IgG2b,κ M1/70  Biolegend 
  PerCP Rat IgG2b,κ M1/70  Biolegend 
  PE-Cy7 Rat IgG2b,κ M1/70  ebioscience 
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APC (Allophycocyanin), BV510 (Brilliant Violet™ 510), FITC (Fluorescein isothiocyanate), PE (Phycoerythrin), 
PerCP, (Peridinin Chlorophyll), PE/Cy7 (Phycoerythrin/cyanine7), AF647 (Alexa Fluor® 647), AF488 (Alexa Fluor® 
488), APC/Cy7 (Allophycocyanin/cyanine7), PB (Pacific Blue™). 
 
4.1.2.2. Antibodies for Immunofluorescence 
Primary antibodies 
  APC-Cy7 Rat IgG2b,κ M1/70  BD Biosciences 
CD11c PerCP 
Armenian 
Hamster 
IgG N418 Biolegend 
  PE-Cy7 
Armenian 
Hamster 
IgG1, λ2 HL3 BD Biosciences 
CD206 
(MMR) 
FITC Rat IgG2a,κ C068C2 Biolegend 
CD3e  APC 
Armenian 
Hamster 
IgG1,κ 145-2C11  BD Biosciences 
CD4 APC-Cy7 Rat IgG2b,κ GK1.5 BD Biosciences 
  FITC rat IgG2a,κ RM4-5 BD Biosciences 
CD45 V450 Rat IgG2b,κ 30-F11  BD Biosciences 
  V500 Rat IgG2b,κ 30-F11  BD Biosciences 
  FITC Rat IgG2b,κ 30-F11  BD Biosciences 
CD8a  PerCP Rat IgG2a,κ 53-6.7 BD Biosciences 
  PB Rat IgG2a,κ 53-6.7 BD Biosciences 
F4/80 AF647 Rat IgG2b Cl:A3-1 AbD Serotec 
  AF488 Rat IgG2b Cl:A3-1 AbD Serotec 
  APC  Rat IgG2a,κ BM8 ebioscience 
  PE Rat IgG2a,κ BM8 ebioscience 
I-A/I-E (MHC 
class II) 
PB Rat IgG2b,κ M5/114.15.2 Biolegend 
Ly-6G/Ly-6C 
(Gr-1) 
PerCP Rat IgG2b, κ RB6-8C5 Biolegend 
  APC Rat IgG2b,κ RB6-8C5  BD Biosciences 
NOS2 PE Rat IgG2a,κ CXNFT eBioscience 
  AF488 Rat IgG2a,κ CXNFT eBioscience 
Specificity Reactivity Host Clonality Supplier 
CD31 mouse hamster 2H8 AbD serotec 
SV40TAg Simian Virus 40 rabbit  poly Santa Cruz 
VCAM-1 (CD106) mouse rat 429 BD Pharmingen 
Gr-1 (Ly6G and Ly6C) mouse rat CRB6-8C5 BD Biosciences 
F4/80 mouse rat CI:A3-1 AbD serotec 
CD11b  mouse rat M1/70 BD Biosciences 
CD68 mouse rabbit poly Abcam 
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Secondary antibodies 
 
4.1.3. Chemicals and Biological Reagents 
CD3 mouse goat poly Santa Cruz 
CD4 mouse rat H129.19 BD Biosciences 
CD8 mouse rat YTS105.18 AbD serotec 
Specificity Conjugation Host Supplier 
anti-goat Alexa Fluor® 488 chicken Invitrogen 
anti-rat Alexa Fluor® 594 chicken Invitrogen 
 Alexa Fluor® 488 chicken Invitrogen 
anti-rabbit Alexa Fluor® 488 chicken Invitrogen 
anti-hamster Alexa Fluor® 594 goat Invitrogen 
Product Supplier 
2.4G2 HSN (Hybridoma Supernatant) 
Kindly provided by Prof. Dr. 
Cherwenka 
Accutase solution SIGMA-Aldrich  
Acetone SIGMA-Aldrich 
Aqua ad injectibilita B. Braun 
BD™ CompBead Compensation Particles Anti-rat/hamster Ig, k BD Biosciences 
BD™ CompBead Compensation Particles Anti-mouse Ig, k BD Biosciences 
BD™ Cytometer Setup & Tracking beads BD Biosciences 
Bovine Serum Albumin (BSA) SIGMA-Aldrich 
Collagenase D Roche  
Dispase® I (neutral protease, grade I) Roche 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Deoxyribonuclease I from bovine pancreas (DNase I) SIGMA-Aldrich  
Dulbecco’s Phosphate Buffered Saline (PBS)  SIGMA-Aldrich  
Ethylenediaminetetraacetic acid EDTA (Versen) 1 % w/v in PBS w/o 
Ca2+/Mg2+ 
Biochrom AG  
Ethanol, Absolute SIGMA-Aldrich 
Ethanol, Absolute (200proof) Molecular Biology Grade Fisher BioReagents 
FACS Clean Solution BD Biosciences 
FACS Flow Sheath Solution BD Biosciences 
FACS Shutdown Solution BD Biosciences 
Fluoromount-G™, with DAPI eBioscience 
Griess reagent (modified) Sigma-Aldrich 
N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES) So-
lution  
SIGMA-Aldrich  
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4.1.4. Cell Culture Media and Supplements 
IgG aus Maus (polyklonal)-unkonj Dianova 
Isopropanol SIGMA-Aldrich 
Ketanest S (25 mg/ml) Pfizer 
NaCl 0.9 % B. Braun 
Nuclease Free Water Ambion 
Protein Block, Serum-Free DAKO 
RNaseZap® Ambion 
Rompun, 2 % Bayer-Schering 
Sandoglobulin (human IgG) CSL Behring 
Sera (Chicken, Goat) Santa Cruz 
Sodium Azide (NaN3) Gbiosciences 
Spitacid Ecolab 
SYTOX® Blue Dead Cell Stain Life Technologies 
TaqMan® Gene Expression Assay GAPDH Mm99999915_g1 Applied Biosystems 
TaqMan® Gene Expression Assay HPRT1 Mm03024075_m1  Applied Biosystems 
TaqMan® Gene Expression Assay IFNg Mm00801778_m1 Applied Biosystems 
TaqMan® Gene Expression Assay IFNg Mm01168134_m1 Applied Biosystems 
TaqMan® Gene Expression Assay iNOS Mm00440502_m1 Applied Biosystems 
TaqMan® Gene Expression Assay IRF1 Mm01288580_m1 Applied Biosystems 
TaqMan® Gene Expression Assay IRF7 Mm00516793_g1 Applied Biosystems 
TaqMan® Gene Expression Assay JAK1 Mm00600614_m1 Applied Biosystems 
TaqMan® Gene Expression Assay STAT1 Mm00439531_m1 Applied Biosystems 
TaqMan® Universal Master Mix II, with UNG Applied Biosystems 
Thioglycolate Medium (Powder) Applichem, Germany 
Tissue-Tek® O.C.T. Compound Sakura, Finetek 
Trypan Blue (0.4 %) SIGMA-Aldrich 
Trypsin-EDTA Solution (1x)  SIGMA-Aldrich 
Universal Mouse Reference RNA Agilent Technologies 
2-Mercaptoethanol SERVA Electrophoresis 
Product Supplier 
Dulbecco’s Modified Eagle’s Medium (DMEM) SIGMA-Aldrich  
RPMI-1640 Medium  SIGMA-Aldrich  
Fetal calf serum (FCS)  Biochrom AG  
Penicillin-Streptomycin (10 000 U/ml, 10 000 µg/ml) (Pen-
Strep) 
Gibco 
L-Glutamine (200 mM) Gibco 
2-Mercaptoethanol (50 mM)  Gibco  
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4.1.5. Buffers, Solutions and Cell Culture Media 
 
 
 
 
neutralizing IFN-γ antibody (R4-6A2 Hybridoma Supernatant) 
kindly provided by Prof. Dr. Rainer 
Zawatzky 
neutralizing IFN-β antibody (7F-D3 Hybridoma Supernatant) 
kindly provided by Prof. Dr. Rainer 
Zawatzky 
Murine IL-2 eBioscience 
Murine IFN-γ CellSystems 
SV-40 TAg peptide 560–568 (SEFLLEKRI) 
DKFZ core facility for peptide syn-
thesis 
Lipopolysaccharide (LPS) from E. coli 0111:B4 SigBayerma 
Endopan-3 kit with 9 supplements PAN-BioTech 
Recombinant Human TNF-α PeproTech 
DETA NONOate Enzo 
Human Umbilical Vein Endothelial Cells (HUVECs), pooled PromoCell 
Thioglycolate Components Volumes 
 
Thioglycolate medium 3 % (w/v) 
ddH2O  
ACK buffer Components Volumes 
 
NH4Cl  150 mM 
KHCO3  10 mM 
(Na2)EDTA  100 μM 
ddH2O  
Trypan blue solution Components Volumes 
 
PBS 1x 
Trypan blue 0.4 % 1:3 (v/v) 
Macrophage medium Components Volumes 
 
DMEM 1x 
FCS 10 % (v/v) 
Pen Strep 100 U/ml, 100 µg/ml 
L-Glutamine 2 mM 
β-mercaptoethanol 0.05 mM  
T cell medium Components Volumes 
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RPMI 1x 
FCS 10 % (v/v) 
Pen Strep 100 U/ml, 100 µg/ml 
L-Glutamine 2 mM 
β-mercaptoethanol 0.05 mM  
HUVEC medium Components Volumes 
 
Endopan 3 1x 
EGF (epidermal growth factor) 0.1 % 
FGF-2 (fibroblast growth factor-2) 0.1 % 
VEGF (vascular endothelial growth factor) 0.1 % 
Ascorbic Acid phosphate 0.1 % 
R3-IGF-1 (insulin-like growth factor-1) 0.1 % 
FBS (fetal bovine serum) 3 % 
Gentamycin/Amphotericin 0.12 % 
Hydrocortison  0.02 % 
Heparin  0.1 % 
Digestion solution Components Volumes 
 
PBS 1x 
Collagenase D 0.2 mg/ml  
Dispase I 0.08 mg/ml  
DNase I 25 µg/ml  
Pancreas digestion mix Components Volumes 
 
PBS 1x 
Collagenase D 0.2 mg/ml  
DNase I 25 µg/ml  
Complete medium Components Volumes 
 
RPMI 1x 
FCS 10 % (v/v) 
FACS buffer Components Volumes 
 
PBS 1x 
FCS 3 % (v/v) 
EDTA 1.5 mM 
2.4G2 HSN 20 % (v/v) 
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4.1.6. Consumables 
FACS blocking solution Components Volumes 
 
FACS buffer 1x 
IgG aus Maus (polyklonal)-unkonj 1:20 (v/v) 
SYTOX Blue solution Components Volumes 
 
SYTOX Blue Dead Cell Stain 1 µl 
FACS buffer 15 ml 
IF-staining buffer Components Volumes 
 
PBS 1x 
BSA 1 % (w/v) 
serum (goat/chicken) 10 % (v/v) 
Product Supplier 
Cell Scraper TPP 
Cell strainer (40 μm, 100 μm)  BD Falcon 
Cell-culture dishes, non-tissue culture treated (Optilux, 100 x 
20 mm) 
BD Falcon 
Cell-culture dishes, tissue-culture treated (100 x 20mm, 150 x 20 
mm) 
TPP 
Cell-culture flasks – tissue-culture treated with filtercap TPP 
Cryomolds® Sakura, Finetek 
Cyrovials with screw cap (2 ml) Greiner Bio-One 
Bepanthen® eye and nose ointment Bayer 
PAP Pen Dako 
Disposable needles – 20 G x 1 1/2 ’’, 0.9 x 40 mm (Sterican) B. Braun 
Disposable needles – 27 G x ¾’’, 0.4 x 20 mm (Neolus 100) Terumo 
Disposable scalpels Feather 
DNA LoBind Tubes (0.5 ml, 1.5ml) Eppendorf 
Falcon conical centrifuge tubes (15 and 50ml) BD Falcon 
LightCycler 480 multiwell plates 384, white Roche 
LightCycler 480 Sealing Foil Roche 
Microscopical glass cover slips R. Langenbrinck 
Multiwell plates, non-tissue culture treated (6-,12-, 24-, 48-, 96-
well (round bottom)) 
BD Corning 
Multiwell plates, tissue-culture treated (6-,12-, 24-, 48-, 96-well TPP 
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4.1.7. Technical Laboratory Equipment 
(round or flatbottom)) 
Parafilm M® Bemis NA 
Pasteur pipettes Corning 
PCR tube (0.1 ml) and cap strips, domed Eppendorf 
Pipette filter tips (10 μl, 20 μl, 100 μl, 200 μl, 1000 μl) Starlab 
Pipette tips (10 μl, 200 μl, 1000 μl) Gilson 
Pipette tips (200 μl) for multi-channel pipettes  Rainin 
Plastic serum pipettes (2 ml) Greiner Bio-One 
Polypropylene round bottom tubes (5 ml) BD Falcon 
Polystyrene round-bottom tube with cell-strainer cap (5 ml) BD Falcon 
Reagent reservoir, sterile (50 ml)  Corning 
Safe-lock tubes (0.5 ml, 1.5 ml, 2.0 ml and 5.0 ml)  Eppendorf 
Serological pipettes (2ml, 5 ml, 10 ml, 25 ml, 50 ml) BD Falcon 
Sterile syringe driven filter (0.22 μm)  Millipore 
Superfrost™ Ultra Plus Adhesion Slides Thermo Scientific 
Syringe, Norm-Ject tuberkulin (1 ml)  Henke Sass Wolf 
Syringes with luer lock tip (1, 5, 10, 30 and 50 ml)  Terumo 
T cell dishes (60, 100), suspension Sarstedt 
Warming pad  
Product Supplier 
137Cs irradiation unit (OB. 58/902-1; FA) Buchler GmbH 
Agilent2100 Bioanalyzer Agilent Technologies 
Analytical Balance (AE163) Mettler Toledo 
Digital calliper gauge Carl Roth 
Cell culture incubator (Heracell 240i) Thermo Scientific 
Cell Sorter (FACSAria™ III) BD Biosciences 
Centrifuge (Heraeus™ Multifuge™ X3 FR) Thermo Scientific 
Centrifuge (Megafuge 2.0R) Heraeus 
Cryotome (CM3050S) Leica 
Dissecting Instruments Fine Science Tools 
Flow Cytometer (FACSCanto™ II) BD Biosciences 
Fluorescence Mircroscope (AxioObserver Z1) Carl Zeiss 
Freezer (-20°C) Liebherr 
Freezer (-80°C) Thermo Fisher Scientific 
Fridge (4°C) Liebherr 
Gammacell 1000 D (137Cs) Best Theratronics 
Gammatron Cobalt 60 device Siemens 
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4.1.8. Software 
Name Company 
Office 2010 Microsoft Cooperation 
EndNote X7.5 Thomson Reuters 
FACSDiva software v.6.1.3 BD Biosciences 
FlowJo software v.X.06 Tree Star, Inc. 
AxioVision LE Rel. 4.8 Carl Zeiss Imaging Solutions GmbH 
ZEN 2012 blue edition Carl Zeiss Microscopy GmbH 
Fiji (Fiji is just ImageJ) LOCI, University of Wisconsin-Madison 
Incscape v.0.91 Freeware 
GraphPad Prism 6 GraphPad Software, Inc. 
Ingenuity® Pathway Analysis (IPA®) QIAGEN 
Gene-E v.3.0.204 Broad Institute, Inc. 
Venny 2.1.0 BioinfoGP, CNB-CSIC 
InteractiVenn VICG, ICMC, USP 
Glassware Schott 
Heatblock (Thermo mixer comfort) Eppendorf 
Ice Machine Hoshizaki 
Liquid Nitrogen Tank (Cryosystem 6000) MVE 
Magnetic stirrer (heatable) Heidolph Instruments 
Micro pipettes (2-1000 µl)  Gilson 
Microcentrifuge (Heraeus™ Fresco™ 17) Thermo Scientific 
Microplate Reader (Infinite M200) Tecan 
Microscope (AxioVert A1) Carl Zeiss 
Microwave Bosch 
Milli-Q® Integral Water Purification System Millipore 
Multichannel pipettes (200 µl; 8, 12 channels) Rainin 
Neubauer haemocytometer Brand 
PCR Machine (PTC-225) MJ Research™ Inc. 
Pipetboy (accu-jet® pro) Brand 
Real-time PCR Machine (LightCycler® 480 II) Roche  
Roller-Mixer (RM5) Karl Hecht 
Spectrophotometer (NanoDrop 2000c) PEQLAB Biotechnology 
Sterile Laminar Flow cabinet (Herasafe KSP) Thermo Scientific 
Vacuum Pump neoLab 
Vortexer (Reax 2000) Heidolph Instruments 
Water Bath (SW21) Julabo 
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Interferome v.2.01 Monash University 
STRING v.10.0 String Consortium 
LightCycler® 480 SW 1.5 Roche 
Tierbase Client v.2009.8.0 4D 
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4.2. Methods 
4.2.1. Murine studies 
4.2.1.1. Mouse strains 
All mice were bred and housed in the central animal core facility of the German Cancer Re-
search Center (DKFZ) under specific pathogen-free conditions. The animal experiments were 
performed according to governmental and institutional guidelines (based on the German 
Animal Welfare Act) and were authorized by local regulatory authorities (Regierungspräsidi-
um Karlsruhe, Germany). Table 16 lists the strains used in this work. 
Table 16. Mouse strains 
 
4.2.1.2. Preparation of murine tissue 
Mice, euthanized with CO2, were disinfected using 70 % ethanol and dissected under the 
laminar flow. The organs of interest were harvested under sterile conditions: spleen, pan-
creas and/or lung were removed and kept in PBS on ice until further use. Tumours were sep-
arated from the pancreatic tissue with the use of a scalpel and forceps; their size (diameter) 
was measured with a calliper before they were either collected in PBS on ice or were placed 
in cryomolds and embedded in OCT-compound. The embedded tissue was gradually frozen 
in an isopropanol-filled freezing container and subsequently stored at -80°C for immuno-
histochemistry. 
 
4.2.1.3. Anaesthesia 
A mixture of Rompun 2 % (20 mg/ml xylazine) and Ketanest S (25 mg/ml ketamine) was pre-
pared in PBS with a final concentration of 2 mg/ml xylazine and 10 mg/ml ketamine. Mice 
were injected intraperitoneally (i.p.) with 66 µl of the mixture per 10 g body weight, which 
provided a 20-30 min duration of anaesthesia. Anaesthetized mice were treated with oph-
thalmic ointment (Bepanthen® eye and nose ointment) and kept warm using a warming pad, 
to prevent desiccation-induced blindness and hypothermia. Pedal and eye blink reflexes 
were monitored every 10 min during anaesthesia, to determine the depth of anaesthesia. 
Strain Description Origin 
C3HeB/Fe (C3H) 
C3H substrain not carrying the mouse mammary 
tumour virus (MMTV) 
Charles River 
RIP1-TAg5 (RT5) 
(C3HeB/Fe background) 
SV40TAg expression, controlled by the rat insulin 
promotor 1 (RIP1) leads to spontaneous develop-
ment of insulinoma in β-islets 
D. Hanahan 
TCRtg/TCRCD8 (TCR8) 
(C3HeB/Fe background) 
Transgenic for an MHC class I-restricted (H2-Kk), 
SV40TAg-specific TCR 
T. Geiger, R. Fla-
vell 
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4.2.1.4. Animal irradiation 
Local low dose irradiation (local LDI) 
Prior to local irradiation, 24-week old RT5 mice were anaesthetized and placed on a warming 
pad in the Gammatron Cobalt 60 therapy unit (Siemens), an open γ-irradiation device. 2 Gy 
were applied to the pancreas by focussing the radiation beam on the abdominal region. To 
reduce stray radiation the caudal and cranial areas were covered with 3 mm lead shields 
(Figure 32). 
 
Figure 32 Schematic representation of mouse local irradiation. 
Anaesthetized RT5 mice were placed back down on warming pads in the Gammatron therapy unit. 
The irradiation beam was focussed on the abdominal region (yellow shaded area) and the caudal and 
cranial areas were shielded with lead plates (grey shaded areas). 
 
Total body irradiation (TBI) 
8-12-week old C3H wt mice were placed in mouse pie cages and transferred to the animal 
irradiation unit OB.58/902-1 (137Cs source, Buchler) where they were subjected to 2 Gy total 
body irradiation (TBI). 
4.2.1.5. Adoptive T cell transfer 
Spleens from TCR8 mice were washed twice with sterile, ice-cold PBS and cut into pieces 
using a scalpel. These fragments were minced through 100 µm cell strainers using the plung-
er of a syringe, while continuously rinsing the fragments with ice-cold RPMI, to obtain a sin-
gle-cell suspension. After centrifugation of the cell suspension at 400 g and 4°C for 7 min, the 
supernatant was discarded and the cells were resuspended in 3 ml ACK (ammonium chloride 
potassium phosphate) buffer per spleen to lyse all erythrocytes. After 60 sec at room tem-
perature, 10 ml RPMI were added to stop the lysis. The splenocytes were centrifuged as be-
fore. Following centrifugation, the supernatant was discarded and the cell pellet was resus-
pended in mouse medium complemented with 10 U/ml mIL-2 and 25 nM TAg peptide 560-
568. To remove residual cell debris, derived from erythrocyte lysis, the cell suspension was 
passed through a 40 µm cell strainer. The number of living cells was determined by counting 
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trypan blue stained cells using a Neubauer haemocytometer. 1.5x107 viable cells were dis-
tributed evenly in a tissue culture treated six-well plate and cultured in mouse medium con-
taining mIL-2 and the TAg peptide 560-568.  
After 72 hrs, the activated and expanded SV40TAg-specific CD8+ T cells were collected, cen-
trifuged and resuspended in PBS. The cell number was adjusted to 25x106 cells/ml and 
200 µl (5x106) of the cell suspension were injected i.p. into RT5 mice. 
4.2.1.6. Elicitation of peritoneal macrophages & peritoneal lavage 
Recruitment of macrophages into the peritoneal cavity can be induced by aged thioglycolate 
medium which causes sterile peritonitis (Li et al., 1997). A 3 % thioglycolate solution was 
prepared from thioglycolate medium powder (AppliChem). For sterilization the solution was 
autoclaved and passed through a 0.22 µm filter. Before use, the solution was kept at room 
temperature for at least 6 weeks to age. C3H wt mice were injected i.p. with 1 ml of the aged 
solution, to induce the recruitment of macrophages into the peritoneal cavity. 72 hrs after 
injection the peritoneal exudate cells (PECs) were harvested by peritoneal lavage. For that, 
the mice were sacrificed with CO2, disinfected using 70 % ethanol and transferred to a lami-
nar flow. Without opening the peritoneal cavity, the ventral skin was removed. To collect the 
peritoneal cells, 10 ml of ice-cold DMEM were injected into the peritoneal cavity with a 27 G 
needle. By withdrawing and reinjecting the medium, the peritoneal cavity was washed and 
the cells were removed. Additionally, the abdomen was gently massaged to loosen attached 
cells before the medium, which contained the PECs, was withdrawn and transferred to a 
centrifugation tube. The cells were kept on ice until further use.  
4.2.1.7. PEC transfer 
For the transfer of PECs into RT5 mice, the thioglycolate-elicited PECs, which were collected 
from C3H wt mice by peritoneal lavage, were centrifuged at 400 g and 4°C for 8 min. After 
centrifugation, the supernatant was discarded and the cells were resuspended in PBS. The 
cell suspension was passed through a 100 µM cell strainer before the cell number was de-
termined. The cell number was adjusted to 5x106 cells per 150 µl which were injected intra-
venously (i.v.) into 24-week old RT5 mice. 
4.2.1.8. PKH26 labelling of peritoneal macrophages 
To track transferred PECs in RT5 mice, the cells were labelled with PKH26 before the transfer. 
To selectively label macrophages, the ‘PKH26 Red Fluorescent Cell Linker Kit for Phagocytic 
Cell Labelling’ (Sigma) was used. The establishment of a protocol to detect transferred peri-
toneal macrophages was part of L. Nögel’s master thesis; therefore this method was already 
published therein. The experiments were conducted by L. Nögel under my supervision. The 
thioglycolate-elicited PECs were stained with PKH26 according to the manufacturers proto-
col (‘PKH26 Red Fluorescent Cell Linker Kit for General Cell Membrane Labelling’ with Diluent 
B instead of Diluent C). All steps were performed at room temperature. In detail, the thiogly-
colate-elicited peritoneal cells were centrifuged (400 g for 8 min). Afterwards, the superna-
tant was removed and the cells were resuspended in PBS. The cell suspension was passed 
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through a 100 µm cell strainer before the cell number was determined. 2x107 cells were cen-
trifuged at 400 g for 5 min, the supernatant was removed and the cells were resuspended in 
1 ml Diluent B. A 2x dye solution was prepared by adding 16 µl of the PKH26 dye stock to 
1 ml Diluent B obtaining a concentration of 16 µM PKH26. 1 ml of the 2x dye solution were 
added directly to the cell suspension and immediately mixed well by pipetting. The staining 
was stopped after 1-5 min by adding 2 ml FCS. 5 ml complete medium were added to the 
tube after 1 min incubation, and the cells were centrifuged (10 min, 400 g). After centrifuga-
tion, the supernatant was removed and the cells were resuspended in 10 ml complete medi-
um. The cell suspension was transferred to a new tube and washed another 2 times with 
complete medium before the cells were resuspended in PBS. The cell number was assessed 
by counting in a Neubauer haemocytometer. 5x106 cells in 150 µl PBS were injected intrave-
nously (i.v.) into 24-week old RT5 mice. 
4.2.1.9. Macrophage depletion 
Macrophages were depleted from RT5 mice by administration of Clodrosome. Clodrosome is 
a suspension of liposomes in PBS. The liposomes contain clodronate disodium salt (5 mg/ml) 
which is cytotoxic. RT5 mice received an initial injection of 200 µl, followed by injections of 
100 µl every 5 days over the course of 3 weeks or for the duration of the experiment. Con-
trol liposomes (Encapsome) did not contain clodronate disodium salt. 
4.2.1.10. iNOS inhibition 
iNOS inhibition in RT5 mice was accomplished by administration of 1400w ((N-[[3-
(Aminomethyl) phenyl]methyl]-ethanimidamide), a selective iNOS inhibitor. To ensure con-
tinuous dosing, 200 µl of the inhibitor at a concentration of 240 µg/µl were filled into slow 
release mini-osmotic pumps which were implanted into RT5 mice. This provided a dose of 
144 mg/kg/d over 2 weeks. Implantation of the mini-osmotic pumps was performed by T. 
Seibel and the procedure is described in his doctoral thesis (Seibel, 2010). Briefly, in a sterile 
environment, ALZET mini-osmotic pumps, containing 1400w or PBS were inserted into a 
25 mm long pocket under the dorsal skin of anesthetized RT5 mice. Afterwards, the wound 
was closed using Ethicon Mersilene 3-0 suture. 
 
4.2.2. Cell culture methods 
All cells were cultured in cell culture plates, dishes or flasks under sterile conditions at 37°C 
and 5 % CO2 (v/v). 
4.2.2.1. Determination of cell number and viability 
To quantify viable cells in a cell suspension, a 10 µl aliquot of each sample was diluted 1:10 
in trypan blue solution and applied to a Neubauer haemocytometer. Trypan blue stains dead 
cells, therefore unstained (live) cells were counted in the four large squares of the counting 
chamber with a hand tally counter. The cell number per ml was calculated using this formu-
la: 
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4.2.2.2. Irradiation of cells 
Thioglycolate-elicited peritoneal cells collected from C3H wt mice by peritoneal lavage were 
centrifuged at 400 g and 4 °C for 8 min. After centrifugation, the supernatant was discarded 
and the cells were resuspended in macrophage medium. The cell suspension was passed 
through a 100 µM cell strainer before the cell concentration was determined. The samples 
were transported on ice to the Gammacell 1000 D, where they were irradiated with 2 Gy. 
After irradiation, the cells were transferred to suspension culture dishes (TC dishes; Sarstedt) 
with 5x105 cells/ml. The cells were incubated at 37°C and 5 % CO2 for the indicated times.  
4.2.2.3. IFN-γ blockade 
For ex vivo irradiation of PECs under IFN blockade, the macrophage medium was supple-
mented with R4-6A2 (Abrams et al., 1992) and/or 7F-D3 (Belardelli et al., 1987) hybridoma 
supernatant (HSN) which was kindly provided by Prof. Rainer Zawatzky. These supernatants 
contain monoclonal antibodies directed against murine IFN-γ (R4-6A2) or IFN-β (7F-D3) and 
have been tested to neutralize 20 IU of the respective interferon at a dilution of 1:3632 (R4-
6A2 HSN) or 1:6700 (7F-D3 HSN). A final concentration of 1:50 was used to provide a surplus 
of neutralizing antibodies, to completely block IFN-γ and IFN-β in culture. 
The thioglycolate-elicited peritoneal cells collected from C3H wt mice were centrifuged 
(400 g, 4 °C, 8 min), the supernatant was discarded and the cells were resuspended in mac-
rophage medium. Each cell suspension was divided into 5 samples, according to the 5 treat-
ment groups listed in the following table. The samples of the unirradiated and irradiated 
group were not treated with neutralizing antibodies. The samples of the Irr + α-IFN-γ group 
and the samples of the Irr + α-IFN-β group were resuspended in macrophage medium con-
taining R4-6A2 HSN or 7F-D3 HSN, respectively. The samples of the Irr + α-IFN-γ/α-IFN-β 
group were resuspended in macrophage medium containing both HSNs. 
 
Treatment group 
unirr 
Irr 
Irr + α-IFN-γ 
Irr + α-IFN-β 
Irr + α-IFN-γ/α-IFN-β 
 
The samples of the indicated groups were then irradiated with 2 Gy at the Gammacell 1000 
D. Following irradiation, the cells were transferred to non-tissue culture-treated 6 well plates 
with 1x106 cells per well in 3 ml medium as indicated. As a positive control, unirradiated 
Nr of cells/ml =  
Nr of counted cells
Nr of counted squares (4)
 x dilution factor (10) x chamber factor (104) 
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PECs were stimulated with 20 ng/ml mIFN-γ. The cells were incubated at 37°C and 5 % CO2 
for the specified times.  
4.2.2.4. HUVEC Culture and Stimulation 
HUVECs were thawed and cultured according to the manufacturer’s instructions. In detail, 
frozen HUVECs, pooled from up to four donors, were commercially acquired (PromoCell) and 
stored in a cryovial in liquid nitrogen. For the experiment, the cells were thawed by placing 
the cryovial in a water bath for 2 min at 37°C. Before opening the vial under the laminar flow, 
it was disinfected with 70 % ethanol. The cells were transferred to a 75 cm2 tissue culture 
flask containing 20 ml pre-warmed HUVEC medium, a basal medium for endothelial cells, 
supplemented with 3 % FBS, 0.1 % FGF-2, 0.1 % VEGF, 0.1 % R3-IGF-1, 0.1 % ascorbic acid, 
0.1 % heparin, 0.12 % gentamicin sulfate amphotericin B and 0.02 % hydrocortisone (PanBi-
otech). After 24 hrs, the cells had attached to the culture flask and the medium was replaced. 
The cells reached 70-90 % confluency after 2-4 days in culture and were subcultured: the 
supernatant was removed and the cells were rinsed with PBS containing 2 % HEPES solution 
(v/v) and 2 % EDTA (v/v; Versen). To detach the cells, 4 ml pre-warmed 1x Trypsin/EDTA so-
lution were added to the flask and incubated for 5-10 min at RT. When the cells detached, 
5 ml FCS were added to stop the enzymatic activity of trypsin and the cell suspension was 
transferred to a centrifugation tube. The cells were centrifuged at 220 g for 3 min and the 
supernatant was discarded. After resuspending the cells in HUVEC medium, the cell number 
and viability was determined.  
For activation with the NO donor DETA NONOate, HUVECs were seeded in 6-well plates with 
1x105 cells per well in 3 ml HUVEC medium. When the cells were confluent, the medium was 
replaced by HUVEC medium containing the indicated concentrations of DETA NONOate 
and/or 10 ng/ml hTNF-α. The cells were stimulated for 18 hrs.  
 
4.2.3. Cell biology methods 
4.2.3.1. Flow Cytometry 
Preparation of single-cell suspensions: 
From RT5 tissues: tumours, lungs and spleens, isolated from RT5 mice, were transferred to 
1.5 ml eppendorf tubes and homogenized with small scissors. Subsequently, the tissue was 
incubated at 37°C in 1 ml digestion solution. Every 10 min the samples were resuspended. 
After 30 min, the cell suspensions were passed through 100 µm cell strainers and any undi-
gested tissue was mashed through with the plunger of a syringe, while the strainer was con-
tinuously rinsed with ice-cold complete medium to stop the enzymatic digestion. Pancreata 
from RT5 mice were incubated at 37 °C in 5 ml pancreas digestion mix for 10 min. They, too, 
were passed through cell strainers. After centrifugation at 400 g and 4 °C for 8 min, the cells 
were resuspended in FACS buffer.  
Freshly isolated PECs: thioglycolate-elicited peritoneal cells collected from C3H wt mice 
were centrifuged (400 g, 4°C, 8 min); the supernatant was discarded and the cells were re-
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suspended in FACS buffer. Subsequently, the cell suspension was passed through a 100 µM 
cell strainer. 
Cultured PECs, HUVECs: the medium was removed and the cells were washed once with PBS. 
To detach the cells, they were incubated for 5 min with 500 µl Accutase solution per well. 
When the cells detached, 1 ml FCS were added and the cell suspension was transferred to a 
centrifugation tube. After centrifugation at (400 g, 4 °C, 8 min), the cells were resuspended 
in FACS buffer.  
 
The single-cell suspensions were transferred to non-tissue culture treated round bottom 96- 
well plates (BD falcon) with 5x105 to 5x106 cells per well. 
 
Staining: all incubation steps were performed on ice, in the dark. The plates were centri-
fuged (400 g, 4°C, 5 min) and the supernatant was discarded. The murine cells were resus-
pended in 100 µl FACS blocking solution, to saturate Fc receptors. HUVECs were blocked 
using FACS buffer supplemented with 1.5 mg/ml Sandoglobulin. After 20 min incubation, 
100 µl FACS buffer were added and the cells were spun down. This was followed by the via-
bility staining with the Zombie NIR™ Fixable Viability Kit or the LIVE/DEAD® Fixable Yellow 
Dead Cell Stain Kit: 100 µl of DMSO were added to one vial Zombie NIR™ dye and 50 µl of 
DMSO were added to one vial LIVE/DEAD® Yellow Stain, to reconstitute the lyophilized dyes. 
The Zombie NIR™ stock solution was diluted 1:1000 and the LIVE/DEAD® Yellow Stain stock 
solution was diluted 1:500 in PBS for the staining. The cells were resuspended in 200 µl of 
the respective diluted viability dye and incubated for 20 min on ice. Subsequently, the cells 
were centrifuged and washed twice with 200 µl FACS buffer to remove unbound dye mole-
cules. For the surface staining, the cells were incubated for 20 min with the antibody mixes 
as defined in Tables 17-20. After the surface staining, the cells were washed twice with 
200 µl FACS buffer and transferred to 5 ml round bottom tubes for acquisition with the FACS 
Canto II.  
Table 17 HUVEC adhesion molecule staining 
Antibody Conjugation Dilution 
CD31 BV421 1:100 
ICAM-1 (CD54) FITC 1:100 
VCAM-1 (CD106) APC 1:100 
E-Selectin (CD62E) PE 1:100 
FACS buffer  Ad 100 µl 
 
Table 18 T cell surface antigen staining 
Antibody Conjugation Dilution 
CD45 V450 1:500 
CD3e  APC 1:100 
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CD4 APC-Cy7 1:100 
CD8a  PerCP 1:100 
FACS buffer  Ad 100 µl 
 
Table 19 Macrophage phenotype staining  
Antibody Conjugation Dilution 
CD11b PerCP 1:100 
F4/80 APC  1:100 
CD206 (MMR) FITC 1:100 
I-A/I-E (MHC class II) PB 1:100 
FACS buffer  Ad 100 µl 
 
Table 20 Myeloid cell population staining 
Antibody Conjugation Dilution 
CD45-V450 V450 1:500 
CD11b PE-Cy7 1:100 
F480 AF488 1:50 
CD11c PerCP 1:100 
CD14 ApC-Cy7 1:100 
CD86 PE 1:100 
Ly-6G/Ly-6C (Gr-1) APC 1:100 
FACS buffer  Ad 100 µl 
 
For flow cytometric analysis of PKH26 positive cells in RT5 mice, the single cell suspensions 
of RT5 tissues were not stained with antibodies against surface antigens and cell viability was 
assessed by adding one volume of SYTOX blue solution to the cells shortly before acquisition 
of the samples at the FACS Canto II. 
 
Intracellular Staining: the cells that were to be stained for iNOS were fixed and permea-
bilized using the FoxP3/Transcription Factor Staining Buffer Set (eBiocscience), according to 
the manufacturer’s instructions: after the surface antigen staining, the cells were washed 
twice with FACS buffer, followed by resuspension in 200 µl Fixation/Permeabilization Solu-
tion (Fixation/Permeabilization Concentrate 1:4 in Fixation/Permeabilization Diluent) and 
incubation on ice, in the dark for at least 30 min. The cells were washed twice in 200 µl 1x 
Permeabilization buffer (Permeabilization Buffer (10X) 1:10 in ddH2O). For intracellular stain-
ing, the cells were resuspended and incubated for 30 min with the iNOS antibody (diluted 
1:200 in 1x Permeabilization buffer). The cells were then washed twice with 200 µl 1x Per-
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meabilization buffer and once with 200 µl FACS buffer. Afterwards, the samples were resus-
pended in 100 µl FACS buffer and were transferred to 5 ml round bottom tubes, for acquisi-
tion at the FACS Canto II. 
 
Acquisition: compensation of spectral overlaps was performed using compensation beads or 
cells stained with the single antibodies used for the respective staining. The compensation 
beads were stained on the same plate as the samples to guarantee identical staining condi-
tions. Furthermore, cells left unstained and cells stained only with the viability dye were 
used as reference samples in the compensation calculations. Compensation was calculated 
automatically by the BD FACS Diva software and was manually verified. The obtained data 
was analysed using the FlowJo Software. The gates were set according to the fluorescence 
minus one (FMO) controls.  
 
IFN-γ secretion assay: to assess the activation state of in vitro stimulated T cells, a flow cy-
tometry based IFN-γ secretion assay was performed by L. Nögel, as described in his master 
thesis. Splenocytes from TCR8 mice were isolated and cultured as described before (Chapter 
4.2.1.5). The cells were collected, centrifuged at 400 g and 4°C for 8 min and resuspended in 
FACS buffer. The cells were distributed to a non-tissue culture treated round bottom 96 well 
plate (BD falcon) with 5x105 cells per well. After Fc receptor blocking, the cells were incubat-
ed with 100 µl IFN-γ catch reagent (1:20 in mouse medium) for 20 min on ice. To remove 
unbound catch reagent, the cells were centrifuged and resuspended in 200 µl pre-warmed 
mouse medium. For cytokine secretion, the cells were incubated at 37 °C and 5 % CO2 for 
30 min. Afterwards the cells were washed with FACS buffer and viability staining with the 
LIVE/DEAD® Fixable Yellow Dead Cell Stain Kit was performed as described before. This was 
followed by surface marker staining (Table 18) including the IFN-γ detection antibody for 
20 min on ice. After washing the cells, they were resuspended in FACS buffer and the sam-
ples were acquired with the FACS Canto II. 
 
4.2.3.2. Immunofluorescence 
5-7 µm cryosections of frozen tissue samples, embedded in OCT compound, were mounted 
on Superfrost Ultra Plus Adhesion Slides. The sections were air-dried at room temperature 
(RT) before they were fixed for 10 min in ice-cold acetone. When the acetone was evapo-
rated, the sections were encircled with a PAP pen creating a hydrophobic barrier around the 
sections. The slides were then transferred to a lightproof humidity chamber for im-
munostaining. First the sections were rehydrated for 20 min using a serum-free protein-
block solution which blocks Fc receptors. Subsequently, the sections were stained with the 
first primary antibody: 100 µl of the respective antibody diluted 1:50 in IF staining buffer 
were pipetted onto the sections and left at RT for one hour or at 4 °C over night. The slides 
were rinsed with PBS to remove excess antibody and washed three times for 5 min in PBS. 
The highly cross absorbed secondary antibodies were diluted 1:200 in IF staining buffer and 
centrifuged for 10 min at 13000 g to precipitate antibody aggregates. The sections were then 
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incubated at RT for one hour with 200 µl of the first secondary antibody. Again the slides 
were rinsed with PBS after the incubation and washed three times for 5 min in PBS. Staining 
of the second primary and secondary antibodies was performed in the same manner. Finally 
a coverslip was sealed to the slide using Fluoromount G, a mounting medium containing 
DAPI (4',6-diamidino-2-phenylindole) to counterstain nuclei.  
For analysis immunofluorescence (IF) images of the sections were taken at the AxioObserver 
Z1 (Zeiss). The images were processed using the AxioVision or Zen blue software (Zeiss) and 
analysed with Fiji software. 
 
4.2.4. Molecular biology methods 
4.2.4.1. RNA isolation & quality assessment 
For RNA works, the workplace and all required equipment was wiped with RNaseZAP® to 
prevent RNase contamination. Moreover, only nuclease and RNase free eppendorf tubes, 
reagents and filter tips were used. 
 
RNA was isolated from freshly isolated or cultured thioglycolate-elicited peritoneal cells. The 
freshly isolated PECs were centrifuged at 400 g and 4 °C for 8 min. After centrifugation, the 
supernatant was discarded and the cells were resuspended in PBS. The cell suspensions were 
passed through 100 µM cell strainers and the cell numbers were determined using a 
Neubauer haemocytometer. Up to 1x107 cells were transferred to 1.5 ml eppendorf tubes, 
centrifuged (400 g, 4°C, 8 min) and the supernatant was discarded. The cells were resus-
pended in 100 µl RLT lysis buffer containing 2-Mercaptoethanol and were homogenized by 
vigorous pipetting and vortexing. The lysates were stored at -80 °C over night or until RNA 
isolation. Cultured PECs were lysed directly in the plate: after removing the supernatant, the 
attached cells were rinsed with PBS. Then 600 µl RLT buffer containing 2-Mercaptoethanol 
were added to the well and the cells were homogenised by pipetting. Finally the lysates 
were transferred to 1.5 ml eppendorf tubes which were vortexed and stored at -80 °C over 
night or until RNA isolation. 
 
RNA from PEC lysates was isolated using the RNeasy Mini Kit (QIAGEN), following the proto-
col ‘Purification of Total RNA from Animal Cells using Spin Technology’ by QIAGEN, including 
the on-column DNase digestion using the RNase-Free DNase Set (QIAGEN). RNA was eluted 
in 30 µl nuclease free water of which 5 µl were used for quality assessment The other 25 µl 
were stored at -80 °C until further use. RNA quantity and purity were determined using the 
NanoDrop 2000c spectrophotometer. RNA integrity was analysed with the Agilent RNA 6000 
Nano Assay, according to the manufacturer`s protocol, on the Agilent 2100 Bioanalyzer. The 
resulting RNA integrity number (RIN) indicated whether RNA was degraded (RIN =1) or intact 
(RIN =10). Samples with RIN > 8 were accepted for downstream analyses. 
MATERIALS AND METHODS 
 
| 98  
4.2.4.2. RNA Sequencing 
The RNA isolated from in vivo or in vitro irradiated PECs was diluted as to the requirements 
of the DKFZ Genomics & Proteomics Core Facility (GPCF) (55 µl with 40 ng/µl) or GATC Bio-
tech (50 µl with 20 ng/µl). The samples were submitted on dry ice for RNA Sequencing. Each 
sample passed the quality control of the GPCF and GATC, respectively. The GPCF used the 
Illumina Hiseq2000 for sequencing with the 50 base pair single read sequencing type and the 
HCS 2.2.58 sequencing software, followed by a FastQC analysis (v. 0.10.0, performed by the 
GPCF) which confirmed successful sequencing of all samples. GATC Biotech used the Illumina 
HiSeq2500. They did not give further details regarding the run. For these samples, FastQC 
analysis (performed by T. Michels) showed contamination with adapter dimers. This howev-
er has no effect on downstream analyses, therefore the samples were used for downstream 
analyses. 
4.2.4.3. RT-qPCR 
Relative gene expression was analysed by reverse transcription quantitative real time PCR 
(RT-qPCR). 
For the reverse transcription (RT) reactions, 800 ng of the RNA were transcribed to comple-
mentary DNA (cDNA) using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). 
Following the manufacturer`s protocol, the RNA template was mixed with 2 µl oligo(dT)18 
primers and incubated at 65°C for 5 min. The mixture was placed on ice and the following 
reagents were added (Table 21). A ‘no reverse transcriptase control’ (-RT) was included to 
determine genomic DNA contamination. 
 
Table 21 RT reaction mix 
Reagent Volume 
5X Reaction Buffer  4 μL 
RiboLock RNase Inhibitor (20 U/μL) 1 μL 
10 mM dNTP Mix  1 μL 
RevertAid M-MuLV RT  1 μL 
 
The reaction mix was then incubated at 60°C for 42 min for cDNA synthesis. Finally the cDNA 
was stored at -20°C. 
 
Prior to quantitative real time PCR (qPCR) of these samples, all TaqMan assays were tested 
with regard to their amplification efficiency using universal mouse reference RNA. The RNA 
was prepared according to the manufacturer’s instructions and transcribed into cDNA (as 
described above). A serial dilution provided solutions with known cDNA concentrations 
(from 16 ng/µl to 0.004 ng/µl). Following the TaqMan Universal Master Mix II protocol, the 
PCR reaction mix was prepared and plated out in a 384-well plate. Table 22 shows the mix 
for one well.  
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Table 22 qPCR reaction mix 
Reagent Volume 
2x TaqMan Universal Master Mix II, with UNG 10 μL 
Taqman assay 1 μL 
Nuclease free water 4 μL 
 
5 µl of the differently diluted cDNA, were added per well; each concentration in triplicates. A 
no template control (NTC) was included to monitor contamination of primer-dimer for-
mation. The plate was sealed by LightCycler 480 Sealing Foil and loaded into the LightCycler® 
480 II (Roche). The qPCR program which was applied is shown in Table 23. 
Table 23 qPCR program 
Cycle Time Temperature cycles 
UNG incubation 02:00 50 °C 1 
Polymerase activation 10:00 95 °C 1 
PCR 
Denaturation 00:15 95 °C 
40 
Annealing/Extension 01:00 60 °C 
Cooling ∞ 10 °C 1 
 
The efficiency was determined using the slope of the qPCR standard curve. With the excep-
tion of the Ifng TaqMan assay, all assays showed acceptable amplification efficiencies (Table 
24). 
Table 24 TaqMan assay amplification efficiencies 
Genesymbol AssayNr. Slope PCR Efficiency 
Ifng Mm01168134_m1 x  - 
Ifng II Mm00801778_m1 x  - 
Jak1 Mm00600614_m1 -3.862 110 
Stat1 Mm00439531_m1 -4.276 117 
Irf1 Mm01288580_m1 -3.42 102 
Irf7 Mm00516793_g1 -3.431 102 
Nos2 Mm00440502_m1 -3.324 100 
Tnf Mm00443258_m1 -3.656 107 
Gapdh Mm99999915_g1 -3.525 104 
Hprt1  Mm03024075_m1  -3.563 105 
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This was followed by qPCR analysis of the sample cDNA using the tested TaqMan assays and 
the TaqMan Universal Master Mix II protocol. 5 µl cDNA at a concentration of 4 ng/µl were 
added to a 384-well plate; each sample in triplicates. 15 µl of the PCR reaction mix were 
added to each well and the plate was analysed with the LightCycler® 480 II (Roche). The 
thereby generated gene expression values were normalized to a reference gene (Hprt) ac-
cording to the ΔΔCt method with a control sample as the calibrator.  
 
4.2.5. Analysis of transcriptomic data 
The transcriptomic data, in form of Fastq files, that was generated by RNA sequencing, was 
analysed by T. Michels using Bioconductor and R according to the ‘Count-based differential 
expression analysis of RNA sequencing data’ (Anders et al., 2013) Briefly, the sequenced 
reads were mapped to the annotated Ensembl mouse reference genome (GRCm38 (mm10)). 
Subsequently, the reads were summarized to the corresponding genes and normalized 
(tophat2). The normalized gene expression values were used for differential comparison 
which was computed using EdgeR. This resulted in differential gene expression data in form 
of Fold Change (FC) and False Discovery Rate (FDR) values for each gene. Thus differentially-
expressed genes were further analysed by Gene-e, STRING, Venny, InteractiVenn, Ingenuity 
Pathway Analysis and Interferome: 
Gene-e (www.broadinstitute.org/cancer/software/GENE-E/): Gene-e was employed to gen-
erate overview heat maps of the differentially expressed genes in the in vivo and in vitro da-
taset on the basis of the normalized read counts (CPM (counts per million)) per gene. The 
software was also used to perform unsupervised hierarchical clustering of the samples and 
the genes. Similar expression patterns between samples were clustered using the distance 
metric ‘One minus Spearman rank correlation’. Expression patterns between genes were 
clustered with the ‘One minus Pearson rank correlation’ using an average linkage for both. 
STRING (http://string-db.org/): For gene set enrichment analysis, gene sets of interest were 
uploaded to STRING. The database generated protein interaction networks showing known 
and predicted, direct (physical) and indirect (functional) associations between the proteins. 
Furthermore, the database tests the gene sets for Gene Ontology (GO) enrichments and 
pathway annotations (Szklarczyk et al., 2015). 
Venn diagrams were generated using Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/) 
and InteractiVenn (http://www.interactivenn.net/)(Heberle et al., 2015; Oliveros, 2007-
2015). The images were processed in Inkscape, to generate scaled Venn diagrams. 
Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity): 
For the identification of pathways that are affected by low dose irradiation, the transcrip-
tome data were analysed through the use of QIAGEN’s Ingenuity Pathway analysis. The 
software maps datasets to the Ingenuity Knowledge Base. Thereby it creates causal net-
works, identifies upstream regulators, overrepresented biological functions and canonical 
pathways. The software also takes into account whether a gene is up- or downregulated 
which enables it to predict whether certain processes are activated or inhibited.  
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Table 25 IPA Analysis settings I 
Selected Cut offs  
Cutoff before duplicate resolution true 
Resolve duplicate on Expression logFC 
Colour using Expression logFC 
Cutoff for logFC 0.585 and consider Both up/down regulated 
Cutoff for p-value 0.05 
Cutoff for q-value 0.05 
Reference set Ingenuity Knowledge Base (Genes Only) 
Relationship to include Direct and Indirect 
Includes Endogenous Chemicals Yes 
Optional Analyses My Pathways My List 
 
Table 26 IPA Analysis settings II 
Filter Summary 
Consider only molecules and/or relationships where 
species = Mouse OR Uncategorized 
confidence = Experimentally Observed OR High (predicted))  
tissues/cell 
lines =  
Other NK cells OR Tissues and Primary Cells not otherwise specified OR CCRF-CEM OR Other 
Granulocytes OR Memory T lymphocytes not otherwise specified OR Monocytes not other-
wise specified OR SR OR Other Organ Systems OR Myeloma Cell Lines not otherwise specified 
OR Spleen OR Mononuclear leukocytes not otherwise specified OR Central memory helper T 
cells OR PBMCs OR Other Memory T lymphocytes OR HMC-1 OR Eosinophils OR Intraepithe-
lial T lymphocytes OR Jurkat OR Lymphocytes not otherwise specified OR Monocyte-derived 
dendritic cells not otherwise specified OR NK cells not otherwise specified OR Other Cell Line 
OR Cell Line not otherwise specified OR Leukemia Cell Lines not otherwise specified OR Mac-
rophages not otherwise specified OR BA/F3 OR Other T lymphocytes OR Pre-B lymphocytes 
OR Memory B cells OR Peritoneal macrophages OR HL-60 OR U937 OR Peripheral blood 
monocytes OR Mature monocyte-derived dendritic cells OR Langerhans cells OR Vd2 Gam-
ma-delta T cells OR Cytotoxic T cells OR Other Cells OR Peripheral blood leukocytes not oth-
erwise specified OR Pro-B lymphocytes OR Vd1 Gamma-delta T cells OR Naive helper T cells 
OR RPMI-8266 OR Immune cell lines not otherwise specified OR Lymph node OR Other Mye-
loma Cell Lines OR Other Mononuclear leukocytes OR Activated CD56dim NK cells OR J-
774A.1 OR Effector memory RA+ cytotoxic T cells OR Other Macrophages OR Other Macro-
phage Cancer Cell Lines OR Activated CD56bright NK cells OR Naive B cells OR Mast cells OR 
RBL-2H3 OR Splenocytes OR Effector memory cytotoxic T cells OR Other Dendritic cells OR 
Th17 cells OR Plasma cells OR Other Peripheral blood leukocytes OR Natural T-regulatory 
cells OR RAW 264.7 OR Activated helper T cells OR Other Immune cells OR Macrophage Can-
cer Cell Lines not otherwise specified OR Activated Vd1 Gamma-delta T cells OR Murine NKT 
cells OR Hematopoietic progenitor cells OR Other B lymphocytes OR K-562 OR U266 OR Th1 
cells OR Neutrophils OR HEL OR Plasmacytoid dendritic cells OR Immature monocyte-derived 
dendritic cells OR Myeloid dendritic cells OR WEHI-231 OR Central memory cytotoxic T cells 
OR Other Lymphoma Cell Lines OR Activated Vd2 Gamma-delta T cells OR J774 OR MOLT-4 
OR CD4+ T-lymphocytes OR Other Tissues and Primary Cells OR Bone marrow-derived mac-
rophages OR BDCA-3+ dendritic cells OR B lymphocytes not otherwise specified OR Granulo-
cytes not otherwise specified OR Bone marrow cells not otherwise specified OR Other Leu-
kemia Cell Lines OR Megakaryocytes OR Other Lymphocytes OR Other Bone marrow cells OR 
Other Monocyte-derived dendritic cells OR Effector T cells OR Effector memory helper T cells 
OR CD56bright NK cells OR Other Immune cell lines OR Th2 cells OR Immune cells not other-
wise specified OR THP-1 OR Organ Systems not otherwise specified OR BDCA-1+ dendritic 
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cells OR T lymphocytes not otherwise specified OR CD56dim NK cells OR Dendritic cells not 
otherwise specified OR Other Monocytes OR Cells not otherwise specified OR NB4 OR Thy-
mocytes OR Lymphoma Cell Lines not otherwise specified OR CD34+ cells OR Microglia OR 
Monocyte-derived macrophage OR Peripheral blood lymphocytes OR Bone marrow-derived 
dendritic cells) 
mol. types = 
biologic drug OR chemical - endogenous mammalian OR chemical - endogenous non-
mammalian OR chemical - kinase inhibitor OR chemical - other OR chemical - protease inhibi-
tor OR chemical drug OR chemical reagent OR chemical toxicant OR complex OR cytokine OR 
disease OR enzyme OR function OR G-protein coupled receptor OR group OR growth factor 
OR ion channel OR kinase OR ligand-dependent nuclear receptor OR mature microRNA OR 
microRNA OR other OR peptidase OR phosphatase OR transcription regulator OR translation 
regulator OR transmembrane receptor OR transporter) 
 
Interferome (http://www.interferome.org/): The Interferome database was searched to 
identify interferon (IFN) regulated genes (IRGs) in the in vivo and in vitro datasets (Rusinova 
et al., 2013). The following search conditions were applied:  
Table 27 Interferome search conditions 
Search Conditions  
Interferome Type Any 
Interferome SubType Any 
Treatment Concentration Any 
Treatment Time Any 
Vivo/Vitro Any 
Species Mus musculus 
System Haemopoietic/Immune 
Organ Any 
Cell 
CD8+ DC; blood monocyte derived macrophages; monocyte derived 
macrophages; whole tissue; monocyte derived DCs; derived macro-
phages; peritoneal exudate cells 
Cell Line Any 
Normal/Abnormal Normal 
Fold Change Up/Down 1.5 
 
4.2.6. Statistical Analysis 
All statistical analyses were performed using GraphPad Prism 6 software, except for the 
analyses of transcriptome data and data from the IFN blockade experiments. The two-sided 
(non-parametric) Mann-Whitney test or the two-sided, unpaired (parametric) t-test was 
used to assess differences between the compared groups. The correlation between the 
number of CD11b+ cells and tumour size was calculated using the Spearman`s rank correla-
tion coefficient test and the survival data was analysed with the Log-rank (Mantel-Cox) test. 
Differences between the treatment groups in the IFN blockade experiment were calculated 
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by Dr. Maria Pritsch using the paired, two-tailed t-test with the SAS software. Significant dif-
ferences are represented by one or more asterisks: * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001. 
Statistical analysis of transcriptome data was performed by T. Michels in the course of 
count-based differential gene expression analysis (Anders et al., 2013) of the raw data. To 
account for the multiple testing error occurring in such analyses, false discovery rate (FDR) 
values were computed for each result (gene). A p-value <0.05 indicates that 5 % of the re-
sults might be false positives. The FDR gives an estimation on how many of the significant 
results are false positives. By accepting results with FDR values <0.05, the possibility of false 
positive results is reduced to 5 %. Furthermore, analysis of the transcriptome data by IPA, 
String and Interferome generated p-values or FDRs, which were computed by the designated 
software or database. Insofar as it was known, the applied tests are stated in the figure leg-
ends.   
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6. SUPPLEMENTS 
Table 28 Commonly upregulated genes 
Gene FC FDR FC FDR Description 
 In vivo In vitro  
Agrn 1.59 0.0346 2.77 0.0425 agrin  
Arfgef3 2.72 0.0292 4.33 0.0150 ARFGEF family member 3  
AW112010 2.78 0.0154 43.93 0.0008 expressed sequence AW112010  
C3 1.61 0.0178 8.68 0.0014 complement component 3  
Cd274 1.74 0.0003 10.64 0.0013 CD274 antigen  
Cfb 4.89 0.0011 93.64 0.0010 complement factor B 
Clec4n 1.94 0.0021 13.81 0.0021 C-type lectin domain family 4, member n 
Cmpk2 2.40 0.0008 9.20 0.0015 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 
Col1a1 2.02 0.0302 4.45 0.0226 collagen, type I, alpha 1 
Col1a2 2.01 0.0088 2.97 0.0429 collagen, type I, alpha 2  
Col4a1 2.98 0.0280 8.16 0.0031 collagen, type IV, alpha 1  
Col5a2 2.19 0.0199 6.10 0.0231 collagen, type V, alpha 2  
Cxcl2 2.87 0.0119 4.05 0.0377 chemokine (C-X-C motif) ligand 2  
Dcn 1.95 0.0035 4.34 0.0114 decorin  
Ddx58 1.97 0.0000 4.26 0.0091 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
Dhx58 2.10 0.0000 2.86 0.0498 DEXH (Asp-Glu-X-His) box polypeptide 58  
Ece1 1.52 0.0019 7.18 0.0042 endothelin converting enzyme 1 
Egfr 2.71 0.0180 4.12 0.0498 epidermal growth factor receptor  
Eif2ak2 1.68 0.0009 3.08 0.0192 eukaryotic translation initiation factor 2-alpha kinase 2  
Fam46c 1.70 0.0037 4.20 0.0231 family with sequence similarity 46, member C 
Fbln2 3.03 0.0000 5.24 0.0092 fibulin 2 
Fcgr4 1.69 0.0000 4.15 0.0023 Fc receptor, IgG, low affinity IV  
Gbp2 1.60 0.0231 10.61 0.0026 guanylate binding protein 2  
Gbp4 3.40 0.0177 96.80 0.0008 guanylate binding protein 4  
Gbp9 2.14 0.0226 16.40 0.0023 guanylate-binding protein 9  
H2-T22 1.74 0.0065 2.90 0.0488 histocompatibility 2, T region locus 22 
Havcr2 1.69 0.0039 3.89 0.0192 hepatitis A virus cellular receptor 2  
Helz2 1.69 0.0001 4.67 0.0094 helicase with zinc finger 2, transcriptional coactivator 
Ifi203 1.60 0.0001 3.28 0.0226 interferon activated gene 203  
Ifi204 2.38 0.0000 3.79 0.0125 interferon activated gene 204  
Ifi44 4.29 0.0000 10.42 0.0008 interferon-induced protein 44  
Ifi44l 3.47 0.0000 8.94 0.0011 interferon-induced protein 44 like 
Ifi47 2.70 0.0000 6.90 0.0044 interferon gamma inducible protein 47  
Ifih1 2.08 0.0000 3.62 0.0125 interferon induced with helicase C domain 1  
Ifit1 10.03 0.0000 14.47 0.0010 interferon-induced protein with tetratricopeptide repeats 1 
Ifit1bl1 12.59 0.0020 10.02 0.0267 interferon induced protein with tetratricpeptide repeats 1B like 1  
Ifit2 17.44 0.0000 22.53 0.0010 interferon-induced protein with tetratricopeptide repeats 2 
Ifit3 27.57 0.0000 9.73 0.0014 interferon-induced protein with tetratricopeptide repeats 3 
Iigp1 7.17 0.0356 448.20 0.0015 interferon inducible GTPase 1  
Il2rb 2.64 0.0059 12.85 0.0342 interleukin 2 receptor, beta chain 
Irf7 3.76 0.0000 14.14 0.0008 interferon regulatory factor 7 
Irgm1 2.25 0.0000 8.92 0.0013 immunity-related GTPase family M member 1 
Irgm2 1.96 0.0005 11.08 0.0018 immunity-related GTPase family M member 2 
Isg15 5.07 0.0000 5.72 0.0092 ISG15 ubiquitin-like modifier 
Kdr 1.64 0.0262 3.71 0.0308 kinase insert domain protein receptor  
continued on the next page 
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Gene FC FDR FC FDR Description 
 In vivo In vitro  
Lamc1 1.57 0.0001 2.45 0.0434 laminin, gamma 1  
Lgals3bp 1.60 0.0000 4.93 0.0053 lectin, galactoside-binding, soluble, 3 binding protein  
Ly6a 5.06 0.0057 121.26 0.0008 lymphocyte antigen 6 complex, locus A  
Ly6c1 7.52 0.0000 87.12 0.0015 lymphocyte antigen 6 complex, locus C1  
Ly6c2 8.06 0.0000 64.58 0.0023 lymphocyte antigen 6 complex, locus C2  
Ly6e 1.94 0.0000 2.50 0.0259 lymphocyte antigen 6 complex, locus E 
Met 2.06 0.0033 3.83 0.0071 met proto-oncogene  
Ms4a4c 3.48 0.0001 13.61 0.0030 membrane-spanning 4-domains, subfamily A, member 4C 
Ms4a6b 1.84 0.0039 13.04 0.0100 membrane-spanning 4-domains, subfamily A, member 6B  
Mt2 2.28 0.0135 2.98 0.0366 metallothionein 2  
Mx1 3.68 0.0000 6.85 0.0119 MX dynamin-like GTPase 1 
Mxd1 1.93 0.0008 3.96 0.0179 MAX dimerization protein 1  
Nlrc5 1.95 0.0008 6.99 0.0029 NLR family, CARD domain containing 5 
Oas1g 3.13 0.0000 2.83 0.0431 2'-5' oligoadenylate synthetase 1G  
Oas2 1.71 0.0018 7.38 0.0033 2'-5' oligoadenylate synthetase 2  
Oas3 5.37 0.0000 8.78 0.0013 2'-5' oligoadenylate synthetase 3  
Oasl2 3.38 0.0000 4.86 0.0057 2'-5' oligoadenylate synthetase-like 2 
Parp12 1.69 0.0005 3.20 0.0275 poly (ADP-ribose) polymerase family, member 12  
Parp14 1.79 0.0000 6.59 0.0018 poly (ADP-ribose) polymerase family, member 14  
Parp9 1.71 0.0001 3.06 0.0424 poly (ADP-ribose) polymerase family, member 9 
Pdgfra 2.27 0.0106 2.82 0.0480 platelet derived growth factor receptor, alpha polypeptide 
Pf4 1.53 0.0178 6.56 0.0076 platelet factor 4  
Plac8 2.04 0.0280 5.23 0.0425 placenta-specific 8 
Rnf213 2.37 0.0000 8.16 0.0013 ring finger protein 213 
Rsad2 5.97 0.0000 10.82 0.0022 radical S-adenosyl methionine domain containing 2 
Rtp4 3.08 0.0000 8.19 0.0015 receptor transporter protein 4  
Serpine1 3.06 0.0000 24.90 0.0010 serine (or cysteine) peptidase inhibitor, clade E, member 1 
Siglec1 1.72 0.0000 4.22 0.0044 sialic acid binding Ig-like lectin 1, sialoadhesin 
Slc39a2 4.25 0.0000 3.27 0.0171 solute carrier family 39 (zinc transporter), member 2 
Slfn1 2.01 0.0002 22.60 0.0010 schlafen 1 
Slfn4 2.40 0.0003 8.16 0.0029 schlafen 4  
Slfn5 1.99 0.0000 3.31 0.0369 schlafen 5  
Spon1 3.34 0.0014 80.62 0.0062 spondin 1, (f-spondin) extracellular matrix protein  
Stat1 1.63 0.0430 4.07 0.0093 signal transducer and activator of transcription 1 
Stat2 1.71 0.0000 4.99 0.0077 signal transducer and activator of transcription 2 
Stfa3 2.32 0.0051 10.67 0.0377 stefin A3 
Tgm2 2.15 0.0000 10.87 0.0010 transglutaminase 2, C polypeptide 
Thbs1 1.78 0.0048 10.83 0.0144 thrombospondin 1  
Tnc 25.58 0.0336 6.65 0.0091 tenascin C  
Trim30a 1.59 0.0001 3.46 0.0109 tripartite motif-containing 30A  
Trim30d 4.44 0.0000 27.13 0.0010 tripartite motif-containing 30D  
Tulp4 1.51 0.0000 2.71 0.0184 tubby like protein 4  
Usp18 5.33 0.0000 4.99 0.0086 ubiquitin specific peptidase 18  
Vcan 2.67 0.0001 7.09 0.0084 versican 
Xaf1 2.33 0.0000 5.01 0.0071 XIAP associated factor 1  
Zbp1 4.57 0.0000 25.25 0.0010 Z-DNA binding protein 1 
Znfx1 1.74 0.0000 3.39 0.0183 zinc finger, NFX1-type containing 1  
92 genes commonly upregulated after in vivo and in vitro irradiation with the FC and FDR values from both 
datasets. With IRGs highlighted in bold. 
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Table 29 IPA Diseases and biological functions (listing the DEGs of the in vivo and in vitro dataset) 
Diseases and 
Bio Functions 
in vivo in vitro 
activation 
z-score Genes in dataset 
activation 
z-score Genes in dataset 
 
Innate im-
mune re-
sponse 
1.94 
Mx1, Lgals9, Havcr2, Stat1, Zbp1, Isg15, 
Ifit2, Fn1, Clec4n, Eif2ak2, Ifih1, Ddx58, 
Bst2, Nlrc5, Igha 
3.44 
Havcr2, Mx2, Stat1, Zbp1, Tlr2, Mmp2, Isg15, Tlr8, 
Trem1, Ifit2, Nod2, Gbp5, Slpi, Clec4n, Eif2ak2, Lcn2, 
Ifih1, Clec4e, Ddx58, Fpr1, Fpr2, Nlrc5 
     
Activation of 
leukocytes 2.76 
Lck, Lgals9, Met, Gzmb, Vcan, Gzma, 
C3, Stat1, Fcgr2b, Il1rn, Itgav, Siglec1, 
Spp1, Npy, Mif, Ccl2, Card11, C1qa, 
Prf1, Bank1, Ddx58, Foxo1, Serpinb9, 
Cx3cr1, Timd4, Cxcl2, Fcgr4, Il2rb, 
Treml2, Cd274, Tnfaip3, Havcr2, Cd74, 
Csf1r, Fn1, Cfh, Cd19, Pou2af1, Thbs1, 
Cd300lf, Cxcr5, Retnla, Apoe, Cd79a, 
Hdac9, Blk, Fcgr1, Fos, Pf4, Nedd4, H2-
Aa, H2-DMa, Tgm2, Cd79b, Nlrc3, 
Csf2rb2, C4b, H2-Ab1, H2-DMb1, Igha 
4.42 
Il12rb1, Trpm2, Met, Lyst, Nos2, Hif1a, Edn1, Vcan, 
Cd86, C3, Fas, Snca, Stat1, Lcn2, Notch1, Siglec1, 
Rasgrp1, Il1b, Il1a, Notch2, Tlr2, Cd1d1, Cd38, Clec4e, 
Cd69, Il4ra, Itgal, Ptgs2, Cish, Bmp2k, Ccl5, Ccl12, Nfk-
biz, Icam1, Stx11, Saa3, Ddx58, Inhba, Cd1d2, Trem1, 
Itga1, Fpr1, Ptges, Cx3cr1, Cxcl2, Fcgr4, Il2rb, Hmox1, 
Mertk, Hsd11b1, Cd274, Slpi, Adora2b, Havcr2, Il15ra, 
Pag1, Cd2, Tgfbr2, Thbs1, Gja1, Tarm1, Slamf6, Nfkbia, 
Satb1, Pf4, Klrk1, Klrb1a, Il21r, Sbno2, H2-Q4, Tgm2, 
Socs1, Tlr8, Prkce, Cd24a, Kcna3, Spn, Fpr2 
Activation of 
myeloid cells 1.39 
Lgals9, Met, Gzma, C3, Stat1, Itgav, 
Spp1, Npy, Mif, Ccl2, Thbs1, Cx3cr1, 
Timd4, Cxcl2, Treml2, Apoe, Havcr2, 
Csf1r, Fn1, Cfh, Fcgr2b, Prf1, Cd300lf, 
Cxcr5, Retnla, Il1rn, Pf4, Tgm2, C4b 
4.24 
Il4ra, Icam1, Met, Cxcl2, Stat1, Cd86, Notch1, Cx3cr1, 
Itga1, Cd1d1, Ccl12, Trpm2, Trem1, C3, Thbs1, Tlr2, 
Clec4e, Ccl5, Edn1, Ptges, Snca, Il1b, Ptgs2, Saa3, Inhba, 
Nos2, Fpr1, Lcn2, Adora2b, Havcr2, Slpi, Gja1, Hmox1, 
Hsd11b1, Sbno2, Prkce, Tlr8, H2-Q4, Pf4, Tgm2, Socs1, 
Fpr2 
Activation of 
phagocytes 1.17 
Lgals9, Met, Gzma, C3, Stat1, Itgav, 
Spp1, Npy, Mif, Ccl2, Thbs1, Cx3cr1, 
Timd4, Cxcl2, Treml2, Apoe, Havcr2, 
Csf1r, Fn1, Cfh, Prf1, Cd300lf, Cxcr5, 
Retnla, Il1rn, Pf4, Tgm2, C4b 
3.56 
Trpm2, Met, Nos2, Edn1, Cd86, C3, Snca, Stat1, Lcn2, 
Notch1, Il1b, Tlr2, Cd1d1, Clec4e, Il4ra, Ptgs2, Ccl5, 
Ccl12, Icam1, Saa3, Thbs1, Inhba, Itga1, Fpr1, Ptges, 
Cx3cr1, Cxcl2, Hmox1, Mertk, Hsd11b1, Slpi, Adora2b, 
Havcr2, Cd24a, Gja1, Pf4, Sbno2, H2-Q4, Tgm2, Socs1, 
Tlr8, Trem1, Prkce, Fpr2 
Activation of 
macrophages 0.74 
Lgals9, Stat1, Il1rn, Itgav, Npy, Mif, 
Ccl2, Thbs1, Cx3cr1, Timd4, Apoe, 
Havcr2, Csf1r, Fn1, Prf1, Cxcr5, Retnla, 
C3, Tgm2 
3.77 
Trpm2, Nos2, Snca, Stat1, Lcn2, Notch1, Il1b, Tlr2, 
Cd1d1, Clec4e, Il4ra, Ptgs2, Ccl5, Ccl12, Icam1, Thbs1, 
Inhba, Ptges, Cx3cr1, Adora2b, Havcr2, Gja1, C3, Sbno2, 
H2-Q4, Tgm2, Socs1, Prkce 
     
Cell movement 2.32 
Lck, Apoe, Cdkn1b, Hdac9, Ccl24, Met, 
Hyal1, Sparc, Egfr, Sgpp1, Fos, Ctsl, 
Vcan, Plau, Ly6c2, Qpct, C3, Pdgfrb, Irf7, 
Stat1, Rgs18, Cfh, Fcgr2b, Itgav, Tnc, 
Spp1, Pf4, Flt1, Npy, Mgll, Mif, Ccl7, 
Ccl2, Tgm2, Rras, Thbs1, Ddx58, Fzd7, 
Irgm1, Mmp13, Cxcl2, Fcgr4, Sphk1, 
Kdr, Il2rb, Treml2, Csf2rb2, C4b, Cfb, 
Slfn4, Pdgfb, Trpv4, Cd274, Alox15, 
Tnfaip3, Dcn, Itgb3, Ciita, Cyp1b1, Cd74, 
Csf1r, Alox5, Fn1, Rgs1, Il1rn, Cd19, 
Cryab, Ccr3, Myrf, Prf1, Serpine1, 
Atp8a1, Stat2, Foxo1, Cd300lf, Cxcr5, 
Cx3cr1, Retnla, Hvcn1, Lyz1, Grk6, 
Col1a1, Cacna1e, Pltp, Net1, Podxl, 
Plxna2, Fbn1, Gba, Pdgfra, Dck, Cttn, 
Cd209a, Col4a1, Pou2af1, Selenbp1 
6.25 
Il12rb1, Mmp11, Mmp14, Ephb3, Trpm2, Met, Abca1, 
Kdm6b, Adora2b, Lsp1, Cxcl16, Ccl6, Esr1, Ctgf, Egfr, 
Rhbdf2, Nos2, Nfkbia, Hif1a, Lrrc16a, Edn1, Vcan, Ednrb, 
Osmr, Trio, Ly6i, Il15ra, C3, C2, Lox, Fosl1, Irf7, Nrp2, 
Stat1, Ralgds, Lcn2, Notch1, Rasgrp1, Il1b, Il1a, Tm4sf1, 
Tlr2, Cd1d1, Cyr61, Tnc, Pde4b, Lrp8, Cd38, Fosl2, Pf4, 
Cxcl1, Clec4e, Cd69, Furin, Ctsc, Il21r, Il4ra, Itgal, Hp, 
Mmp2, Adamts7, Ptgs2, Ccl5, Ccl12, Acta2, H2-Q4, 
Lrrk2, Icam1, Tgm2, Rara, F13a1, Itga9, Prex1, Fgl2, 
Thbs1, Ddx58, Pvr, Inhba, Cmklr1, Trem1, Itga1, S1pr1, 
Fpr1, Irgm1, Kcna3, Ptges, Gja1, Fpr2, Nod2, Cxcl2, 
Fcgr4, Serpinb2, Kdr, Il2rb, Cfb, Slfn4, Hmox1, Mmp8, 
Sod2, Cav1, Cd274, Slpi, Abr, Dcn, Cdk1, Timp3, Pttg1, 
Cd86, Lmnb1, Jag1, Cd2, Olr1, Siglece, Nt5e, Lif, Apln, 
Serpine1, Socs1, Stat2, Mmp10, Gpr183, Spn, Cx3cr1, 
Socs3, Wfdc17, Sod3, Col1a1, Epha2, Chdh, Cd34, Lyst, 
Fas, Vldlr, Epha4, Serpine2, Marco, Pdgfra, Cxcl3, Tjp1, 
Col4a1, Dusp4, Tgfbr2, Nfkbiz, Tgfbi, Saa3, Prkce, 
Cd24a, Rapgef2 
Cell movement 
of myeloid 
cells 
2.26 
Apoe, Ccl24, Hyal1, Ctsl, Vcan, Plau, 
Qpct, C3, Spp1, Pf4, Ccl2, Tgm2, Thbs1, 
Irgm1, Cxcl2, Sphk1, Kdr, Il2rb, Treml2, 
C4b, Cfb, Trpv4, Tnfaip3, Cd74, Csf1r, 
Alox5, Il1rn, Flt1, Cttn, Ccr3, Myrf, 
Cxcr5, Col1a1, Itgb3, Gba, Col4a1, Mif, 
Serpine1, Cx3cr1, Grk6 
3.92 
Il12rb1, Trpm2, Abca1, Lsp1, Ctgf, Nos2, Hif1a, Edn1, 
Vcan, Il15ra, C3, C2, Fas, Lcn2, Il1b, Il1a, Tlr2, Cyr61, 
Pde4b, Pf4, Cxcl1, Cd69, Il4ra, Itgal, Hp, Ptgs2, Ccl5, 
Ccl12, Nfkbiz, Icam1, Tgm2, Prex1, Thbs1, Inhba, Trem1, 
S1pr1, Fpr1, Irgm1, Ptges, Fpr2, Cxcl2, Kdr, Il2rb, Cfb, 
Hmox1, Mmp8, Cav1, Timp3, Lmnb1, Cd2, Nt5e, Tgfbr2, 
Socs1, Cmklr1, Itga1, Mmp10, Spn, Socs3, Sod3, Col1a1, 
Slpi, Nfkbia, Cxcl3, Col4a1, Serpine1, Itga9, Cx3cr1, 
Nod2 
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Cell movement 
of phagocytes 1.97 
Col1a1, Apoe, Ccl24, Hyal1, Trpv4, 
Tnfaip3, Itgb3, Ctsl, Vcan, Plau, Qpct, 
C3, Cd74, Csf1r, Alox5, Il1rn, Itgav, Gba, 
Spp1, Pf4, Flt1, Cttn, Cd209a, Col4a1, 
Mif, Ccl2, Myrf, Serpine1, Thbs1, Irgm1, 
Cx3cr1, Cxcl2, Sphk1, Kdr, Treml2, C4b, 
Grk6, Cfb 
4.01 
Il12rb1, Trpm2, Abca1, Lsp1, Ctgf, Nos2, Hif1a, Edn1, 
Vcan, Il15ra, C3, C2, Fas, Nrp2, Lcn2, Il1b, Il1a, Tlr2, 
Cyr61, Pde4b, Cd38, Pf4, Cxcl1, Cd69, Itgal, Hp, Ptgs2, 
Ccl5, Ccl12, Nfkbiz, Icam1, Prex1, Thbs1, Inhba, Cmklr1, 
Trem1, S1pr1, Fpr1, Irgm1, Ptges, Fpr2, Cxcl2, Kdr, Cfb, 
Hmox1, Mmp8, Cav1, Timp3, Cd86, Lmnb1, Nt5e, 
Tgfbr2, Socs1, Itga1, Mmp10, Spn, Socs3, Sod3, Col1a1, 
Slpi, Nfkbia, Marco, Cxcl3, Il4ra, Col4a1, Serpine1, Itga9, 
Cx3cr1, Nod2 
Cell movement 
of macrophag-
es 
1.09 
Apoe, Vcan, Plau, Spp1, Pf4, Ccl2, 
Thbs1, Irgm1, Cx3cr1, Kdr, Trpv4, 
Tnfaip3, Csf1r, Il1rn, Mif, Myrf, Itgb3, 
Cd74, Gba, Flt1, Serpine1 
2.90 
Il12rb1, Hmox1, Nos2, Hif1a, Edn1, Vcan, Il15ra, Il1b, 
Il1a, Tlr2, Cyr61, Pf4, Itgal, Ptgs2, Ccl5, Ccl12, Icam1, 
Thbs1, S1pr1, Irgm1, Ptges, Fpr2, Cx3cr1, Kdr, Cav1, 
Timp3, Lmnb1, Tgfbr2, Socs1, Itga1, Mmp10, Sod3, Ctgf, 
Il4ra, Serpine1 
     
Viral Infection -2.39 
Lck, Lgals9, Cd274, Ctsl, Cd74, Itgav, 
Spp1, Oasl1, Hmga1, Cxcl2, Sphk1, H2-
Ab1, Pou3f1, Igha, Mx1, Apoe, Gzmb, 
Dhx58, Rsad2, Itgb3, Gzma, Eif2ak2, C3, 
Irf7, Stat1, Fn1, Fcgr2b, Ifih1, Il1rn, 
Zbp1, Oasl2, Cd19, Cd209a, Ccl2, Isg15, 
Prf1, Stat2, Ddx58, Serpinb9, Ifit2, Bst2, 
Ifit1bl1, Pf4 
-2.50 
Mertk, Cd274, Nos2, Il1b, Tlr2, Klrk1, Itgal, Tgfbr2, 
Socs1, Fpr1, St3gal5, Cxcl2, Hmox1, Cav1, Slpi, Dhx58, 
Lsp1, Irf1, Rsad2, Mx2, Eif2ak2, C3, Irf7, Cflar, Stat1, 
Ifih1, Zbp1, Oasl2, Ccl5, Nfkbiz, Isg15, Stx11, Stat2, 
Ddx58, Tlr8, Abcb1a, Ifit2, Ch25h, Socs3, Ifit1bl1, Nfkbia, 
Fas, Pf4, Ccl12, H2-Q4, Apln, Icam1 
Diseases and biological functions predicted by IPA to be increased (red) or decreased (blue) in PECs after in vivo 
or in vitro irradiation. The DEGs of the two datasets for each Disease and biological function are listed under 
‘Genes in dataset’. Activation z-score ≥ |2|; p-value <0.0001 considered significant. Insignificant values shown 
in black.  
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Figure S33 Protein network of genes upregulated in PECs in response to LDI 
Protein-protein interactions of the proteins encoded by the 92 genes upregulated after both in vivo and in vitro 
irradiation, visualized by STRING. The nodes represent proteins. Highlighted in red are the proteins associated 
with the respective GO term indicated in the upper left corner of the subfigure. The coloured areas highlight 
the protein clusters which predominantly comprise proteins involved in an innate immune response (yellow) or 
cell migration (green).The edges represent physical and functional connections between the proteins. 
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Table 30 IPA Upstream regulators (IFN signalling) (listing the DEGs of the in vivo and in vitro dataset) 
Upstream 
regulator 
in vivo in vitro 
activation 
z-score Genes in dataset 
activation 
z-score Genes in dataset 
IRF3 5.63 
Stat1, Parp12, Helz2, Oas2, Stat2, 
Ube2l6, Nt5c3, Parp14, Irgm2, Ddx58, 
Slfn1, Plac8, Phf11b, Ifih1, Dhx58, 
Irgm1, Ifi204, Cmpk2, Oasl1, Ifi47, 
Fcgr1, Oas1g, Oasl2, Mx1, Irf7, Trim30d, 
Isg15, Usp18, Rsad2, Ifit1, Ifit1bl1, Ifit2, 
Ifit3  
6.01 
Oas1g, Dhx58, Samd9l, Parp12, Phf11d, Ifih1, Stat1, 
Cd86, Ddx58, Helz2, Oasl2, Usp18, Stat2, Tap1, 
Plac8, Isg15, Cd69, Parp14, Ifi47, Igtp, Oas2, Fam26f, 
Mx2, Irgm1, Cmpk2, Ifit1bl1, Rsad2, Irgm2, Ifi205, 
Ifit3b, Irf7, Ccl5, Ifit1, Ifit2, Slfn1, Trim30d, Gbp5, 
Nos2  
IRF7 5.47 
Stat1, Parp12, Helz2, Oas2, Stat2, 
Ube2l6, Nt5c3, Parp14, Irgm2, Ddx58, 
Slfn1, Plac8, Phf11b, Ifih1, Dhx58, 
Irgm1, Ifi204, Cmpk2, Oasl1, Ifi47, 
Fcgr1, Oas1g, Oasl2, Mx1, Irf7, Trim30d, 
Isg15, Usp18, Rsad2, Ifit2, Ifit3, Ifit1bl1 
5.73 
Oas1g, Dhx58, Samd9l, Parp12, Phf11d, Ifih1, Stat1, 
Ddx58, Helz2, Oasl2, Usp18, Stat2, Tap1, Plac8, 
Isg15, Cd69, Parp14, Ifi47, Igtp, Oas2, Fam26f, Mx2, 
Irgm1, Cmpk2, Rsad2, Irgm2, Ifi205, Ifit3b, Irf7, Ccl5, 
Ifit2, Slfn1, Trim30d, Gbp5, Ifit1bl1  
IRF5 4.17 
Stat1, Parp12, Oas2, Stat2, Ube2l6, 
Nt5c3, Ddx58, Ifih1, Dhx58, Cmpk2, 
Oasl1, Oas1g, Oasl2, Irf7, Isg15, Rsad2, 
Ifit2, Ifit3  
3.93 
Oas1g, Dhx58, Parp12, Ifih1, Stat1, Ddx58, Oasl2, 
Stat2, Isg15, Cxcl1, Oas2, Cmpk2, Rsad2, Ifit3b, Irf7, 
Ifit2, Dapk2 
IFN-γ 4.09 
Fcgr2b, Ece1, Pf4, Csf1r, Hmga1, Gbp2, 
C3, Stat1, Eif2ak2, Fcgr4, Stat2, Cd274, 
Thbs1, Rab20, Ly6e, Nlrc5, Irgm2, 
Ddx58, Slfn1, Il1rn, Ifih1, Plau, Col5a2, 
Bst2, Irgm1, Ifi204, Slfn4, Spp1, Chst3, 
Ifi47, Fcgr1, Angptl4, Serpine1, Oas1g, 
Gbp4, Mx1, Irf7, Retnla, Cd163, Cfb, 
Isg15, Flt1, Rsad2, Iigp1, Ly6c2, Ccl7, 
Ccl2, Ifit2, Fos, Mgl2, Il7r, Kdr, Ciita, 
Col1a2, H2-DMa, Col1a1, Fn1, H2-Ab1, 
H2-Eb1, Cd74, H2-Aa, Cxcl2, H2-Ob, 
Ms4a4c  
7.67 
Cflar, Ly6e, Sbno2, Hif1a, Oas1g, Ctsh, Nfkbia, 
Ifi202b, Eif2ak2, Adora2b, Fas, Itgal, Ifih1, Icam1, 
Nfkbiz, Serpina3f, Stat1, Cd86, Fcgr4, Ddx58, Bst1, 
Stat2, Tap1, Wfdc17, Sod2, Ndrg4, Nod2, C2, Isg15, 
Col5a2, Irf1, Cxcl1, Il12rb1, Pf4, Ifi47, Igtp, Nlrc5, 
Ece1, Il1a, C1rb, Ccl12, Slfn4, C3, Mx2, Irgm1, Mefv, 
Ass1, Gbp2, Cd274, Rsad2, Thbs1, Tlr2, Irgm2, Il15ra, 
Socs1, Clec4e, Gm4070, Ifi205, Cp, Cish, Gbp2b, Irf7, 
Ccl5, Edn1, Ch25h, Tjp1, Ptges, Flt4, Mmp2, Ifit2, 
Slfn1, Crlf1, Serpine1, Gbp7, Gbp3, Il1b, Ptgs2, Socs3, 
Tgtp2, Timp3, Il18bp, Inhba, Gbp5, Nos2, Acod1, Cfb, 
Gbp4, Gbp8, Ly6i, Iigp1, Lcn2, Ubd, Trem1, Il23r, 
Col1a2, Acta2, Kdr, Cxcl2, Col1a1, Ccnd2, Ctsc, 
Abcb1a, Abca1, Vldlr, Hmox1, Ms4a4c, Arg2, Saa3, 
Ctgf  
IFN-α 4.95 
Fcgr2b, C3, Stat1, Eif2ak2, Oas2, Stat2, 
Siglec1, Ddx58, Slfn5, Slfn1, Il1rn, 
Phf11b, Ifih1, Dhx58, Bst2, Ifi204, Slfn4, 
Egfr, Fcgr1, Oas1g, Mx1, Irf7, Prf1, Zbp1, 
Isg15, Usp18, Ifit1bl1, Ifit2, Gzmb, Ifit3, 
Ifitm2, Fos  
5.88 
Oas1g, Dhx58, Eif2ak2, Slfn5, Fas, Phf11d, Ifih1, 
Icam1, Stat1, Prkce, Egfr, Cd86, Siglec1, Ddx58, 
Ccnd2, Usp18, Stat2, Isg15, Cd69, Irf1, Oas2, Ccl12, 
Slfn4, C3, Mx2, Mefv, Ifit1bl1, Il15ra, Socs1, Ifi205, 
Gbp2b, Ifit3b, Irf7, Ch25h, Ifit2, Slfn1, Zbp1, Socs3, 
Tgtp2, Cd38, Nos2, Il21r, Il12rb1 
IFN-β1 3.76 
Gbp2, Stat1, Eif2ak2, Parp12, Stat2, 
Itgb3, Ddx58, Ifih1, Dhx58, Bst2, Oas1g, 
Gbp4, Mx1, Irf7, Zbp1, Isg15, Ifit1, Ccl2, 
Ifit2, Cd274, Thbs1, Nt5c3, Nfix, Irgm2, 
Irgm1, Ifi27l2a, Ifi204, Cmpk2, Fbn1, 
Ifi47, Cryab, Fbln2, Trim30d, Usp18, 
Rsad2, Ifit3, Itgav, Fos  
5.16 
Oas1g, Dhx58, Eif2ak2, Parp12, Ifih1, Stat1, Cd86, 
Ddx58, Stat2, Nod2, Isg15, Irf1, Ccl12, Mx2, Gbp2, 
Socs1, Gm4070, Irf7, Ccl5, Ifit1, Ch25h, Ifit2, Gbp7, 
Zbp1, Gbp3, Tgtp2, Gbp5, Nos2, Gbp4, Gbp8, Nfkbie, 
Cd24a, Lamb1, Ctla2b, Usp18, Fbln2, Cxcl1, Ifi47, 
Igtp, Irgm1, Cmpk2, Serpinb2, Cd274, Rsad2, Thbs1, 
Irgm2, Clec4e, Ifi205, Ifit3b, Trim30d, Acod1, Notch1 
STAT1 3.50 
Fcgr2b, Pf4, C3, Stat1, Eif2ak2, Irgm1, 
Fos, Rnf213, H2-Eb1, Oasl1, Fcgr1, Mx1, 
Irf7, Prf1, Retnla, Isg15, Ifit1, Gzmb, 
Gbp2, Ciita, Ly6e, Apoe, Cfb, Ifitm2, 
Cxcl2  
4.47 
Eif2ak2, Fas, Icam1, Stat1, Cd86, Ccnd2, Tap1, 
Abca1, Isg15, Irf1, Pf4, Igtp, Klrk1, Rnf213, C3, Mx2, 
Irgm1, Il15ra, Socs1, Gbp2b, Irf7, Ccl5, Ifit1, Ch25h, 
Socs3, Nos2, Acod1, Lcn2, Ly6e, Gbp2, Ptgs2, Cfb, 
Hif1a, Cxcl2, Tgtp2  
Upstream regulators, associated with IFN signalling, predicted by IPA to be activated in PECs after in vivo or in 
vitro LDI. The DEGs of the two datasets for each Upstream regulator are listed under ‘Genes in dataset’. Activa-
tion z-score ≥ |2|; p-value <0.0001 considered significant.  
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Table 31 Upstream regulators (TLR agonists) (listing the DEGs of the in vivo and in vitro dataset) 
Upstream 
regulator 
in vivo in vitro 
activation 
z-score Genes in dataset 
activation 
z-score Genes in dataset 
LPS 6.31 
Slc15a3, Pf4, Csf1r, Plin2, Ctsl, 
Hmga1, Gbp2, C3, Stat1, Cd300lf, 
Irak2, Eif2ak2, Stat2, Cd274, 
Thbs1, Nt5c3, Tnfaip3, Mif, Rgs1, 
Dcn, Nlrc5, Irgm2, Slfn1, Il1rn, 
Odc1, Met, Tgm2, Alox5, Alox15, 
Irgm1, Fos, Ifi204, Cmpk2, Sphk1, 
Spp1, Apoe, Chst3, Fbn1, Treml2, 
Ifi47, H2-Aa, Cxcl2, Cryab, 
Angptl4, Fbln2, Serpine1, Ser-
pinb9, Oas1g, Gbp4, Mmp13, 
Ifi44l, Mx1, Irf7, Serpina3n, 
Cd163, Trim30d, Cfb, Isg15, Ccl24, 
Usp18, Flt1, Rsad2, Ly6c2, Ccl7, 
Ifit1, Ccl2, Ifit2, Tnc, Ifit3, Itgav, 
Kdr, Rab20, Herpud1, Ifrd1, 
Col1a2, Plau, Col5a2, Col3a1, 
Col6a1, Oasl1, Il2rb, Vcan, Col4a1, 
Iigp1, Fcgr2b, Birc3, Pdgfb, Foxo1, 
Ptgs1, Nfix, Tgfb2, Col1a1, Sparc, 
Fn1, H2-Ab1, Cd74, Cxcr5, Ccr3  
9.65 
Cflar, Dusp4, Hif1a, Oas1g, Notch2, Nfkbia, Ifi202b, 
Eif2ak2, Birc3, Adora2b, Il4ra, Fas, Itgal, Cd24a, 
Icam1, Osmr, Met, Nfkbiz, Cxcl2, Stat1, Cd86, 
Lamb1, Il1f9, Dcn, Ccnd2, H2-Q4, Usp18, Stat2, 
Tap1, Wfdc17, Sod2, Fbln2, Notch1, Satb1, Il21r, 
Isg15, Cd69, Zc3h12c, Irf1, Slc7a11, Cxcl1, Pde4b, 
Pf4, Tnc, Cxcl16, Jag1, Ifi47, Cd1d1, Igtp, Nlrc5, 
Il1a, Gja1, Ccl12, Trem1, C3, Mx2, Irgm1, Ifi44l, 
Cmpk2, Lif, Ass1, Hp, Mmp14, Serpinb2, Gbp2, 
Cd274, Rsad2, Thbs1, Tgm2, Hmox1, Tlr2, Irgm2, 
Il15ra, Socs1, Clec4e, Ifi205, Cish, Gbp2b, Ifit3b, 
Irf7, Ccl5, Ifit1, Cyr61, Edn1, Ptges, Flt4, Mmp2, 
Ifit2, Slfn1, Arg2, Serpine1, Gbp3, Il1b, Trim30d, 
Ptgs2, Socs3, Tarm1, Tgtp2, Cd38, Saa3, Inhba, 
Ctgf, Fpr2, Nos2, Acod1, Fpr1, Marco, Cfb, Gbp4, 
Ly6i, Lcn2, Tsc22d1, Col1a2, Stx11, S1pr1, 
Cdc42ep2, Slc31a2, Kdr, Ctsc, Abcb1a, Ralgds, 
Serpine2, Col5a2, Col5a1, Vcan, Col4a1, Mefv, 
Col5a3, Olr1, Gpr84, Il2rb, Ch25h, Timp3, H2-M2, 
Iigp1, Lmnb1, Rara, Nfkbie, Col1a1, Abca1, Slc40a1  
poly I:C 5.65 
Gbp2, C3, Stat1, Eif2ak2, Oas2, 
Stat2, Sp100, Cd274, Thbs1, 
Tnfaip3, Rgs1, Ly6e, Nlrc5, Ddx58, 
Ifih1, Dhx58, Bst2, Fos, Slfn4, 
Oasl1, Fcgr1, Cxcl2, Oas1g, Oasl2, 
Mx1, Irf7, Trim30d, Zbp1, Isg15, 
Oas3, Rsad2, Iigp1, Ifit1, Ccl2, 
Ifit2, Gzmb, Ifit3, Fcgr2b, Birc3  
7.02 
Ly6e, Oas1g, Dhx58, Eif2ak2, Etnk1, Birc3, Il4ra, 
Fas, Ifih1, Icam1, Cxcl2, Stat1, Cd86, Ddx58, Oasl2, 
Stat2, Abca1, C2, Isg15, Cd69, Irf1, Cxcl1, Nlrc5, 
Oas2, Il1a, Klrk1, Slfn4, C3, Mx2, Oas3, Olr1, Gbp2, 
Cd274, Rsad2, Thbs1, Tlr2, Il15ra, Socs1, Ifit3b, 
Irf7, Ccl5, Ifit1, Ifit2, Zbp1, Il1b, Trim30d, Ptgs2, 
Tarm1, Nos2, Fpr1, Marco, Iigp1  
CpG oligonu-
cleotide 
1.24 Thbs1, Serpine1, Gbp4, Mmp13, 
Trim30d, Ccl7, Rassf4, Fcgr2b  4.45 
Notch2, Fas, Icam1, Nfkbiz, Cd86, Sod2, Notch1, 
Abca1, C2, Cxcl1, Olr1, Gpr84, Thbs1, Tlr2, Clec4e, 
Gbp2b, Serpine1, Il1b, Trim30d, Ptgs2, Nos2, 
Marco, Gbp4, Ptges  
Resiquimod 1.83 Irak2, Cxcl2, Irf7, Ccl7, Ccl2, Plau, 
Spp1, Ccl24, Herpud1  3.39 
Nfkbiz, Cxcl2, Sod2, Cxcl1, Gpr84, Tlr2, Clec4e, Irf7, 
Ccl5, Il1b, Ptgs2, Nos2, Fas, Il1a, Ccl12, Inhba 
TLR agonist upstream regulators predicted by IPA to be activated in PECs after in vivo or in vitro LDI. The DEGs 
of the two datasets for each Upstream regulator are listed under ‘Genes in dataset’. Activation z-score ≥ |2|; p-
value <0.0001 considered significant. Grey shaded values are below the threshold.  
  
SUPPLEMENTS 
 
| 132  
 
Table 32 Upstream regulators (PRR signalling) (listing the DEGs of the in vivo and in vitro dataset) 
Upstream 
regulator 
in vivo in vitro 
activation 
z-score Genes in dataset 
activation 
z-score Genes in dataset 
DDX58 3,05 
Stat1, Eif2ak2, Stat2, Ifih1, Mx1, Irf7, 
Ifi44, Isg15, Rsad2, Ifit1, Ifit2, Ifit3, 
Ddx58  
4,02 
Tor1aip2, Eif2ak2, Ifih1, Stat1, Gem, Stat2, Isg15, Irf1, 
Mx2, Ifi44, Rsad2, Socs1, Gbp2b, Ifit3b, Irf7, Ccl5, 
Ifit1, Ifit2, Socs3, Ddx58 
MAVS 4,23 
Stat1, Parp12, Oas2, Stat2, Ube2l6, 
Nt5c3, Ddx58, Dhx58, Cmpk2, Oasl1, 
Oas1g, Oasl2, Irf7, Isg15, Rsad2, Ifit1, 
Ifit2, Ifit3  
4,07 
Oas1g, Dhx58, Parp12, Stat1, Ddx58, Oasl2, Stat2, 
Isg15, Oas2, Cmpk2, Rsad2, Ifit3b, Irf7, Ccl5, Ifit1, 
Ifit2, Il1b  
TBK1 2,81 Mx1, Cmpk2, Rsad2, Irf7, Ifit1, Ifit2, 
Iigp1, Cxcl2 4,08 
Sh3bp5, Icam1, Nfkbiz, Cxcl2, Cxcl1, Il1a, Fgl2, Mx2, 
Cmpk2, Rsad2, Tlr2, Il15ra, Irf7, Ccl5, Ifit1, Edn1, Ifit2, 
Ptgs2, Inhba, U90926, Marco, Iigp1, Tsc22d1, Il1b 
IFIH1 2,75 Oas2, Bst2, Oas1g, Mx1, Irf7, Lck, Isg15, 
Ly6c2 2,76 Oas1g, Fas, Isg15, Oas2, Mx2, Cish, Irf7, Ly6i 
TLR3 4,94 
Mx1, Gzmb, Cd274, Cmpk2, Rsad2, 
Rgs1, Ifih1, Gbp2, Tnc, Oasl2, Npy, 
Usp18, Ccl7, Ccl2, Serpine1, Oasl1, 
Serpinb9, Ifit2, Iigp1, Stfa3, Cxcl2, 
Stfa2l1, Treml2, Ifi204, Ifit3, Irf7, Stat1, 
Il1rn, Isg15, Ddx58, Oas1g, Ifi47 
6,16 
Ifi202b, Fas, Ifih1, Nfkbiz, Cxcl2, Cd86, Furin, Oasl2, 
Usp18, Abca1, Cd69, Irf1, Cxcl1, Tnc, Il1a, Klrk1, 
Ccl12, Mx2, Cmpk2, Ier3, Gbp2, Cd274, Stfa3, Rsad2, 
Hmox1, Ifi205, Gbp2b, Ifit3b, Ccl5, Edn1, Ifit2, Arg2, 
Serpine1, Gbp3, Il1b, Ptgs2, Socs3, Saa3, Nos2, 
Acod1, Iigp1, Lcn2, Oas1g, Stat1, Ddx58, Isg15, Ifi47, 
Irf7, Ptges  
TLR7 2,22 Stat2, Tnfaip3, Cxcl2, Mx1, Irf7, Isg15, 
Rsad2, Cdkn1b  3,13 
Nfkbia, Cxcl2, Cd86, Stat2, Sod2, Isg15, Cxcl1, Mx2, 
Gpr84, Rsad2, Socs1, Irf7, Ccl5, Il1b, Irf1, Ccl12 
TLR9 4,53 
Stat2, Cd274, Npy, Stfa3, Ifi204, Sphk1, 
Cxcl2, Serpine1, Oasl2, Mx1, Irf7, Isg15, 
Usp18, Rsad2, Ccl7, Ifit1, Ccl2, Ifit2, 
Tnc, Ifit3, Stfa2l1  
6,01 
Ugcg, Ifi202b, Fas, Sgms2, Nfkbiz, Cxcl2, Cd86, Furin, 
Oasl2, Usp18, Stat2, Wfdc17, Abca1, Isg15, Smpdl3b, 
Cd69, Tnc, Il1a, Mx2, Ier3, Cd274, Stfa3, Rsad2, 
Hmox1, Socs1, Ifi205, Cish, Ifit3b, Irf7, Ccl5, Ifit1, 
Edn1, Ifit2, Arg2, Serpine1, Il1b, Ptgs2, Socs3, Saa3, 
Nos2, Acod1, Lcn2, St3gal5, Lyst 
MYD88 4.16 
C3, Tnfaip3, Il1rn, Met, Cmpk2, Spp1, 
Oasl1, Cxcl2, Serpine1, Ms4a4c, Mgl2, 
Irf7, Isg15, Rsad2, Ifit1, Ccl2, Ifit2, 
Gzmb  
6.80 
Cflar, Hif1a, Nfkbia, Sh3bp5, Icam1, Met, Nfkbiz, 
Cxcl2, Cd86, Pstpip2, Ednrb, Isg15, Zc3h12c, Cxcl1, 
Pde4b, Jag1, Acsl1, Il1a, Gdap10, C3, Mefv, Cmpk2, 
Hp, Acpp, Mmp14, Olr1, Rsad2, Tlr2, Cish, Ms4a4c, 
Irf7, Ccl5, Ifit1, Ch25h, Ptges, Mmp2, Ifit2, Serpine1, 
Il1b, Ptgs2, Socs3, Mmp8, Cd38, Saa3, Inhba, Fpr2, 
Nos2, Acod1, Fpr1, U90926, Marco, Irf1, Tsc22d1 
TICAM1 4.41 
Tnfaip3, Irgm2, Met, Irgm1, Ifi204, 
Cmpk2, Oasl1, Ifi47, Cxcl2, Serpine1, 
Ms4a4c, Mx1, Irf7, Cfb, Isg15, Rsad2, 
Ifit1, Ccl2, Ifit2, Ifit3  
6.48 
Tor1aip2, Cflar, Nfkbia, Icam1, Met, Nfkbiz, Cxcl2, 
Cd86, Pstpip2, Ednrb, Isg15, Irf1, Cxcl1, Pde4b, Jag1, 
Ifi47, Igtp, Acsl1, Il1a, Gdap10, Ccl12, Mx2, Irgm1, 
Mefv, Cmpk2, Rsad2, Tlr2, Irgm2, Il15ra, Socs1, 
Ifi205, Ifit3b, Ms4a4c, Irf7, Ccl5, Ifit1, Ch25h, Ifit2, 
Serpine1, Ptgs2, Socs3, Cd38, Il18bp, Fpr2, Acod1, 
Fpr1, Cfb, Tsc22d1, Il1b  
Upstream regulators, associated with PRR signalling, predicted by IPA to be activated in PECs after in vivo or in 
vitro LDI. The DEGs of the two datasets for each Upstream regulator are listed under ‘Genes in dataset’. Activa-
tion z-score ≥ |2|; p-value <0.0001 considered significant.  
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Figure S34 Effects of proinflammatory stimuli on iNOS levels of peritoneal macrophages 
iNOS expression in peritoneal macrophages following in vitro stimulation with LPS and or IFN-γ. Flow cytomet-
ric analysis of thioglycolate-elicited PECs from C3H wt mice after stimulation with 20 ng/ml LPS and/or 
20 ng/ml IFN- γ for 24 hrs. Control cells were cultured in medium only. Representative dot plots and quantita-
tive analysis of CD11b/iNOS
+
 PECs. Only single, viable cells were included in the analysis. Data shown as mean ± 
SEM (n=2-3 mice per group). 
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